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ABSTRACT
The effects of type I (insulin-dependent ) diabetes mellitus on the hepatic cytochrome P450- 
dependent mixed-function oxidase system was investigated in both chemically-induced and 
spontaneously diabetic rats. Sex-specific influences on these changes were evaluated in 
male and female streptozotodn-induced diabetic rats. Further studies examined the ability 
of hepatic fractions from both chemically-induced and spontaneously diabetic rats to 
bioactivate known chemical carcinogens in the Ames mutagenicity assay. The role of ketone 
bodies and hyperglycaemia in the diabetes-induced alterations were investigated in rats 
rendered hyperketonaemic by dietary manipulation. Finally, the effects on hepatic drug 
metabolism of hypertension, using spontaneously hypertensive rats, type II (non insulin- 
dependent) diabetes using the spontaneously hyperglycaemic mouse and 
hyperinsulinaemia, by insulinoma transplantation in the rat were also determined.
Streptozotocin-induced diabetes was associated with significant elevations of the enzym e 
activities catalysed by the cytochrome P450 lA, IIB, HE, IIIA and IVA sub-families, a finding  
confirmed by immunological analysis. These alterations were a consequence of the diabetic state 
and not the diabetogen -per se, as shown by the inclusion of a group of rats which received  
nicotinamide concurrently with streptozotocin to counter the effect of the diabetogen. Long-term  
streptozotocin-diabetic rats continued to display elevations of the cytochrome P450 lA  and IIB 
families. H owever, after four weeks, the severity of ketosis declined and the elevation in  
activities of the cytochrome P450 HE, IIIA and IVA families became less pronounced. Investigation  
of sex-related alterations in the diabetes-induced changes revealed that induction was alw ays 
more pronounced in the male than the female.
The spontaneously diabetic BB rat exhibited similar alterations of hepatic 
cytochrome P450 families as those observed in the streptozotocin-induced diabetic rats.
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However, in BB rats, all of the changes apparent at one month following onset of the 
disease were similarly observed in six month diabetic animals. Hepatic fractions from both 
chemically-induced and spontaneously-diabetic rats were markedly more efficient at 
activating selected chemical carcinogens in the Ames mutagenicity assay. However, these 
fractions were less efficient at activating the aromatic amine, 2-aminofluorene, suggesting 
that diabetes modulates other enzyme systems capable of drug metabolism.
The mechanism responsible for the diabetes-induced changes in hepatic drug 
metabolism has been proposed to involve ketone bodies. In our experiments using rats 
rendered hyperketonaemic by dietary manipulation, we found that similar alterations of 
hepatic drug metabolism occurred as previously observed in diabetic animals. As the 
hyperketonaemic animals were normoglycaemic, it can be concluded that it is the ketone 
bodies that have a major role in the diabetes-induced changes in hepatic drug metabolism 
and not hyperglycaemia. However, hyperketonaemia failed to modulate the levels of 
cytochrome P450 IIIA as seen in the diabetic animals, indicating that other mechanisms are 
involved. Further work examining the effect of specific ketone bodies revealed that acetone 
was a potent inducer of cytochrome P450 lA, IIB and HE proteins. This study also 
demonstrated that ketone bodies could not modulate the levels of cytochrome P450IVA.
These studies provide compelling evidence for a direct link between ketone bodies 
and the induction of the cytochrome P450 lA, IIB and HE subfamilies. Clearly, the 
mechanism of cytochrome P450 IHA and IVA induction are dependent on other factors. 
However, in the case of cytochrome P450 IVA subfamily our studies suggest that the 
increased levels of circulating free fatty acids, accompanying type I diabetes, are 
responsible for the induction.
Finally, our investigations into the effects of type II diabetes, hypertension and 
hyperinsulinaemia on hepatic drug metabolism revealed that type II diabetes and
i i i
hypertension have little effect on the cytochrome P450 families investigated. However, 
hyperinsulinaemia was associated with a selective induction of the cytochrome P450 lA 
subfamily, indicating that perturbations of endogenous insulin levels may have marked 
influences on hepatic drug metabolism and consequently the toxicity /  carcinogenicity of 
chemicals.
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Chapter 1
Introduction
1.1 Diabetes Mellitus
Diabetes mellitus has been identified in many animal species but there appears to 
be a higher incidence of the disease in humans where it is a leading cause of morbidity and 
mortality amongst the adult population (Peiris and Gustafson, 1986). Major complications 
associated with the disease include; retinopathy, nephropathy, peripheral vascular 
disease and neuropathy (Perring et al. 1985; Clements and Bell, 1986).
Diabetes can be characterised into three distinct types, in each of which subtypes 
have been identified (National Diabetes Data Group, 1979).
Type I, Insulin-dependent diabetes mellitus
Usually characterised by abrupt onset of symptoms, insulinopenia and dependence
on injected insulin to sustain life, and proneness to ketosis. Classically, this type of diabetes 
occurs in juveniles and it was formerly termed juvenile diabetes. However, it can be 
recognised and become symptomatic for the first time at any age. In addition to the ketosis- 
prone stage, this type of diabetes can also be recognised in a preketosis-prone stage. Type I
diabetes mellitus appears to be heterogeneous in terms of genetics and environmental factors 
that precipitate the disease (Rotter and Rimoin, 1978). Genetic factors are thought to be 
important in most patients, as expressed by the associated increased or decreased frequency 
of certain histocompatibility antigens (Cudworth and Woodrow, 1976). Abnormal immune 
response and autoimmunity are also thought to play an etiologic role, and islet cell 
antibodies are frequently present at diagnosis in this type of diabetes.
Type II, non insulin-dependent diabetes mellitus
This type of diabetes frequently occurs with minimal, or no symptoms of the 
metabolic alterations associated with type I diabetes. Patients are not dependent on insulin 
for prevention of ketonuria and are not prone to ketosis. However, they may become ketotic 
in certain instances such as severe stress caused by infection or trauma. There may be normal 
levels of insulin, mild insulinopenia or above normal levels of insulin associated with 
insulin resistance. Most patients who develop type II diabetes usually do so after the age of 
40, although type II diabetes can occur in younger people. Type II diabetes has a genetic 
basis which appears to be more evident than for type I diabetes. Environmental factors 
superimposed on genetic susceptibility are undoubtedly involved in the onset of this type of 
diabetes. Excessive weight gain leading to obesity is probably an important factor in its 
pathogenesis. Type II diabetes has been subdivided according to the presence or absence of 
obesity, revealing that in Western societies 60 - 90% of all type II diabetics are obese. 
Hyperglycaemia and glucose intolerance are usually improved by weight loss. In this type 
of diabetes islet cell antibodies have not been found although it is possible for type II 
diabetics to progress to type I diabetes mellitus (National Diabetes Data Group, 1979).
Other types of diabetes
In this subclass diabetes forms part of certain other conditions and syndromes. For 
example, diabetes may be secondary to pancreatic disease or removal of pancreatic tissue, 
endocrine diseases such as acromegaly, Cushing's syndrome, glucagonoma or 
somatostatinoma, or the administration of certain drugs, hormones or chemicals that cause 
hyperglycaemia. Finally, diabetes may also be associated with defective insulin receptors 
present on the cells.
1.2 Animal models of diabetes mellitus
Syndromes resembling human diabetes occur spontaneously in many animal species 
and can also be induced by treating animals with drugs or viruses, excising the pancreas or 
manipulating the diet (Salans and Graham, 1982). None of the known animal models can, 
without reservation, be taken to reproduce all the characteristics of human diabetes, but 
they are believed to illustrate various types of etiology and pathogenetic mechanisms that 
in principle could operate in man.
1.2.1 Animal models of type II diabetes mellitus
Most animal models of type II diabetes show the same characteristics of obesity
and elevated plasma insulin as human type II diabetics. One of the most common models is 
the genetically hyperglycaemic obese mouse. This strain originated in the early 1940's at 
the Jackson Laboratory, Maine. In these animals the obesity gene {ob), is recessive, with 
the homo2ygous recessive animal becoming obese and weighing three to four times as much 
as their lean littermates. They also develop severe insulin resistance and diabetes. Other 
animal models are also due to the inheritance of a single gene. For example the diabetic 
idb/db) mouse or the Zucker or fatty ifa/fa) rat. The spontaneously obese rhesus monkey 
may be a particularly useful model of human obesity and diabetes.
Other models of type II diabetes have been developed employing chemical and 
surgical means, or by manipulating the diet. Surgically damaging the ventromedial nucleus, 
a part of the brain involved with the endocrine system and feeding behaviour, results in an 
obesity syndrome similar to that of the genetically obese hyperglycaemic mouse. 
Chemicals such as gold thioglucose and monosodium glutamate injected intraperitoneally
and into the brain respectively, can also damage the hypothalamus with similar results. | 
In the case of monosodium glutamate, injection completely abolishes growth hormone 
secretion. This results in the induction of several P450 isoforms also induced in type I 
diabetes a disease associated with altered,growth hormone levels.
1.2.2 Animal models of type I diabetes mellitus
The study of animals displaying spontaneous diabetes has shown that the majority 
are models of type II diabetes. The lack of models for type I diabetes resulted in the use of 
chemically induced diabetes and pancreatectomised animals. However, new models for 
this type of diabetes have been established in rodents and are now being used more widely 
to study this form of the disease.
Insulin-dependent diabetes is usually characterised by:
1. An abrupt onset of overt diabetes
2. Dependence on injected insulin to sustain life
3. Proneness to ketoacidosis
4. Massive lymphocyte infiltration around or in pancreatic islets
5. The appearance of islet antibodies and islet surface antibodies in 
the plasma
Chemically produced insulinopenic conditions are not always associated with 
dependence on insulin, lymphocytic infiltration or the production of islet cell antibodies in 
the plasma. Therefore, although these models display the main characteristics of type I 
diabetes, they are by no means completely representative of all the pathophysiological 
conditions.
To date only two spontaneously diabetic animal models of type I diabetes have 
been characterised for research. These are the Bio-Breeding (BB) Wistar rat (Marliss et  
al, 1982) and the non-obese diabetic (NOD) mouse (Tochino, 1987).
The spontaneously diabetic BB rat
The spontaneously diabetic BB rat was discovered in 1974 (Chappel, 1983), in a
commercial breeding laboratory (the Bio-Breeding laboratories, Ottawa, Ontario). The 
strain appears very susceptible to pulmonary and other infections by common varieties of 
bacteria, mycoplasma and viruses. Two major factors are involved in the insulitis, a genetic 
and an immunological component, with multiple lines of evidence suggesting that altered 
immunity is involved in the aetiology of the syndrome.
Overt insulin-dependent diabetes occurs from 40-140 days with a mean age at onset 
of glucosuria of about 90 days. From onset the animals are dependent on exogenous insulin for 
survival. The dramatic feature of this form is the rapidity of progress from normal to 
grossly diabetic, with a time course measurable in hours to days (Nakhooda et al, 1978). 
Typically, hyperglycaemia (20-30mM), polyuria and polydipsia (100ml/day) and 
ketonuria (2-3mmol/day), weight loss and dehydration develop. The state is accompanied 
by hypoinsulinaemia (detectable within 4-8 days) and relative or absolute 
hyperglucagonaemia. Urea nitrogen and 3-methylhistidine excretion double, renal 
ammoniagenesis increases 6-fold (Nakhooda et al, 1980) and elevations in the levels of 
blood branched chain and other amino acids occur (Nakhooda et al, 1977). In contrast to 
human diabetes, blood alanine is normal and it is the glutamine levels that are elevated.
The BB rat also exhibits similar diabetic complications to those encountered in  
human diabetic patients such as retinopathy and neuropathy. The BB rat appears to be the 
most appropriate, currently available, model for the study of both acute and chronic 
metabolic alterations and complications associated with type I diabetes m ellitus (Marliss 
et al., 1982; Shafirir et a l ,  1988)
1.2.3 Chemically-induced Type I diabetes mellitus
The relatively recent discoveries of the BB rat and the NOD mouse models of type I 
diabetes will prove invaluable models for investigating the pathogenesis of the disease in 
humans. Although more relevant to human insulin dependent-diabetes, the spontaneously 
diabetic models have not been extensively used. This has been largely due to the limited 
supply of the animals, their expense and the intensive care that they require. The more 
commonly used models are induced by chemical means. The two most frequently employed 
diabetogens are streptozotocin and alloxan, although alloxan is now infrequently used 
because of its extrapancreatic toxicity.
Alloxan
The diabetogenic effect of alloxan was first discovered by Dunn et ah, (1943) while 
investigating the nephrotoxicity of a series of uric acid derivatives including alloxan. 
Alloxan (2,4,5,6, tetraoxohexahydropyrimidine) is an unstable and reactive compound 
that exists in several tautomeric forms (Figure 1.1). Alloxan is readily reduced to dialuric 
acid (Rerup, 1970).
Streptozotocin
Streptozotocin (Figure 1.1), the common name for 2-deoxy-2-(3-methyl-3-
nitrosoureido)-D-pyranose, is an antibiotic isolated from Streptomyces achromogens. This 
agent has antibacterial and antitumor properties, as well as being carcinogenic and 
diabetogenic.
The mechanism of alloxan and streptozotocin diabetogenicity
The alloxan-dialuric acid coupling consumes oxygen and produces hydrogen 
peroxide when a reducing agent is present. The production of H2 O2 , attributed to the
Figure 1.1 The two most commonly used diabetogenic agents and their possible 
reactive intermediates.
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quinone structure of alloxan (Dunlin et al., 1983), can be inhibited by superoxide dismutase, 
catalase and hydroxyl scavengers such as benzoate and ethanol, suggesting that the Haber- 
Weiss reaction is the source of the hydroxyl radicals (Dunlin et al., 1983). Alloxan-
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mediated production of free radicals and its interaction with glutathione has been 
investigated by Winterbourne and Munday (1989), who demonstrated that alloxan 
undergoes redox cycling producing H2 O2 . Alloxan reacted in small quantities with 
glutathione producing an unidentified adduct which gradually accumulated. Thus, the 
mechanism of alloxan toxicity depends on its ability to produce free radicals, but the 
question remains as to why the P-cells of the pancreas are so highly susceptible to alloxan 
toxicity. One possibility is selective uptake of alloxan, although in vivo studies have 
shown that the liver takes up alloxan as rapidly and extensively as the P-cells but is 
resistant to its toxicity. There is evidence for higher concentrations of alloxan produced 
reactive oxygen species within P-cells than in other tissues. Malaisse (1982) concluded that 
both the capacity to take up alloxan and the sensitivity to oxygen species must be taken 
into account when examining tissue susceptibility to alloxan. Therefore, the P-cell 
susceptibility to alloxan may be due to the accumulation of alloxan in the cells and the 
poor ability of these cells to protect themselves against the deleterious effects of the 
generated reactive oxygen species (Malaisse-Lagae et al, 1981).
Streptozotocin contains a glucose moiety which is responsible for its selective 
uptake by the p-cell. Without this moiety little P-cell toxicity occurs (Anderson et a l,  
1976). Once within the p-cell it is believed that streptozotocin is metabolised by scission of 
the 2’-carbon and the methyl nitrogen. The N-nitrosoureido moiety is retained in the cell 
causing the cytotoxicity (Karunanayke et a l ,  1975a, 1975b). This moiety is believed to 
break down into the methyl carbonium ion (Calabresi and Parks, 1980) or methyl radical 
(Uchigata et a l ,  1982) which can alkylate and cross-link DNA. The DNA damage 
activates the enzyme poly (ADP-ribose) synthetase which is involved in DNA repair and 
requires NAD+ (Wilson et al, 1984). Activation of this enzyme may deplete the cellular 
levels of NAD+ leading to cytotoxicity. Inhibitors of this enzyme have prevented the 
decrease in cellular NAD+ following streptozotocin administration and furthermore, 
treatment of animals with nicotinamide before and during streptozotocin treatment has 
also protected against the toxicity of the diabetogen (Dunlin et a l ,  1969; Schein et a l.
1967). Work by Okamato and Yamamoto (1983) has shown that poly (ADP-ribose) 
synthetase inhibitors did not prevent strand breaks from occurring, but that these inhibitors 
did prevent diabetes. Therefore, p-cells may survive with residual DNA damage within 
their genome and it has been reported that even after a year following the combined 
administration of alloxan or streptozotocin with poly (ADP-ribose) synthetase inhibitors, 
diabetes did not develop.
A variety of free radical scavengers have been reported to protect against the 
diabetogenic effect of streptozotocin, but not all of the findings are consistent (Boquist 1989; 
Oberley 1988). However, it is possible that if the target of free radicals or reactive 
intermediates generated by alloxan or streptozotocin respectively, is the DNA, then a 
common mechanism involving poly (ADP-ribose) synthetase activity could explain the 
toxicity of these compounds to the cell. This coupled with selective uptake of streptozotocin 
by the P-cell and the poor ability of the p-cell to protect itself against reactive species may 
explain the diabetogenicity of these compounds (Oberley, 1988).
1.3 Hepatic drug metabolism
The evolutionary success of all species is dependent on the ability to adapt to an 
ever changing environment. Since the first animals inhabited the land they have been 
exposed to a multitude of different environmental chemicals. The necessity to utilise some 
of these chemicals and effectively detoxify others has led to the development of highly 
complex enzyme systems within present day animals. Man in particular is exposed to a 
plethora of diverse chemical agents in the air he breaths, the food he eats and the water 
he drinks. Of major concern has been occupational exposure to many natural and man-made 
chemicals used routinely in industrial processes, some of which have been associated with 
human cancer.
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All xenobiotics once introduced into the body, either deliberately or accidentally, 
undergo metabolism predominantly in the liver. The metabolism of xenobiotics can be 
largely divided into two distinct processes; those involving primarily oxidation of the 
compound (Phase I metabolism) and those associated with the conjugation of the Phase I 
metabolite with endogenous substrates such as glucuronic acid, sulphate, some amino acids 
or glutathione (Phase II metabolism). In general, the resulting metabolite conjugate is much 
more polar than the parent compound, thus facilitating its excretion in the urine and bile 
(Brenner, 1977).
Although xenobiotic metabolism primarily results in the detoxification or 
deactivation of compounds, there are occasions when metabolism can result in the 
production of reactive intermediates, a process termed "bioactivation". Many chemicals 
requiring bioactivation are quite often chemically inert per se and biologically innocuous 
but are rendered highly toxic by normal xenobiotic metabolism (Guengerich and Lieber, 
1985). Most reactive intermediates pos^s an electrophilic character and-readily attack the 
nucleophilic centers of cellular molecules by non-enzymic and covalent interaction (Miller 
and Miller, 1976). At particular risk are the sulphydryl groups of functional proteins and 
the purine and pyrimidine bases of DNA. Alternatively, these intermediates may react 
with molecular oxygen producing free radicals which can then initiate lipid peroxidation 
or attack the DNA. The interaction of these intermediates with critical cellular 
macromolecules can result in cytotoxicity, immunotoxicity, mutations and cancer if not 
prevented by the cell (Figure 1.2; Heidelberger, 1975).
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The cell has several defence mechanisms towards reactive intermediates and free 
radicals including; deactivation by non-functional nucleophilic conjugating species, such as 
glutathione, catalysed by glutathione-S-transferases and the presence of catalase and 
superoxide dismutase to deactivate hydrogen peroxide and the superoxides respectively. 
Obviously, the levels of cellular conjugating species and enzymes will determine the 
ability of the cell to protect itself against the cytotoxic actions of such species (Guenthner 
and Oesch, 1981).
The reactive intermediates produced by the bioactivation of xenobiotics, although 
a serious problem, are not usually the predominant species resulting from metabolism. The 
reason is that a single compound may have many different possible metabolic products of 
which only a few may be biologically reactive. Therefore, the amount of reactive 
intermediate formed will be dependent on the rate of the competing pathways of 
bioactivation and detoxification. It can be concluded, that the toxicity of a compound is not 
simply a consequence of its molecular structure and physicochemical properties alone, but 
also of the enzyme complement of the exposed animal. These enzymes systems are 
predominantly under genetic control but can be modulated by a number of factors including; 
environmental compounds (Alvares, 1979), nutritional status (Campbell and Hayes, 1974) 
and disease (Kato, 1977). Such factors can disturb the delicate balance between the 
bioactivating and detoxifying systems and thus the response to chemical toxins and 
therapeutic agents. An impairment of drug metabolism can result in accumulation of the 
drug with adverse responses on repeated administration, whereas stimulation of 
metabolism can lead to a reduced response or complete abolition of the desired 
pharmacological effect.
Perhaps the most dramatic alterations in metabolism are encountered during 
disease, especially those which compromise hepatic function directly such as, hepatitis, 
cirrhosis of the liver and hepatocarcinoma. The complex interactions of various endogenous 
regulatory chemicals are disturbed producing pronounced modulation of xenobiotic
13
metabolism. Exposure to toxic chemicals during disease, even those of normally low 
toxicity, can have prolonged and sometimes fatal consequences. Even diseases which are not 
necessarily associated with liver dysfunction, such as diabetes mellitus have also been 
shown to perturb xenobiotic and endogenous metabolism. This is presumably due to the fact 
that the enzymes systems associated with xenobiotic metabolism are partly regulated by 
the circulating levels of endogenous substrates. One such enzyme ^stem is the cytochrome 
P450 mediated mixed-function oxidase system, probably the single most important enzyme 
system involved in xenobiotic metabolism.
The cytochrome P450-dependent mixed-fimction oxidase system
The cytochrome P450 system is actively involved in the endogenous metabolism of a 
variety of substrates such as; fatty acids, vitamins, bile acids, prostaglandins and steroids 
(Yang and Lu, 1987). However, it is the involvement of this system in the metabolism of 
almost every xenobiotic that has initially aroused the most intense interest.
The key enzymic components of the system are the flavoprotein NADPH- 
cytochrome P450-oxidoreductase and the haemoprotein cytochrome P450. After the initial 
characterisation of the haemoprotein by Omura and Sato (1961), it became evident through 
further purification efforts that multiple forms of cytochrome P450 existed in mammals and 
other species. These different isoforms of cytochrome P450 had different, often overlapping 
substrate specificities. Most cytochrome P450 mediated metabolism results in the insertion 
of one atom of oxygen, from atmospheric 0%, into the substrate. Depending on the particular 
reaction and the nature of the various unstable intermediates, different reactions can occur 
(Table 1.)
The net result of the multiplicity of the cytochrome P450's and their diverse and 
overlapping substrate specificities is the ability to metabolise a multitude of chemicals.
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thereby representing the major enzyme system involved in Phase I metabolism. The 
cytochrome P450 system also responds to environmental and endogenous substrates by being 
inducible by a wide variety of compounds including; phénobarbital, 3-methylcholanthrene, 
ethanol, clofibrate and pregnenolone-16 a-carbonitrile (PCN). Each inducing agent is now 
known to exert a characteristic impact on both the induction of total cytochrome P450 and 
the levels of specific isoforms. Furthermore, with certain inducing agents, the overall 
amount of cytochrome P450 may not be altered because some of the isoforms may be induced 
as others are concomitantly repressed. In addition, some forms of cytochrome P450 are 
refractory to all known inducing agents, termed constitutive cytochrome P450, which are 
largely active in endogenous metabolism. The cytochrome P450 content can also be modified 
by age, sex, diet and state of health, and being so intricately involved in Phase I 
metabolism provides some explanation for the differences observed in xenobiotic 
metabolism associated with these factors.
The cytochrome P450 gene family so far consists of 13 gene families, including two 
bacterial, two yeast, one insect and eight vertebrate families ( Nebert and Gonzalez,1985). 
The gene families are designated by Roman numerals beginning with I and with gaps being 
left in the family numbers to allow for the addition of newly discovered gene families. Sub­
families are denoted with sequential capital letters and genes within a sub-family by 
sequential Arabic numerals (Table 2 ).
Families I through IV primarily code for catabolic enzymes found in the liver and 
to some extent in extrahepatic tissues, whereas families XVII, XIX, XXI and XXII code for 
the cytochrome P450's involved in steroid biosynthesis. Gonzalez (1989) and Nebert and 
Gonzalez (1987) have recently reviewed the current concepts of cytochrome P450 evolution, 
structure, function and regulation.
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Table 1. Reactions of the cytochrome P450 mixed-function oxidase system
Reaction Example
Aromatic hydroxylation
Aliphatic hydroxylation
Epoxidation
N-Dealkylation
O-Dealkylation
S-Dealkylation
N-Oxidation
S-Oxidation
Phosphothionate oxidation 
Dehalogenation 
Alcohol oxidation
3-hydroxylation of lignocaine 
Phenobarbitone hydroxylation 
Epoxidation of benzo[a]pyrene 
N-demethylation of diazapam 
Dééthylation of ethoxyresorufin 
Deamination of amphetamine 
N-oxidation 2-acetylaminofluorene 
S-oxidation of chlorpromazine 
Oxidation of parathion 
Dehalogenation of halothane 
Oxidation of ethanol
Gibson and Skett (1986)
1.4 Alterations of hepatic drug metabolism by type I diabetes 
mellitus
1.4.1 Phase I metabolism
It is now well documented that diabetes mellitus induced by streptozotocin or 
alloxan is associated with alterations in the hepatic metabolism of xenobiotics. Dixon e t  
al. (1961) first reported the prolonged sleeping time of animals to hexobarbital and the 
decreased metabolism of chlorpromazine and codein after treatment with alloxan.
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Subsequent studies showed a general depression of the metabolism of numerous substrates 
including; the N-demethylation of aminopyrine (Chawalit et al.,1982; Reinke et al.,1978; 
Toda et a l, 1987), benzphetamine (Watkins et a l, 1988) and ethylmorphine (Peng et a l, 
1983); the hydroxylation of benzo[a]pyrene, phenylbutazone and zoxazolamine are also 
depressed (Ackerman and Leibman, 1977; Kato and Gillette, 1965; Dajani and Saheb, 1974).
Further studies revealed that in chemically-induced type I diabetes mellitus the 
metabolism of some compounds was enhanced by the diabetic state. These included; the 
hydroxylation of aniline and the O-demethylation of p-nitroanisole, O-deethylation of 7- 
ethoxycoumarin and the N-demethylation of dimethylnitrosamine (Toda et a l,1987; 
Luangingkasoot e ta l, 1988; Al-Turk et a l, 1980; Peng et a l, 1983). Interestingly Eacho and 
Weiner (1980) found a decrease in aniline hydroxylation and p-nitroanisole déméthylation 
in hepatocytes isolated from streptozotocin diabetic rats, although this may be due to the 
rapid conjugation of the phase I metabolites within the hepatocytes.
Chemically-induced type I diabetes has not only been associated with alterations 
of xenobiotic metabolism, but also endogenous steroid and vitamin metabolism. The serum 
levels of 1,25-dihydroxy vitamin Dg are reduced but as the levels of 25-hydroxy vitamin Dg 
are unaffected it appears that it is the 1 -hydroxylase activity of the kidney that is 
impaired in diabetes. Steroid hydroxylation has also been shown to be impaired in both 
hepatocytes (Hussin and Skett, 1988) and microsomal preparations (Skett, 1986; Reinke et 
a l, 1978).
Modulation of the cytochrome P450 mixed-function oxidase system by type 
I diabetes.
The involvement of the cytochrome P450 system in the metabolic modifications 
associated with type I diabetes was first documented by the studies of Past and Cook (1980,
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1982) who isolated a diabetes-inducible cytochrome P450, subsequently termed P450j in the
rat and P4503a in the rabbit (Ryan et al, 1986) but now termed P450 IIEl. This isoform of
P450 has been shown to have a high turnover rate for aniline hydroxylation and 
dimethylnitrosamine déméthylation. The isoform has been isolated and characterised
from both alloxan and streptozotocin induced animals and is also inducible by a variety of
small molecules such as ethanol (Ryan et a/,1986), isoniazid (Ryan et a l, 1985) and acetone
(Koop et al., 1985) as well as some physiological states such as fasting (Lorr et al, 1984).
There is evidence that other families of cytochrome P450 are modulated by type I 
diabetes mellitus including; P450 lA, P450 IIB, families (loannides et a l, 1988; Flatt et a l,  
1989). Sex dependent alterations in the levels of specific constitutive forms of
cytochrome P450 involved in steroid hydroxylase activity have also been characterised 
(Favreau and Schenkman, 1988a) and it has also been suggested that type I diabetes is 
associated with an increase in the microsomal FAD-monooxygenase (Rouer et a l, 1987), an 
enzyme system also involved in xenobiotic metabolism.
In drug metabolism studies employing the BB rat, usually at 4 months of age, and 
removing their insulin therapy for four days, changes similar to those observed in 
streptozotocin- and alloxan-treated animals have been reported, including; increases in the 
activities of aniline p-hydroxylase and dimethylnitrosamine N-demethylase and a 
concomitant increase in the levels of cytochrome P450 IIEl (Favreau and Schenkman, 1988b; 
Bellward et a l, 1988; Dong et a l, 1983). From the data available for the spontaneously 
diabetic rat it appears that there is a good correlation with the metabolic alterations 
induced by alloxan or streptozotocin.
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1.4.2 Phase II Metabolism
The major conjugating reactions of phase II metabolism have been investigated in 
both alloxan and streptozotocin diabetic rats and mice. The effects appear to be substrate 
specific suggesting that there is specific induction of certain isoforms of the major 
conjugating enzyme families, as already indicated with respect to the mixed-function 
oxidase system.
UDP-Glucuronosyl transferase
The UDP-glucuronosyl transferase activity towards 1-naphthol, testosterone and 
phenacetin has been shown to be suppressed in type I diabetes, whereas the activity 
towards diethylstilboestrol and oestrone was unaffected (Watkins and Klaassen, 1988; 
Grant and Duthie, 1987; Younes et a/.,1980). In the case of p-aminophenol there are 
conflicting reports, Hinohara (1974) found increased conjugation while Morrison and 
Hawksworth (1984) reported a decrease. Similarly, in hepatocytes isolated from 
streptozotocin- or alloxan-diabetic rats there was decreased glucuronidation of 1 - 
naphthol and phenolphthalene / (Grant and Duthie, 1987) due to decreased levels of UDP- 
glucuronic acid. However, Eacho et a l, (1981), also using isolated hepatocytes, reported 
that the accelerated formation of UDP-glucuronic acid was responsible for the increased 
UDP-glucuronic acid conjugation of p-Nitroanisole and p-Nitrophenol.
2 0
Glutathione-S-transferase
The role of glutathione conjugation in the deactivation of reactive intermediates 
has led to active investigation of both the levels and activities of glutathione-S- 
transferase. The activity towards ethracrynic acid and sulphobromophthalein conjugation 
was decreased (Watkins et al.,1987) as well as the conjugation of l-chloro-2,4- 
dinitrobenzene in both hepatocytes and cytosolic preparations from streptozotocin-diabetic 
rats (Grant and Duthie, 1987; Watkins et a l,1988). In contrast Rouer et al. (1981) found that 
the streptozotocin-treated mouse displayed an increased conjugating capacity towards this 
substrate. However, this increase may have been diabetogen modulated since it was not 
prevented by simultaneous administration of nicotinamide and not induced in alloxan- 
treated animals (Agius and Gidari, 1985). No alteration was found when epoxy-p- 
nitrophenoxy propane was the substrate for glutathione-S-transferase in streptozotocin 
induced animals (Younes et a l, 1980)
It would appear that specific isoforms of the glutathione-S-transferase are either 
induced of repressed by diabetes, or that the cellular levels of glutathione are affected. 
The levels of reduced glutathione have been investigated by Hassing et al. (1979) and 
Younes et al. (1980) who found a decrease in cellular levels of glutathione in streptozotocin- 
treated animals. When Grant and Duthie (1987) examined the ability of hepatocytes 
isolated from streptozotocin animals to resynthesise glutathione after cellular depletion, 
they observed that although the cellular levels were lower than normal, there was an 
increased ability to synthesise the tripeptide from L-methionine, indicating that the 
cystathionine pathway was more efficient in these animals. Hassing et al; (1979) has also 
found that the plasma of uncontrolled human diabetics contains a lower concentration of 
glutathione than normal individuals.
Other phase II enzymes such as epoxide hydrolase and sulphate conjugation have
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not been adequately studied. In streptozotocin-treated mice the hydrolysis of 
benzo[a]pyrene 4,5-oxide was increased (Rouer et al., 1981) whereas no alteration was 
evident when styrene oxide was employed. Thomas et al., (1989), investigating the 
cytosolic epoxide hydrolase activity in alloxan and streptozotocin-induced diabetic rats, 
found an increased activity and suggested that this may be due to the increased 
peroxisomal ^-oxidation occurring during diabetes.
Sulphate conjugation of 1 -naphthol was shown to be increased in hepatocytes from 
streptozotocin diabetic rats (Grant and Duthie, 1987).
Alterations of phase II metabolism in spontaneously diabetic animals has not been 
adequately studied to date, although on the evidence of phase I metabolism, it is probable 
that the alterations observed with streptozotocin and alloxan treated animals would be 
similar to those in the spontaneously diabetic animal.
1.4.3 Extrahepatic metabolism in diabetes mellitus
Extrahepatic metabolism in diabetic animals has attracted little attention over 
the years with only a few published studies available. In streptozotocin-treated animals 
the O-deethylation of 7-ethoxycoumarin and the hydroxylation of benzo[a]pyrene was 
increased in the gastrointestinal tract but in contrast the pulmonary activities were 
decreased indicating that the effects of diabetes are organ-specific (Stohs et ah, 1979; Al- 
Turk et a t, 1980).
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1.4.4 Sex differences in the diabetes m ellitus induced alterations of 
hepatic drug metabolism
Sex differences in drug metabolising enzymes in type I diabetes have been 
identified in both chemically-induced and spontaneously diabetic rats. The 
déméthylation of aminopyrine is depressed in the male rat but elevated in the female and 
the activities of hexobarbital and aryl hydrocarbon hydroxylase activities are 
diminished only in males (Reinke et ah,1978; Reinke et ah, 1979; Kato et ah, 1970; Kato 
and Gillette, 1965; Warren et ah, 1983). Skett and Joels (1985) investigating the sex- 
dependent déméthylations of lignocaine and imipramine found that only the activity in 
the male was suppressed.
As is to be expected sex-differences are apparent in steroid metabolism, however, 
the effect of diabetes is to abolish the differences, with higher 7a-hydroxylase in the 
male resulting in activities similar to that of the female, whereas the 4a- and 6 p- 
hydroxylases and 17-oxosteroid reductase are suppressed, again resulting in activities 
similar to those of the female (Skett, 1986). All of these differences may be correlated to 
sex-specific alterations of the cytochrome P450 proteins in response to diabetes. Sex- 
dependent responses to streptozotocin accounting for the alterations appear unlikely as the 
characteristics and severity of the diabetes is similar in both male and female animals 
(Skett and Joels, 1985).
1.4.5 Alteration of hepatic drug metabolism in human diabetics.
The influence of type I diabetes on hepatic drug metabolism has been poorly studied 
in humans. The disease is effectively controlled by insulin therapy which has been
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extensively shown to alleviate the life-threatening symptoms and correct the metabolic 
alterations in animals. However, the metabolism of some compounds has been studied 
including; phenacetin and antipyrine which showed depressed metabolism although 
insulin corrected the alteration (Dajani et at.,1974; Murali et a l, 1983). Surprisingly, even 
in insulin corrected diabetes the plasma half-life of antipyrine was prolonged when 
compared to controls (Daintith et al., 1976). In vivo studies showed that hepatic 
cytochrome P450 levels were significantly higher in diabetics with normal livers when 
compared to control patients with normal livers (Salmela et aZ.,1980). It would appear, 
therefore, that even in effectively controlled diabetics the cytochrome P450 compliment is 
altered so as to impair the metabolism of antipyrine.
1.4.6 The effect of type I diabetes mellitus on chemical toxicity
The involvement of cytochrome P450 in the bioactivation of chemicals and the fact 
that diabetes modulates the levels of isoforms, makes it highly probable that the toxicity 
of various chemicals will be altered.
It has been known for some time that diabetic rats are more susceptible to the 
hepatotoxic effects of some haloalkanes such as; bromobenzene, carbon tetrachloride, 
chloroform, 1,1,2,-trichloroethane and other hepatotoxins (Watkins et al., 1988, Hanasono 
et al., 1975). The induction of cytochrome P450 IIEl, capable of catalysing the production of 
the trichloromethyl radical from carbon tetrachloride (Watkins et al., 1988, Brady et a l, 
1989) may explain this increased toxicity. The inducing effects of ethanol on this isoform 
has suggested that it may be this isoform which, in part, explains the increased 
hepatotoxicity of these haloalkanes following ethanol pretreatment (Maling et al., 1975, 
Traiger and Plaa, 1972). This cytochrome has also been shown to metabolise fluorinated
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anesthetics resulting in the release of fluoride ions which are known to be nephrotoxic 
(Pantuck et a l, 1987; Rice et a l, 1980; Hoffman et a l, 1989). In contrast. Price and follow 
(1982) found that the streptozotocin diabetic rat was more resistant to the hepatotoxic 
effects of paracetamol. The half-life of the drug was shorter in the diabetic rat (Price and 
follow, 1983) suggesting increased overall metabolism. They concluded that the diabetic rat 
had a greater capacity to conjugate the compound with glucuronic acid and sulphate, the 
major pathways of paracetamol metabolism, thus preventing the generation of the reactive 
species. This is an unexpected finding since the P450IIE1 and P450 IA2 proteins have been 
shown to catalyse the formation of the toxic metabolite (Raucy et a l, 1989) and both 
proteins are induced by diabetes (loannides et a l, 1988). The effects of ethanol 
pretreatment on paracetamol toxicity has also been investigated in mice where, in contrast 
to diabetes, it was found to potentiate hepatotoxicity (Peterson et a l, 1980).
Diabetes also increased the metabolism of benzene (Johansson and Ingelman- 
Sundberg, 1988), accelerated the cellular depletion of glutathione after menadione 
administration to hepatocytes from streptozotocin-diabetic rats (Grant and Duthie, 1988) 
and modified the metabolism of diethyl ether (Brady et a l, 1988).
Perhaps the most significant effect of diabetes is the potentiation of the 
dimethylnitrosamine hepatotoxicity (Lorr et a l, 1984). Cytochrome P450 IIEl has been 
'^associated with the ability to N-demethylate dimethylnitrosamine, presumably through 
unstable intermediates of N-hydroxylation, causing bioactivation of the compound (Tu and 
Yang, 1985). The metabolism of several nitrosamines by P450 IIEl has been investigated 
with the isoform displaying a range of activities towards the various substrates (Peng e t 
a l, 1983). The pretreatment of mice with ethanol has been associated with a marked 
enhancement of the mutagenicity of dimethylnitrosamine in in vitro mutagenicity assays 
(Glatt et a l, 1981) and hepatic subcellular fractions from streptozotocin-diabetic rats have 
shown an increased propensity to bioactivate known chemical carcinogens (Flatt et at., 
1989). These studies lend support to the suggestion that human diabetics may be at higher
25
risk to the toxicity of environmental chemicals because of the induction of the P450 IIEl 
isoform of cytochrome P450.
1.5 Mechanism of the diabetes-induced modulation of chemical 
metabolism and toxicity
It would appear that the modulation of the cytochrome P450 isoforms can explain
most of the metabolic alterations associated with diabetes mellitus. The mechanism of this 
modulation is still unclear although several theories have been postulated.
Type I diabetes is accompanied by many severe physiological abnormalities 
including;
1. Hyperglycaemia
2. Hypoinsulinaemia
3. Hyperketonaemia
4. Reduced growth hormone secretion
5. Alterations in endogenous androgens and other 
hormones.
Hyperglycaemia and its effects on drug metabolism were studied by Ackerman and 
Leibman (1977) who showed that prolonged infusion of glucose, failed to modify drug 
metabolism, and chronic hyperglycaemia actually resulted in a decrease of some activities 
such as aniline hydroxylase (Hartshorn et a t,1979). The investigation of compounds that 
induce cytochrome P450 IIEl revealed that acetone was one of the most potent inducers and 
that other physiological states such as fasting were also accompanied by increases in P450
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IIEl (Mehendale et a l, 1977; Lorr et al., 1984). This suggests that ketone bodies may be 
responsible for the modification in the cytochrome P450 isoforms. The major ketone bodies 
are acetoacetate and 3-hydroxybutyrate formed from the partial oxidation of free fatty 
acids in the mitochondria. Acetoacetate equilibrates with 3-hydroxybutyrate and both are 
released into the blood stream. Acetone is formed from the non-enzymic decarboxylation of 
acetoacetate. When carbohydrate utilisation is impaired and free fatty acid levels rise, 
due to increased lipolysis, ketones form the third most important blood borne energy fuel for 
extrahepatic tissues after glucose and free fatty acids. The primary physiological role of 
ketones is to serve as substrate in the brain, a tissue that does not take up free fatty acids. 
So during carbohydrate deprivation, as in type I diabetes, ketone bodies limit the 
expenditure of glucose in the brain and spare proteins which would otherwise be 
catabolised.
Bellward et a l, (1988) suggested that ketones were probably the most important 
inducer of cytochrome P450 IIEl although the modulation of other cytochrome P450 
families by these compounds has not been investigated. The hypoinsulinaemic state also 
effects the levels of other hormones in the diabetic animal, some of which may themselves 
play a role in the regulation of cytochrome P450 levels. It is highly probable that the 
mechanism of modification of metabolism cannot be attributed to a single specific 
parameter but is the result of the concerted effects of many factors.
1.6 Alterations of hepatic drug metabolism by type II diabetes 
mellitus
The influence of type II diabetes on hepatic drug metabolism appears to be much 
less pronounced. No major differences in mixed-function oxidase activity or glutathione-S- 
transferase activity between genetically diabetic (dhjdh) mice, genetically obese
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hyperglycaemic (ob/ob) mice and their respective controls were observed (Rouer et a l, 
1981; Rouer and Leroux, 1980; Herberg, 1988).
Aims of the Project
Previous work has suggested that insulin-dependent diabetes mellitus is associated with 
altered metabolism of various drugs predominantly metabolised in the liver. As a number of 
these drugs are metabolised by the cytochrome P450-dependent mixed-function oxidase 
system, initial research will investigate the hepatic levels of five inducible cytochrome 
P450 isoforms in various animal models of type I diabetes mellitus. These studies will also 
investigate the any sex-dependency for the alteration in these isoforms and also the 
propensity of hepatic fractions from these diabetic animals to bioactivate known chemical 
carcinogens using the Ames mutagenicity assay.
Further work will aim to establish the physiological mechanism responsible for these 
alterations in cytochrome P450 levels particularly the role of the elevated levels of ketone 
bodies accompanying type I diabetes mellitus.
Finally, other disease states where abnormal circulating insulin levels are present with be 
investigated in respect to hepatic drug metabolism. It is envisaged that these studies will 
concentrate on the effects of hyperinsulinaemia.
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Chapter 2
Materials and M ethods
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2.1 Materials
Molecular Probes, Eugene, OR., USA Ethoxyresorufin, pentoxyresonifin, resorufin.
BDH Chemicals, Poole, Dorset.
Sigma Chemicals, Poole, Dorset.
National Diagnostics, Aylesbury, 
Bucks.
Ammonium acetate. Aniline HQ, Acetic add. 
Ammonium persulphate. Sodium dithionite. 
Potassium cyanide. Hydrochloric add. Sodium 
hydroxide. Copper sulphate (Pentahydrate), 
Potassium sodium tartrate. Sodium carbonate. 
Sodium hydrogen carbonate. Magnesium chloride. 
Acetyl acetone. Hydrazine, Formaldehyde, 
Glycerol, Mercaptoethanol, Glycine, Sodium 
chloride. Potassium dihydrogen orthophosphate. 
Disodium hydrogen orthophosphate. Potassium 
chloride. Potassium hydroxide, 4-Nitrocatechol, 
Agarose, isoamyl alcohol.
Cytochrome c (Grade IV ), NADPH (Grade I), 
NADP (Grade I ), Tris buffer, NADH (Grade HI), (3- 
D-hydroxybutyrate dehydrogenase (Grade II ), 
Glucose-6 -phosphate (Grade I ), Glucose-6 - 
phosphate dehydrogenase (Grade XXIII), NAD+ 
(Grade TV ), Lauryl sulphate, Bromophenol blue, 
N,N,N',N'-Tetramethylethylenediamine, Triton 
X-100, 3,3-Diaminobenzidine, Peroxidase labelled 
Donkey anti-sheep. Peroxidase labelled Goat anti­
rabbit, MOPS buffer. Glutathione reductase (Grade 
IV), 5,5'-dithiobis-(2-nitrobenzoic acid), Laurie 
acid, p-Nitrophenol, Folin-Ciocalteau phenol 
reagent. Rabbit anti-human growth hormone 
antibody, Nitrosopiperidine,
Nitrosopyrrolidine.
Acrylagel, Bis-Acrylagel.
Anderman 6  Co Ltd. 
Kingston-on-Thames, Surrey.
London Analytical and 
Bacteriological Media Ltd, Salford, 
Lancs.
Nitrocellulose sheets. 
Lab M Agar.
Gibco, Paisley, Scotland.
Oxoid, Ltd., Basingstoke, 
Hampshire.
Wako Fine Chemicals, 
4040 Neuss 1 , FRG.
Vogel Bonner E plates. 
Oxoid No. 2  Nutrient broth.
Glu-P-1, Trp-P-2, Trp-P-1
Antibodies to P450 BB and P450IV family were generously supplied by Dr. G.G. Gibson, 
University of Surrey, those to P450 IDA by Dr. C.R. Wolf Imperial Cancer Research Fund, 
Hugh Robson Building, George Square, Edinburgh and antibodies to P450 DE by Dr D Koop, 
Dept. Environmental Health Sciences, Case and Western School of Medicine, Ohio, USA.
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2.2 Methods
2.2.1 Animals and animal pretreatment.
Male and female wistar albino rats (180 - 200g) were purchased from the Animal
■ ■ 1
Breeding Unit, University of Surrey. The animals were housed in cages with softwood ; 
sawdust bedding, being allowed food (Sprats Animal Diet Nol) and water ad libitum. A 12 i
hour light, 12 hour dark cycle was in operation (0700 - 1900) light at 220C and 50% j
:  ^ I
; humidity. ----------------------------------------------           _  I
2.2.2 Preparation of hepatic subcellular fractions
Hepatic subcellular fractions were prepared essentially as described previously 
(loannides and Parke, 1975); livers were immediately excised and washed in ice-cold 1.15% 
(w /v) KCl to remove excess blood. The livers were subsequently weighed, scissor-minced 
and homogenised in 3 volumes of ice-cold 1.15% (w /v) KCl using a motor driven Potter- 
Elvehjem glass teflon homogeniser. The homogenate was adjusted to 25% (w /v) by further 
addition of 1.15% (w /v) KCl and centrifuged at 9,000g for 20 minutes in a JA-17,14x50ml 
aluminium angle-headed rotor in a Beckman J2-21 centrifuge. The supernatant (S9 fraction) 
was decanted off and stored at -20 C^ until required. The S9 fraction was never stored for 
periods longer than 3 months.
Microsomal suspensions (105,000g pellet resuspended) were prepared from the S9 
fraction by centrifugation in a Beckman LS-7 ultracentrifuge with a 70Ti (12x10ml titanium 
angle-headed rotor) or a 65Ti (8x10ml titanium angle-headed rotor) at 105000g for 60 
minutes. The resulting 105,000g supernatant (25% cytosolic fraction), or the resuspended 
pellet (25% microsomal suspension), were used immediately.
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2.2.3 Microsomal Assays
Determination of microsomal and cytosolic protein
Microsomal and cytosolic protein were determined essentially as described by 
Lowry et al (1951) using bovine serum albumin (fraction V) as the standard.
Protein samples were diluted 1:20 for microsomes and 1:100 in the case of cytosol 
with 0.5M sodium hydroxide. Protein standards (0 - 500 pg bovine serum albumin per ml of 
0.5M sodium hydroxide) were prepared. Aliquots (0.5ml) of protein standards, blanks and 
samples were further diluted with 0.5ml of 0.5M sodium hydroxide. To each tube was 
added 5ml of freshly prepared "copper reagent" (1:1:100, Copper sulphate (1% w /v), 
potassium sodium tartrate (2 % w /v) and sodium carbonate (2 % w /v), and after mixing 
allowed to incubate at room temperature for 10 minutes. Folin-Ciocalteau phenol reagent 
was diluted with an equal volume of 0.5M sodium hydroxide, 0.5ml added to each tube and 
the solution immediately mixed. After a further incubation of 30 minutes at room 
temperature the absorbance of the blue solution was read at 720nm. The amount of protein in 
each sample was calculated from a standard curve.
Total cytochrome P450 determination
Microsomal cytochrome P450 was determined essentially as described by Omura 
and Sato (1964). Total cytochrome P450 was measured as the difference spectrum of the 
reduced cytochrome P450-carbon monoxide bound complex versus the reduced cytochrome
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P450 between 390-500nm using the Kontron Uvikon 860 spectrophotometer.
Microsomal suspension (25%) was diluted 1:6 with potassium phosphate buffer 
O.IM, pH 7.6 to give a final volume of 3ml, Following reduction of cytochrome P450 by the 
addition of sodium dithionite (approximately lOmg) the diluted microsomes were divided 
between two 1.5ml disposable plastic cuvettes and a base line was recorded between 390- 
500nm. Carbon monoxide was then bubbled through the test cuvette (30 seconds at a rate of 
approximately 2 bubbles sec-t) and the difference spectrum recorded. The total cytochrome 
P450 content was calculated from the absorbance difference between A4 5 0  nm" 
employing an extinction coefficient of 91mM-  ^ cm-i- The necessity to store the liver samples 
as post-mitochondrial fractions (S9) at -20^C rather than as microsomal suspensions at - 
80^C resulted in lower values for total cytochrome P450 levels. This was consistantly 
observed throughout but was necessary in order to use the samples in the Ames test. It has 
also been shown that many of the chemicals used to stabilise microsomal P450 when 
freezing to -80^C, such as glycerol or dimethylsulphoxide are ubstrates for P450 IIEl and 
could have effected the determination of activity of this isoform in the samples.
Cytochrome bg determination
Microsomal cytochrome bg was determined essentially by the method of Omura and
Sato (1964). Cytochrome bg content was determined as the difference spectrum between the
dithionite-reduced and oxidised forms of the cytochrome.
Microsomes were diluted 1:6 with O.IM potassium phosphate buffer, pH 7.6 to give
a final volume of 3ml,, The microsomes were divided between two cuvettes and a baseline
obtained between 390-500nm. Sodium dithionite (approximately 5mg) was added to the
test cuvette and the difference spectrum recorded under aerobic conditions. The cytochrome
bs content was determined from the absorbance difference A426nm “ A4 ionm employing an
extinction coefficient of 185mM"^  cm-i-
NADPH-cytochrome c reductase activity
NADPH-cytochrome P450 reductase (EC 1 .6.2.4) was assayed by following the
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reduction of the non-physiological electron acceptor, cytochrome c (Williams and Kamin, 
1962), at 3 7 0 c  using a Varion/Caiy 2200 spectrophotometer. Into the reference and sample 
cuvettes the following reagents were added;
; Sample Reference 
(ml) (ml)
50mM Potassium phosphate buffer, pH 7.6
containing lOmM potassium cyanide. 1.8 1.9
O.lmM cytochrome c 1.0 1.0
Microsomal suspension (25%) 0.2 0.2
After a suitable preincubation period, to obtain a steady baseline, the reaction was 
initiated by the addition of 0.1ml of NADPH (SOmM in 1% w /v  sodium hydrogen 
carbonate) to the sample cuvette. The reduction of cytochrome c was followed at 550nm by 
recording the increase in absorbance. The concentration of the ferrous cytochrome c formed 
was calculated using an extinction coefficient of 18.5mM-^cm- .^
Aniline p-hydroxylase activity
The microsomal p-hydroxylation of aniline was determined essentially as
described by Guarino et al., (1969). The following reaction mixture was prepared in 
duplicate and incubated at 370C in a shaking water bath for 15 minutes. Standards 
containing O-lOOjiM p-aminophenol were also incorporated into the assay.
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0.3M Tris-HCl Buffer, pH 7.6 0.5ml
40mM Aniline hydrochloride, pH 7.6 0.5ml
lOOmM Magnesium chloride 0.1ml
10mMNADP+ 0.1ml
lOOmM Glucose-6-phosphate 0.1ml
Glucose 6-phosphate dehydrogenase (lOunits/ml buffer) lOOpl
Microsomal suspension (25%) ■ 0.5ml
The reaction was terminated by the addition of solid sodium chloride which causes 
the protein to precipitate out of solution and the product, p-aminophenol, extracted into 
ether (12ml) containing 1.5% (v /v ) isoamyl alcohol. Ether aliquots (10ml) were then added  
to 0.5M tri-potassium orthophosphate (4ml), to which phenol (1% w /v )  was added prior to 
use, and extracted for 30 minutes on a rotary shaker. The absorbance of the resulting blue 
aqueous solution was read at 620nm and enzyme activity was calculated with reference to 
the standards.
Dimethylnitrosamine N-demethylase activity
The determination of dimethylnitrosamine N-demethylase activity was based on 
the method of Holtzman et al. (1969). Formaldehyde standards (0-lOOp.M) and the 
following incubation mixtures were prepared:
50mM Potassium phosphate buffer, pH 7.2 0.6ml
150mM Magnesium chloride 0.1ml
NADPH generating system 0.1ml
Microsomal suspension (25%) 0.1ml
NADPH generating system : NADP+ (O.lmM), Glucose-6-phosphate (lOmM), Glucose-6- 
phosphate dehydrogenase (lOunits/ml in buffer).
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The reaction mixture was pre-incubated for 3 minutes and the reaction initiated by 
the addition of 0.1ml of dimethylnitrosamine (lOmM) to each tube. After a further 
incubation of 10 minutes the reaction was terminated by the addition of ice-cold 12.5% 
(w /v) trichloroacetic acid. The tubes were left on ice for 5 minutes and then centrifuged for 
10 minutes in a bench centrifuge to precipitate the protein. Supernatant (1ml) was added to 
freshly prepared Nash reagent (4M ammonium acetate containing 4m l/l acetyl acetone, 
1ml; Nash, 1953) and heated in a water bath at 500C for 10 minutes. After cooling 
absorbance at 412nm was recorded and the demethylase activity calculated with reference 
to the formaldehyde standards.
p-Nitrophenol hydroxylase activity
The hydroxylation of p-nitrophenol was followed essentially by the method of 
Reinke et al. (1985) as modified by McCoy and Koop (1988). The following were added to 
test tubes in duplicate.
0.2M Potassium phosphate buffer, pH 6.8 0.65 ml
Ascorbate (ImM) 0.1 ml
p-Nitrophenol (ImM) 0.1ml
Microsomal suspension (25%) 50)j1
The reactants were incubated for 3 minutes at 37^C in a shaking water bath and the 
reaction initiated by the addition of 0.1ml of NADPH (lOmM). After a further 10 minute
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incubation the reaction was terminated by the addition of 0.5ml of ice-cold 0.6N perchloric 
acid. The protein was precipitated by centrifugation at 3000rpm for 10 minutes. lOM 
Sodium hydroxide (0.1ml) was then added to 1ml of the supernatant and the solutions 
mixed. The absorbance was then read at 536nm using a Kontron Uvikon spectrophotometer. 
The p-nitrophenol hydroxylase activity was calculated from a standard curve (O-lOOfiM 4- 
nitrocatechol).
Erythromycin N-demethylase activity
The microsomal erythromycin N-demethylase activity was performed as described by 
Wrighton et a l, (1985b). To duplicate test tubes the following were added:
50mM Potassium phosphate buffer, pH 7.25 0.6ml
Magnesium chloride (150mM) 0.1ml
Erythromycin (lOmM) 0.1ml
Microsomal suspension (25%) i 0.1ml
The tubes were pre-incubated for 3 minutes at 37 OC and the reaction initiated by the 
addition of 0.1ml NADPH (lOmM). After a further 10 minute incubation the reaction was 
terminated by the addition of 0.5ml of ice-cold 12.5 % (w /v) trichloroacetic acid. The tubes 
were then centrifuged at 3000rpm for 10 minutes to remove the protein. The supernatant 
(1ml) was then added to freshly prepared NASH reagent (4M ammonium acetate contain 
4m l/l acetyl acetone). The tubes were heated in a water bath at 500C for 30 minutes and 
after cooling the absorbance was read at 412nm using a Kontron Uvikon spectrophotometer. 
The erythromycin N-demethylase activity was calculated from standards (0-100|iM
formaldehyde) which were run in parallel.
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Ethylmorphine-N-demethylase activity
Ethylmorphine N-demethylase was measured essentially by the method of Lu et 
a l, (1972) and was performed as for the erythromycin N-demethylase assay except that 
O.OIM ethylmorphine was used instead of O.OIM erythromycin and that the tubes were 
incubated at room temperature with the NASH reagent.
Laurie add hydroxylase activity
The microsomal activity of lauric acid co-hydroxylase was assayed essentially as 
described by Parker and Orton, (1980). The following reagents were prepared and aliquoted 
into test tubes;
Lauric add (ImM) 200|il
[14C] Lauric acid (lOpG/ml) lOpl
0.5M Tris-HQ Buffer, pH 7.4 1.65ml
Microsomal suspension (25%) lOOpl
The reaction was initiated by the addition of 40pl of NADPH (40mM) and the 
tubes incubated in a shaking water bath at 370C for 10 minutes. The reaction was 
terminated by the addition of 3M HCl (0.2ml) and the lauric add and its metabolites were 
extracted into ether (10 mis). The upper layer was removed and evaporated to dryness 
under nitrogen. The resulting residue was dissolved in 60 pi of methanol and 25|il spotted 
onto a silica gel G TLC plate. The plates were developed in a solvent system comprising 
hexane: diethyl ether: acetic acid (70:28:1) and the radioactivity determined using a
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Berthold LB2842 plate scanner. This method measures the 12- and 11-hydroxy metabolites 
of lauric acid. Therefore, the interpretation of this data may reflect the activities of 
several P450 isoforms which can hydroxylate lauric acid at either the 12 or 11 positions. It 
will not be evident which of these metabolites are affected by the treatments employed on 
the basis of this data.
Determination of alkoxyresorufin O-dealkylase activity
The method of Burke and Mayer (1974) was essentially used for the measurement
resorufin formation from ethoxyresorufin and pentoxyresorufin by microsomes from their 
respective dealkylation reactions.
The following reagents were added to a 3ml fluorimetric cuvette:
O.IM Tris-HCl buffer, pH 7.8 2.0ml
Microsomal suspension 50)il
0.53mM Ethoxyresorufin 3pl
or
l.OmM Pentoxyresorufin 5pl
All fluorimetric assays were performed using a Perkin Elmer LS5 luminescence 
spectrophotometer set to an excitation wavelength of 510nm and emission wavelength of 
586nm with excitation and emission slit widths of lOnm and 2.5nm respectively. A baseline 
was recorded prior to initiation of the reaction by the addition of lOpl of NADPH (50mM in 
1% w /v  sodium hydrogen carbonate). The reaction was monitored continuously until a 
measurable gradient was obtained (approximately 2 minutes) and the initial rate of the 
reaction calculated from the slope. The instrument was calibrated using aliquotes (lOpl) of 
resorufin (O.lmM)
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2.2.4 Cytosolic enzyme activities 
Total glutathione
Total glutathione was determined by the method of Akerboom and Sies (1981) at 
3 7 0 c  using a Varian/ Cary 2200 spectrophotometer. The cytosol was further diluted 50 fold 
with 1.15% (w /v) potassium chloride. Diluted cytosol (1ml) was added to 1ml of perchloric 
acid (2M) containing 4mM EDTA. 2M Potassium hydroxide (1ml) containing 0.3M MOPS 
was then added and the resulting solution adjusted to approximately pH 7. Glutathione 
standards (O.lmM - 0.8mM) were prepared and carried through the same procedure.
In a 4.5ml cuvette the#following were mixed:
O.IM potassium phosphate buffer, pH 7.0 and 
containing 2.5mM EDTA 1.0 ml
NADPH (4mg/ml in 1.0% (w/v) sodium hydrogen carbonate) 0.05ml
Glutathione reductase (6units/ml buffer) 0.02ml
Sample or standard 0.1ml
The reaction was initiated by the addition of lOOjil of 3.8mM 5,5-dithiobis(2-nitro)benzoic 
acid (DTNB) in 1% (w /v) sodium hydrogen carbonate and monitored at 412nm. The 
concentration of glutathione in the cytosol was calculated from a curve constructed using 
initial rates.
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Cytosolic glutathione-S-transferase activity
Glutathione-S-transferase activity in the cytosolic fraction was determined by an 
adaptation of the method devised by Habig et a l (1974).
1,2-Dichloronitrobenzene (DCNB) is a good substrate for many of the glutathione-S- 
transferase enzymes, with conjugation resulting in the formation of S-(2-chloro,4- 
nitrophenyl) glutathione. This reaction can be measured spectrophotometrically as an 
increase in absorbance at 340nm and is proportional to the enzyme activity in the sample.
The reaction was performed at 25^0 using a Varian/Cary 2200 split beam 
spectrophotometer with reference and sample cuvettes containing the following :
Sample Reference
(ml) (ml)
O.IM Sodium phosphate buffer, pH 73  1.8 1.9
25mM DCNB (in absolute ethanol) 0.1 0.1
5mM reduced glutathione 0.1 0.1
After recording a baseline, 0.1ml of cytosol, diluted 1:5 with buffer, was added to 
the sample cuvette, mixed and the change in absorbance measured at 340nm. All solutions 
were prepared immediately prior to use and kept on ice.
Glutathione-S-transferase activity was calculated from initial rate of the 
reaction, assuming a molar extinction coefficient of 8.5mM-^cm- .^
The glutathione-S-transferase activity towards 3,4-dinitrochlorobenzene (CDNB)
4 1
was also determined using the above protocol but substituting CDNB (25mM in ethanol) for 
DCNB and measuring the reaction at 340nm.
Glutathione reductase activity
The glutathione reductase activity of hepatic cytosol was performed as described
by Carlberg and Mannervik (1975). Cytosol was diluted a further 1:50 with O.IM sodium 
phosphate buffer, pH 7.5 containing 0.1% (w/v) EDTA.
The following reactants were placed into two cuvettes:
Sample Reference
Oxidised glutathione (17.5mM) 0.2ml
FAD (0.3mM) 0.1ml
Diluted cytosol 3.0ml 3.5ml
The reaction was initiated by the addition of 200pl of NADPH (2mM in 1% (w /v) 
sodium hydrogen carbonate) to the sample cuvette and the reaction monitored at 334nm 
using a Varian/Cary 2200 spectrophotometer. The glutathione reductase activity was 
calculated using the extinction coefficient of 4.3mM-^cm- .^
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2.2.5 Determination of plasma parameters
During all studies involving diabetic animals blood samples were collected from 
the tail vein at regular time intervals, during experiments and at time of death. Blood was 
transferred into heparinised blood vials and placed on ice. Plasma was obtained following 
the centrifugation of the heparinised blood at SOOOrpm and stored at -200C until required.
Determination of plasma glucose concentration
Plasma glucose was determined using a glucose analyser II by the method of 
Stevens et ah (1971). The method is based on the glucose oxidase reaction where an oxygen 
electrode is employed to determine the concentration of glucose in the test sample. The 
apparatus is calibrated with a known glucose standard.
Determination of plasma 3-hydroxybutyrate and acetoacetate 
concentrations
Plasma 3-hydroxybutyrate and acetoacetate were determined by a modification of 
the method of Li et aZ.,(1980). The method is based on the reversible reaction:
NAD"  ^ n a d h
CHq—CH -CH 2-CO O ' -----------  —  --------- ^  CH3— Ç — C H 2-C O O -
1 3-hydroxybutyrate II
OH dehydrogenase ^
3-Hydroxybutyrate Acetoacetate
NAD"  ^ N A D H
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The following reagents were added to cuvettes for the determination of 3-hydro?ybutyrate:
O.IM Tris-HCl buffer, pH 95 500pl
2.5mM NAD+ in buffer 480|il
Sample or test 20pl
The reaction was initiated by the addition of lOpl of hydroxybutyrate 
dehydrogenase (61.U.) and the change in absorbance at 340nm recorded for 30 seconds using 
a Kontron Uvikon spectrophotometer. Hydroxybutyrate or acetoacetate standards (sodium 
and lithium salts respectively) were prepared, 0-20mM, and the rate of reaction 
determined. The concentration of the ketone body was calculated from the respective 
standard rate curve. For acetoacetate determination SOOpl of O.IM potassium phosphate 
buffer, pH 7.0 and 480pi of 180pM NADH were used instead of the Tris-HCl buffer and 
NAD+ respectively.
2.2.6 The Ames Salmonella mutagenicity test
Mutagenicity was determined by the procedure of Maron and Ames (1983) with
slight modifications. All glassware and heat stable solutions were autoclaved at 1200C for 
20 minutes prior to use, and all experimental manipulations were performed in a class 2 
laminar flow cabinet.
The bacterial tester strains
Salmonella typhimurium strains TA98, and TA1530 were stored as permanent 
frozen cultures maintained at -800C using dimethylsulphoxide as the cryoprotective agent
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(0.8% v/v). When required an overnight culture was prepared from the respective frozen 
stock. This was achieved by inoculating nutrient broth containing ampicillin (25p.g/ml) for 
TA98 or nutrient broth without ampicillin for TA1530 with a platinum loop and incubating 
at 3 7 0 c  for 10 hours in a shaking water bath. The resulting culture was then used in the 
Ames test.
Testing for strain properties
The Salmonella tester strains contain different types of histidine mutations, with 
TA98 able to detect frameshift mutations and TA1530 able to detect base-pair substitutions. 
In addition to this mutation each strain has two other mutations which greatly enhance 
their susceptibility to mutagens. These are the loss of the excision repair mechanism (uvrB) 
and the inability to synthesise the lipopolysaccharide cell wall {rfa). In some strains, such 
as TA98, sensitivity has been further increased by the introduction of plasmid (pKMlOl), 
which confers both ampicillin resistance and an error-prone repair system to the bacteria.
Each new bacterial culture was tested for viability and spontaneous mutation rate. 
Cultures were also routinely checked to ensure that all strain characteristics were 
maintained.
Histidine requirement
A solution containing histidine and biotin (O.IM histidine and 0.5mM biotin),
0.1ml, was spread onto the surface of a Vogel Bonner plate and allowed to dry. An 
overnight bacterial culture was then streaked onto the plate as well as onto a histidine- 
free plate and these plates were then incubated overnight at 37^C. The histidine mutation
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was present if bacterial growth was observed only on the plate supplemented with 
histidine.
rfa mutation and R-factor detection
Bacterial culture (0.1ml) was added to 2ml of agar (agar 0.6%(w/v) and sodium
chloride 0.5% w /v  containing 5mM histidine and 25pM biotin) and immediately poured onto 
Vogel Bonner E plates. When the agar had solidified, a sterile filter paper disc (1cm 
diameter) was placed onto the center of the plate and either lOOpl of crystal violet 
(Img/ml), for the rfa test or lOOpl of ampicillin (8mg/ml in 0.02M sodium hydroxide) for 
the presence of plasmid, pipetted onto the filter paper. The plates were then incubated 
overnight at ST^ C and the presence of a zone of inhibition around the filter paper indicated 
the presence of either the rfa mutation or the plasmid.
Bacterial viability
The viability of an overnight culture was assessed by colony growth on agar (2ml) 
with a high histidine and biotin concentration (5mM histidine and 25pM biotin). The 
bacterial culture was serially diluted in nutrient broth to a final dilution of 1 in 10 .^ One 
hundred microlitres of the final dilution were then added to 2ml of agar and poured onto a 
Vogel Bonner E plate and incubated overnight at 370C. The total number of colonies were 
counted and the viability (number of bacteria/ml) of the original culture calculated.
Spontaneous reversion rate
The spontaneous reversion rate was tested during each Ames test by incorporating 
blanks (solvent replacing test compound) into the test. Typical spontaneous reversion rates
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fo r  T A 98  a n d  T A 1530  w ith  S9 a c tiv a tio n  sy s te m  a re  15 to  46  a n d  3 to  18 re sp e c tiv e ly .
The pre-incubation Ames test
Fresh overnight cultures were prepared as previously described and the following 
activation systems prepared:
10% 59 25% 59
(ml) (ml)
59 liver fraction 1.0 25
0.33M Potassium chloride 1.0 1.0
0.08M Magnesium chloride 1.0 1.0
0.02M Sodium phosphate buffer, pH 7.4 5.0 35
0.02M NADP+ and 0.025M Glucose-6-phosphate 2.0 2.0
Depending on the mutagen being used either a 10%S9 or 25%S9 activation system 
was employed.
2.2.7 SDS-PAGE and Western blotting analysis of microsomal 
cytochrome P450 proteins
Solubilisation of hepatic microsomal preparations
Solubilisation of the microsomal suspensions (25%) was achieved by the addition
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of 10|il of solubilisation buffer (O.IM potassium phosphate buffer, pH 7.4, containing 10% 
w/V sodium cholate and 2% w /v  Emulgen 911) for every mg of microsomal protein and 
mixing for 40 minutes at 40C. The preparations were then stored at -200C until required.
Discontinuous sodium dodecyl sulphate polyacrylamide slab gel 
electrophoresis of hepatic microsomal proteins.
The method devised by Laemelli (1970) was used for the separation process 
performed at room temperature.
Reagents
Lower Gel Buffer: 1.5M Tris-HQ, pH 8.8 containing
0.4% (w /v) sodium dodecyl sulphate (SDS)
Upper Gel Buffer: 0.5M Tris-HCl, pH 8.3, containing 0.4% (w /v) SDS
Electrode Buffer: 25mM Tris-HCl, pH 8.3, containing 192mM glycine
and 0.1% (w /v) SDS
Sample Buffer: 125mM Tris-HQ, pH 6.8, containing 4.6% (w /v) SDS, 
30% (v/v) glycerol, 0.002% (w /v) bromophenol blue and 
10% (v/v) P~mercaptoethanol.
Acrylagel:
Bis-Acrylagel.
Commercially available.
Commercially available.
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M e t h o d
A vertical slab gel apparatus constructed in the Biochemistry Department 
workshop was used. The gel was cast in a glass cassette, with perspex side and bottom 
spacers and held together with buU-dog clips. The dimensions of the cast gel were 120mm x 
110mm xl5m m .
The glass front and back plates were washed with Decon detergent, rinsed with tap
water and then distilled water and finally cleaned with acetone and left to dry. The 
cassette was assembled and sealed with 2% (w /v) molten agar and then clamped in a 
vertical position. The lower running gel was prepared as follows:
Lower Gel Buffer 6.25ml
Bis-Acrylagel 3.38ml
Acrylagel 8.11ml
Distilled water 7.14ml
Ammonium persulphate (10% w /v) 125fil
Polymerisation was initiated by the addition of 20ja.l of N ,N ,N ’N'-tetra- 
methylethylenediamine (TEMED). This amount was sufficient for one gel with final 
acrylamide concentration of 10% (w/v). The solution was poured into the cassette to a 
height of 8cm. A thin layer of distilled water was placed on top of the gel solution to ensure 
a flat interface between the lower and upper gels. Polymerisation of the lower gel was 
complete in approximately 30-40 minutes, at which time the layer of water was removed.
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was then prepared:
Upper Gel Buffer 2.5ml
Bis-acrylagel 0.4ml
Acrylagel 1.0ml
Distilled water 6.0ml
Ammonium persulphate (10% w / v) lOOpl
Again polymerisation was initiated by the addition of 20|il of TEMED and the 
upper stacking gel poured into the cassette above the lower running gel. A perspex comb was 
introduced into the upper gel to form the sample wells and after approximately 30 minutes 
the gel had polymerised. The final concentration of acrylamide in the upper stacking gel 
was 3% (w /v). The comb was removed and a small amount of electrode buffer was 
introduced into the sample wells to maintain their integrity. The bottom perspex spacer 
was removed and the cassette placed into the electrophoresis tank. The solubilised 
microsomes were diluted an equal volume of sample buffer to give a final protein 
concentration of 2mg/ml and boiled for 3 minutes in a water bath prior to loading into the 
sample wells. Electrode buffer was then placed in the upper and lower reservoirs of the 
tank, and any air bubbles trapped beneath the lower gel were removed with a clean 
syringe.
Electrophoresis was carried out immediately following sample loading at a 
constant current of 20mA using a Pharmacia EPS 500/400 power pack until the bromophenol 
blue band had migrated into the lower gel. The current was subsequently increased to 40mA 
until the bromophenol blue band had migrated to the lower edge of the lower running gel 
when the current was switched off. The cassette was removed from the electrophoresis tank 
and the glass plates separated. The lower gel was separated from the upper stacking gel 
and used for the transfer of proteins onto nitrocellulose paper for western blotting analysis.
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Western blotting
The following buffers were prepared:
Transfer Buffer:
Tris 2QmM
Glycine 15QmM
Methanol 15% (v/v)
Phosphate Buffered Saline :
Sodium chloride 8% (w/v)
Potassium dihydrogen orthophosphate 0.2% (w /v)
Disodium hydrogen orthophosphate 2.9% (w /v)
Potassium chloride 0.2% (w /v)
Wash Buffer:
PBS 10% (v/v)
Bovine serum albumin (fraction V) 1% (w/v)
Triton X-100 0.2% (v/v)
Substrate Buffer:
O.IM Tris-HCl, pH 7.5
5 1
M e th o d
The lower running gel was removed from the cassette and placed into transfer buffer
(50mls) for 30 minutes to allow the buffer to permeate the gel and replace the electrode 
buffer. During this time the gel will also shrink as it equilibrates with the transfer buffer. 
After equilibration the gel was removed and placed into the transfer cassette (figure 
2.3.3.1). The cassette is prepared under transfer buffer and all air bubbles removed by 
rolling with a test tube.
Figure 2.3.3.1 Transfer cassette construction
I
g
I
O
g
SCOTCHBRITE
FILTER PAPER
GEL
NITROCELLULOSE
FILTER PAPER 
SCOTCHBRITE
Once assembled the cassette was placed into the transfer tank with the 
nitrocellulose sheet closest to the positive electrode. The transfer was performed at a 
constant voltage of 60v for 1 hour after which time the cassette was opened and the 
nitrocellulose sheet placed into 50 mis of wash buffer and rocked for 2 hours. Depending on 
the cytochrome P450 proteins to be detected different primary and secondary antibodies 
were used (table 2.3.3.1). All primary antibodies were diluted to a final volume of 50 mis 
with wash buffer and placed onto the nitrocellulose sheet for 1 hour, after which time it 
was replaced with fresh wash buffer. Fifteen minutes later this was replaced with a 
second 50ml aliquot of wash buffer and the sheet washed for a further fifteen minutes. The
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peroxidase linked secondary antibody was then diluted in 50 mis of wash buffer and added 
to the nitrocellulose sheet for 1 hour. The nitrocellulose sheet was then washed twice with 
50mls of wash buffer for 15 minutes before the pre-substrate wash was added. The pre­
substrate wash (10% v /v  PBS) was left for 10 minutes before the substrate was added (50mg 
3,3 diaminobenzidine in 100ml of O.IM tris-HCl, pH 7.5 containing 20p.l 30% H2 O2 ) until the 
bands appeared. The reaction was terminated by washing the nitrocellulose sheet several 
times with copious quantities of ice-cold distilled water.
Table 2.3.3.1 Primary and secondary antibody information
P450 Family 
P450IA
P450 HE
P450IVA
P450 HB 
P450 niA
Primary antibodv
Sheep IgG 
1:10(X)0 dilution
Sheep IgG 
1:5000 dilution
Sheep IgG 
1:5000 dilution
Rabbit IgG 
1:2000 dilution
Rabbit IgG 
1:2000 dilution
Secondary antibodv
Peroxidase linked 
donkey anti-sheep 
IgG 1:2000 dilution
Peroxidase linked 
donkey anti-sheep 
IgG 1:2000 dilution
Peroxidase linked 
donkey anti-sheep 
IgG 1:2000 dilution
Peroxidase linked 
Goat anti-rabbit 
IgG 1:2000 dilution
Peroxidase linked 
Goat anti-rabbit 
IgG 1:2000 dilution
Antibodies to P450 lA l recognises both 1A1 and 1A2 proteins. Antibodies to P450 IIBl 
recognise both the B1 and B2 proteins as well as a third protein of lower molecular weight 
which is present in the liver of Wistar rats. Antibodies to P450I1E1 were a gift from Dr D  
Koop, Case and Western School of Medicine, USA and recognise a single protein, P450IIE1. 
Antibodies to cytochrome P450 IVA recognise two proteins of slightly differing molecular 
weight which correspond to P4504A1 and a secondary protein uncharacterised at present. 
Finally, antibodies to P450IIIA were supplied by Dr CR Wolf, Imperial Cancer Research 
Fund, Edinburgh and recognise several of the proteins in this family.
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Chapter 3
Hepatic drug m etabolism in Streptozotocin- 
induced type I diabetes m ellitus
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3.1 Modulation of hepatic mixed-function oxidase activity by 
streptozotocin-induced type I diabetes mellitus
Chemically-induced diabetes mellitus has been the primary model for the majority 
of investigations into the effects of the disease on drug metabolism. The use of 
streptozotocin as the diabetogenic agent has now replaced the use of the more toxic alloxan 
as the diabetogen of choice. Although, streptozotocin induces a form of diabetes that 
resembles the physiological alterations associated with human insulin-dependent 
diabetes, the effect of the diabetogen per se, as well as the disease state itself, on drug 
metabolism must be clearly established.
Many studies have established that streptozotocin-induced type I diabetes is 
associated with marked alterations of hepatic biotransformation (Dixon et al., 1963; 
Reinke et al., 1978). The metabolism of many of the compounds studied can be attributed to 
the cytochrome P450 dependent mixed-function oxidases and specifically to various 
families of that system. The identification of a diabetes-inducible isoform of cytochrome 
P450 (P450j in the rat or isozyme 3a in the rabbit) termed P450 UEl (Ryan et ah, 1986) has 
aroused much interest, especially as it has been associated with the activation of 
nitrosamines (Peng et al.,1983) and the ability to bioactivate paracetamol to its 
hepatotoxic metabolite (Raucy et a l, 1989). The bioactivation of paracetamol and some 
nitrosamines, although catalysed by P450 UEl, are reactions also catalysed by other P450 
isoforms albeit at different rates and substrate concentrations (Raucy et a l, 1989; Gonzalez, 
1989). Many of the previous studies have investigated alterations in drug metabolism by 
employing substrates metabolised by more than one isoform of cytochrome P450. This can 
present problems when evaluating the effects of diabetes on the cytochrome P450 oxidase 
system.
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The use of specific diagnostic substrates whose metabolism is catalysed 
predominantly or exclusively by single isoforms will enable the effects of streptozotocin- 
induced diabetes on the activities of specific isoforms to be more adequately characterised. 
The use of exogenous insulin has already been shown to partially reverse the effects of the 
streptozotocin-induced alterations in hepatic drug metabolism and concurrent 
administration of nicotinamide with streptozotocin can block the diabetogenic effect of the 
compound (Ledoux et ah, 1988). In the present study the effect of the diabetogen per se on 
drug metabolism and the alterations caused by the ensuing diabetes were investigated. In 
order to evaluate the effect and extent of reversal by insulin of the diabetes-induced 
alterations, one group of streptozotocin-induced diabetic rats received daily insulin 
injections throughout the study. Moreover another group that received streptozotocin was 
also injected with nicotinamide which is known to block the diabetogenic effect of the 
compound. In this way the effects of the diabetogen on drug metabolism may be discerned 
from those inherent to the chemical.
One of the inherent problems of using selective substrates is that other, as yet 
uncharacterised P450 isoforms may also metabolise the substrate. Therefore, 
immunological detection of specific P450 proteins was also employed using monospecific 
antibodies to selected P450 proteins.
Animal pretreatment
Male Wistar albino rats (180-200g) were randomly divided into four groups, each 
comprising four animals. One group served as control, the second received a single 
intraperitoneal injection of streptozotocin (65mg/kg) dissolved in 0.5M sodium citrate 
buffer, pH 4.5; the third group received, in addition to streptozotocin (65mg/kg), two 
intraperitoneal injections of nicotinamide (350mg/kg), one 10 minutes before and another 3 
hours after the administration of streptozotocin; finally, the fourth group received, in 
addition to streptozotocin, single daily doses of insulin subcutaneously once overt 
diabetes was established (day 3). All animals were killed 21 days after treatment and 24
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hours after the last administration of insulin. In all cases livers were immediately excised, 
hepatic microsomal fractions prepared and mixed-function oxidase activities determined 
(Chapter 2). Body weight gain, food and water intake were monitored daily and terminal 
blood samples were obtained from the animals by decapitation at time of death. Animals 
receiving insulin treatment were dosed daily with a single subcutaneous injection of 4 I.U. 
per day from day 4 until day 10 when the dose was increased to 8 I.U. In order to confirm the 
findings of the enzyme assays antibodies raised against specific cytochrome P450 proteins
were employed for immunological analysis of the hepatic microsomal proteins (Chapter 2).
Insulin was long acting ultralente (40iu/m l) insulin from Novo Industrials. In comparison to 
the dose administered to human diabetics the streptozotocin-diabetic rat is resistant to the 
effects of this insulin and high doses must be given for adequate control to be obtained.
Results
Rats treated with streptozotocin alone exhibited hyperphagia, polydipsia, 
polyurea and reduced body weight gain (Figure 3.1). These effects could be partially 
reversed by the daily subcutaneous administration of insulin. They also exhibited 
markedly higher plasma glucose and ketone body concentrations when compared to control 
rats or streptozotocin-treated rats given nicotinamide or daily insulin injections (Table 3.1).
Table 3.1 Plasma glucose and ketone body concentrations in streptozotocin-treated 
diabetic rats
Acetoacetate (mM)
+
Group Glucose (mM) 3-Hydroxy^bufyrate (mM)
Control
Streptozotocin
diabetic
Streptozotocin and 
nicotinamide treatment
Insulin treated 
streptozotocin diabetic
5.6 ±0.2
25.6 ± 4.1***
5.8 ±0.3 
14.9 ±3.8**
0.34 ±0.10 
0.98 ± 0.16*
0.30 ± 0.10
0.40± 0.14
Values represent mean ± s.e.m. for four animals.
*** p<0.001, **p<0.01 compared to control
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Figure 3.1 Effects of streptozotocin-induced diabetes (STZ), combined streptozotocin and
nicotinamide treatment (STZ + Nic) and insulin treated streptozotocin-induced 
diabetes (STZ + Ins) on body weight gain, water and food intake.
A verage  b o d y  w e ig h t g a in
400-1
CONTROL
STZ+Nic
STZ
STZ+Ins
350-
300-
250-
200 -
150
21 28140 7
Day
A v erag e  w a te r  in ta k e
300 n
200 -
100-
21 28140 7
Day
A verage  fo o d  in ta k e
50-1
40-
30-
20 -
21 28140 7
Day
Insulin treated animals received 4 I.U. daily from day 4 until day 10 when the dose was
increased to 8 I.U. daily. 5 8
The plasma glucose concentrations of the diabetic animals receiving daily insulin 
therapy were elevated over control at time of death, 24 hours after the last insulin 
injection, although the total ketone body concentration was only slightly elevated. 
Microsomal protein, total cytochrome P450 and cytochrome bg content showed no significant 
elevations in any of the groups when compared to controls. However, there was a 
significant increase in the NADPH-cytochrome c reductase activity in the streptozotocin- 
treated animals but not in those which received streptozotocin concurrently with 
nicotinamide, or those receiving daily insulin (Table 3.2).
Table 3.2 Effects of streptozotodn-induced diabetes (STZ). streptozotocin and
nicotinamide treatment (STZ + Nic) and insulin-treated streptozotocin 
diabetes (STZ + Ins) on some microsomal parameters.
PARAMETER
Control
GROUP
STZ STZ+Nic STZ+Ins
Microsomal protein 35.4+4.1 39.1+3.2
( m g /g liver)
Cytochrome P450 0.3+0.03 0.38±0.05
(nmol /  mg protein)
Cytochrome bg 
(nmol /  mg protein)
0.25+0.05 0.31±0.05
NADPH cytochrome c 36+4 139±5"
reductase
(nmol /  min /  mg protein)
36.4±3.8
0.29+0.04
0.30±0.Q2
38+4
35.0±4.0
0.29+0.02
0.32±0.04
42±6
Values represent mean ± s.e.m for four animals. p<0.001 compared to control
Streptozotocin diabetic animals were associated with a marked increase in 
ethylmorphine and erythromycin N-demethylase activities (Figure 3.2) and also in 
ethoxy- and pentoxyresorufin O-dealkylases, dimethylnitrosamine N-demethylase and
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lauric acid hydroxylase activities (Figure 3.3). These changes in microsomal activity could 
be y reversed by the daily administration of insulin to the diabetic animals and
concurrent administration of nicotinamide with streptozotocin prevented all the 
streptozotodn-induced increases. Immunodetection of specific isoforms of cytochrome P450 
associated with the altered enzyme activities confirmed that the levels of these 
cytochrome P450 proteins were elevated as a result of the diabetic state.
Immunoblot analysis of the cytochrome P450 lA, JIB, HE, niA and IVA sub-families 
supported the findings of the enzyme assays with the diabetic animals showing induction 
of the P450 proteins, an effect that was antagonised by the daily administration of insulin 
to the diabetic animals. Animals concomitantly treated with streptozotocin and 
nicotinamide did not show any induction of the P450 proteins (Figures 3.4 A-E).
Figure 3.2 Ethvlmorphine and ervthromvcin N-demethvlase activities.
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Figure 3.3 The effects of streptozotodn-induced diabetes on specific cytochrome P450 
catalysed reactions.
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Figure 3.4 Immunoblot analysis of microsomes from streptozotodn-induced diabetic 
rats using anti-cytochrome P450 lA, IIBl, IIEl, IIIA and 
IVA polyclonal anti-bodies
Figure A 
P450 lA
Figure B 
P450IIB1
Figure C 
P450nEl
Figure D 
P450IIIA
Lane, 1 and 2 Control rat microsomes
3 and 4 Streptozotocin-diabetic rat microsomes
5 3-Methylcholanthrene-induced microsomes
6 and 7 Streptozotodn and nicotinamide treated rat microsomes 
8 and 9 Insulin-treated streptozotocin-diabetic rat microsomes
Lane land 2 Control rat microsomes
3 and 4 Streptozotocin-diabetic rat microsomes
5 Phenobarbital-induced microsomes
6 and 7 Streptozotodn and nicotinamide treated rat microsomes 
8 and 9 Insulin-treated streptozotocin-diabetic rat microsomes
Lane 1 Control rat microsomes 2 Isoniazid-induced rat microsomes
3 Streptozotocin and nicotinamide treated rat microsomes
4 Insulin-treated streptozotocin-diabetic rat microsomes
5 Streptozotocin-dial^tic rat microsomes
Lane 1 Control rat microsomes 2 Streptozotocin-diabetic rat microsomes
 3 PCN-induced rat microsomes _
4 Streptozotocin and Nicotinamide treated rat microsomes
5 Insulin-treated streptozotocin-diabetic rat microsomes
Figure E Lane 1 Control rat microsomes 2 Streptozotocin-diabetic rat microsomes
P450IVA 3 Clofibrate-induced rat microsomes
4 Streptozotocin and nicotinamide treated rat microsomes
5 Insulin-treated streptozotocin-diabetic rat microsomes
Microsomal proteins were resolved by electrophoresis in a 10% (w /v) SDS-polyacrylamide gel and 
transferred to nitrocellulose. In all cases 20pg of solubilised microsomal protein was loaded except 
for the positive controls when only 10|ig of protein was loaded.
Positive controls
Animal pre-treatment
3-methylcholanthrene (25mg/kg in com oil) for 3 days. 
Phénobarbital (80mg/kg in saline) for 3 days 
Isoniazid (0.1% (w/v) in drinking water) for 7 days 
PCN (lOOmg/kg in com oil) for 3 days 
Clofibrate (80mg/kg in saline) for 3 days
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Discussion
Rats receiving a single intraperitoneal injection of streptozotocin displayed the
characteristic physiological changes of hyperglycaemia, hyperketonaemia, polydipsia 
and hyperphagia associated with overt insulin-dependent diabetes mellitus. Concomitant 
administration of nicotinamide with streptozotocin prevented the onset of the diabetic 
syndrome possibly by the mechanism previously discussed (Chapter 1). Moreover, daily 
treatment of streptozotocin diabetic rats with insulin resulted in control of the diabetic 
state, reducing the plasma glucose and ketone concentrations .
Streptozotocin treated rats exhibited markedly higher metabolism of all 
substrates studied, as well as increased NADPH-dependent reduction of cytochrome c, as 
previously reported b y  other groups (Ackerman and Liebman 1977, Reinke et ah, 1978, 
loannides et ah, 1988, Thomas et ah, 1987, Peng et ah, 1983). The changes in the 
mixed-function oxidase activities in streptozotocin-treated rats are entirely attributable to 
the diabetic state rather than the diabetogen per se, as concurrent administration of 
nicotinamide with streptozotocin prevented the onset of diabetes as well as the alterations 
in mixed-function oxidase activity.
Daily insulin treatment of the streptozotocin diabetic animals also partially 
reversed the changes in activities. It must be noted that the insulin regime employed was 
based on water consumption versus insulin dose and therefore represents a very poorly 
controlled state with possibly both hyper- and hypoinsulinaemia occurring during each 24 
hour period.
The induction of ethoxyresorufin O-deethylase activity, an enzyme activity 
predominantly associated with the P450 lA subfamily, is of particular interest as this 
subfamily has been implicated in the bioactivation of many carcinogens (loannides and
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Parke, 1987). The confirmation of this finding by western blot analysis also reveals that it
is the P450 IA2 isoform that appears to be more highly induced in the diabetic state. This
isoform has already been shown to bioactivate some of the most potent mutagens such as 
Glu-P-1 (loannides et af.,1988). Why this isoform should be induced is unclear at present.
The increase in dimethylnitrosamine N-demethylase in chemically-induced 
diabetes has been attributed specifically to the induction of cytochrome P450 DEI which is 
confirmed by immunoblot analysis. The induction of this isoform of cytochrome P450 may 
have implications for the propensity of the diabetic to metabolise a range of nitrosamines 
encountered in the environment. Cytochrome P450IIÉ1 has already been shown to 
metabolically activate certain nitrosamines (Peng et a l ,  1983) and also to convert 
paracetamol to its reactive quinoneimine intermediate responsible for its hepato toxicity 
(Raucy et a l,  1989). The cytochrome P450 IIB subfamily has also been associated with the 
activation of some cyclic nitrosamines (Ayrton et al, 1987). The P450 IIB subfamily is also 
concerned with the effective deactivation of many therapeutic drugs and its induction may 
well affect the pharmacokinetics of drugs given to human diabetic patients to treat the 
multitude of complications to which they are prone.
The increases observed in the rates of N-demethylation of erythromycin and 
ethylmorphine, two drugs that have been used as diagnostic substrates for the P450 IIIA 
subfamily (Wrighton et aï., 1985a ) indicates induction. This subfamily is involved in the 
metabolism of many drugs such as midazolam (Fabre et a l, 1988), mephenytoin (Shimada 
and Guengerich, 1985), cyclosporin (Bertauld-Peres et al., 1987) and the macrolide 
antibiotics, troleandomycin and erythromycin (Wrighton et al, 1985b) and will thus alter 
the pharmacologic effects of these drugs.
Streptozotocin-diabetic rats also displayed a higher activity of lauric acid 
hydroxylase, an activity associated with the P450 IVA subfamily of haemoproteins 
(Tamburini et al, 1984 ). This subfamily plays an important role in the metabolism of
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endogenous substrates, being involved in the oxidation of fatty acids such as lauric and 
arachidonic acids (Bains et a l ,  1985, Sharma et al, 1988). Insulin-dependent diabetes 
mellitus is associated with high levels of fatty acids and it may be that the induction of 
the cytochrome P450 IVA subfamily is an adaptive response to the alterations in the levels 
of these lipids through fatty acid hydroxylation and subsequent ^-oxidation.
In summary, streptozotodn-induced diabetes is associated with alterations in the 
levels of cytochrome P450 activities of the xenobiotic metabolising families. These effects 
are attributable to the diabetic state and not the diabetogen per se and can be partially 
reversed by daily administration of insulin. The observed increases in the cytochrome P450 
families studied may have a profound effect on the ability of the diabetic individual to 
effectively metabolise and thus eliminate the many drugs used to treat the complications 
of this disease. Increased deactivation may reduce plasma levels of drugs so that the 
therapeutic effect is decreased or even totally abolished. On the other hand diabetics may 
be vulnerable to the toxicity of chemicals that rely on the cytochrome P450 proteins 
induced by diabetes for their activation. Since the streptozotocin-induced changes in 
mixed-function oxidase activity are similar to those occurring during starvation or 
following exposure of animals to ethanol or acetone it has been suggested that the 
hyperketonaemia, common to all the conditions, may mediate the alterations in 
cytochrome P450 activities in diabetes and some other conditions (Peng et al.,1983). It has 
also been suggested that the depressed body weight gain of streptozotocin-treated animals 
may be responsible for the alterations in hepatic drug metabolism. This is quite possible, as 
animals on restricted food intake also show some alterations of hepatic drug metabolism 
similar'tb that observed in diabetes. The common factors to both situations is depressed 
body weight gain and the production of ketone bodies. Streptozotocin-induced diabetes 
results in insulinopaenia causing an inability of the animal to assimilate absorbed 
nutrients. Therefore superficially, it may appear that the depressed body weight gain is 
responsible for the alterations, in all probability the depressed body weight gain is a 
consequence of the pathophysiological condition arising from p-cell destruction.
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3.2 Sex-differences in streptozotocin-induced type I diabetes 
mellitus
Many factors can influence the metabolism of xenobiotics including; pathological
conditions, physiological parameters and the effect of exogenous agents. The effect of 
diabetes mellitus on the cytochrome P450 system has already been discussed but it is 
important to investigate the effect of the disease in both sexes. Numerous studies have 
shown that sex-differences are observed in the metabolism of a variety of compounds 
(Reinke et a l ,  1978, 1979; Warren et a l,  1983; Skett, 1986). Although in normal healthy 
individuals sex differences appear to be of little clinical relevance, it is possible that in 
certain disease states they may become pronounced and clinically relevant.
Sex-dependent metabolic differences in rats are believed to be determined 
primarily by events occurring during the neonatal period, when the secretion of testicular 
androgens in the male imprints a latent masculine potential onto the otherwise feminine 
pattern (Morgan etal,1985; Jansson et al.,1985; Kato et a l ,  1986). Castration of males at 
birth results in a more feminine pattern of several sexually differentiated characteristics in 
adult life, including; gonadotropin secretion and sexual behaviour. However, castration of 
adult males does not alter, or only slightly effects, the already differentiated masculine 
characteristics, à
Sex-related differences have been recognised in the rat hepatic microsomal 
cytochrome P450 dependent metabolism of steroids and many of the qualitative and 
quantitative differences in microsomal xenobiotic metabolism can be attributed to the 
expression of sex-specific P450 isoforms. On the regulation of hepatic cytochrome P450, 
studies have shown that endocrine hormones such as testosterone, oestradiol and growth
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hormone participate in the regulation of constitutive forms in the adult animal including 
the expression of the male specific P450 nCl l  (rat P450h) and P450 IIC13 (rat P450g) and 
the female specific P450 IIC12 (rat P450i). In addition the phenobarbital-inducible forms of 
cytochrome P450, P450 IIBl and IIB2 (P450b and e respectively) have also been shown to be 
under the influence of growth hormone. In contrast, the cytochrome P450 III family is not 
inducible by sex steroid hormones but the de novo synthesis is stimulated by a variety of 
glucocorticoids and other high molecular weight compounds (Wrighton et al., 1985a; 
1985b). This subfamily does show sex-dependent differences in activity with the levels 
declining in female rats with age, such that adult male rats have higher constitutive 
levels of liver cytochrome P450 HI proteins than adult females (Halvorson et ah, 1988; 
Gonzalez et ah, 1986). More recently the effect of growth hormone on other P450 isoforms 
has been investigated including P450 IIEl (P450j) which suggest that the circulating levels 
of endogenous hormones may have an important role in determining the P450 complement of 
ah individual (Yamazoe et ah, 1989b).
Streptozotocin-induced diabetes results in a major perturbation of circulating insulin 
levels. The effect of this disturbance on other hormone secretory patterns has not been fully 
investigated although in male diabetic rats there is evidence of decreased testosterone 
(Baxter et ah,1981) and growth hormone secretion (Yamazoe et al.,1989a). The sex-specific 
P450 isoforms, being partially regulated by the levels of these hormones, will most 
probably be affected by streptozotocin-diabetes. The effects of streptozotocin-induced 
diabetes in male and female rats was investigated to evaluate whether the disease 
resulted in more pronounced sex-specific alterations of xenobiotic metabolism and P450 
activities.
Animal pretreatment
Ten male and ten female Wistar albino rats (180-200g) were obtained from the
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Experimental Biology Unit, University of Surrey. Each sex was divided into two groups 
consisting of five animals each. One group of each sex served as control while the other was 
rendered diabetic by the intraperitoneal administration of streptozotocin (65mg/kg), 
dissolved in O.IM sodium citrate buffer, pH 4.5. Daily water and food intake were 
monitored together with body weight gain. All animals were killed 21 days after 
administration, terminal blood samples obtained and plasma glucose and ketone body 
concentrations determined. The livers were inunediately excised and microsomes prepared 
as previously described (Chapter 2). Mixed-function oxidase activities were determined 
and immunological detection of specific cytochrome P450 apoproteins performed where 
appropriate.
Results
All streptozotocin animals displayed polydipsia, hyperphagia and depressed
body weight gain when compared to their respective controls. Blood glucose and ketone 
body concentrations were significantly increased over the respective control animals but 
there was no significant differences between the severity of the hyperglycaemia or 
hyperketonaemia between the diabetic male or female groups (Table 3.2.1).
Although the diabetic female animals displayed a decrease in total microsomal 
protein, this was not significant when compared to the control group and there was no 
significant difference between the male diabetic animals or their controls. Total carbon 
monoxide discernible cytochrome P450 levels were significantly increased in the diabetic 
female group and there was a significant difference between the control male and control 
female group, the latter being lower, although not between the diabetic groups (Table
3.2.2). Cytochrome bg levels tended to be higher in the diabetic groups, but the difference 
was not significant. In contrast to our first study there was no increase in the NADPH  
dependent reduction of cytochrome c as a result of the diabetic condition the reason for this 
remains unclear (Table 3.2.2).
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Table 3.2.1 Plasma glucose and ketone body concentrations in male and female diabetic 
rats
3-Hydroxybufyrate (mM)
+
Group Glucose (mM) Acetoaoetate (mM)
Control Male 
Diabetic Male 
Control Female 
Diabetic Female
6.8 ± 0.24 
30.4 ± 5.0* 
6.5 ± 0.54 
33.0 ± 7.4*
0.45 ±0.01 
1.40±0.ir** 
051 ±0.03 
1.21 ± 0.19**
Values represent mean ± s.e.m. for five animals
*** p<0.001 **p<0.01 when compared to respective controls.
The effect of streptozotocin-induced diabetes on the ethoxyresorufin O-deethylase 
and pentoxyresorufin O-depentylase activity of both male and female groups was to 
significantly increase both activities when expressed per mg microsomal protein (Table
3.2.3) or per nmol P450 (Figure 3.2.1).
Table 3.2.2.
rats
GROUP
PARAMETER
Control
Male
Diabetic
Male
Control
Female
Diabetic
Female
Microsomal Protein 
(mg /g  liver) 42.3 ±2.5 42.6 ± 3.8 40.0 ±4.4 35.4 ± 1.6
Total cytochrome P450 
(nmol /  mg protein) 0.55 ±0.03 0.62 ±0.05 0.32 ±0.04+ 0.54 ±0.08*
Cytochrome bg 
(nmol /  mg protein) 0.68 ± 0.03 0.75 ±0.04 0.67±0.07 0.90 ±0.10
NADPH cytochrome c 
reductase
(nmol/ min /  mg protein) 14.5 ±0.3 16.5 ±2.7 16.3± 2.7 13.5 ± 0.8
* p<0.05 for diabetic versus control +p<0.01 for male control versus female control 
Values represent mean ± s.e.m. for five animals .
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The microsomal metabolism of p-nitrophenol to 4-nitrocatechol was significantly 
increased in the male and female diabetic animals both when expressed per mg protein 
(Table 3.2.3) or per nmol P450 (Figure 3.2.1). Both diabetic male and female animals 
showed an increase over control animals in the hydroxylation of lauric acid (Table 3.2.3.), 
but only the diabetic male group displayed a significant difference when the activities 
were expressed per nmol P450 (Figure 3.2.1.). Similarly both male and female diabetic rats 
exhibited a significant induction of ethylmorphine N-demethylase activity when 
expressed per mg microsomal protein (Table 3.23). However, when expressed per nmol P450 
only the male diabetic rats showed a significant increase (Figure 3.2.1). These findings 
were confirmed by immunoblot analysis (Figure 3.2.2).
Table 3.2.3 Some isoform specific cvtochrome P450 activities in the streptozotocin 
diabetic male and female rat.
PARAMETER
GROUP
Control Diabetic Control Diabetic
Male Male Female Female
Ethoxyresorufin
O-deethylase
(pmol/ min/ mg protein) 10.4 ± 2.5
Pentoxyresorufin
O-depentylase
(pmol/ min/ mg protein) 1.9 ± 0.3
p-Nitrophenol
hydroxylation
(nmol/ min/ mg protein) 0.5 ± 0.1
Lauric acid hydroxylase
(nmol/ min/ mg protein) 0.99 ± 0.2
Ethylmorphine
N-demethylase
(nmol/ min/ mg protein) 13.2 ± 0.18
24.6 ± 2.5* 
(236)
10.4 ± 1.0*** 
(584)
2.84 ± 0.3*** 
( 588)
8.7 ±2.0
1.5 ±0.3
0.55 ± 0.04
3.36 ±0.18*** 1.1 ±0.12
(339)
28.6 ± 1.0*** 
(218)
12.5 ±0.1
31.4 ±9.1* 
(361)
7.8 ± 1.4* 
(520)
1.46 ± 0.3* 
(265)
2.05 ± 0.1*** 
(186)
13.4 ± 0.2* 
(107)
Values represent mean ± s.e.m. for five animals. *p<0.05 **p<0.01 ***p<0.001
compared to respective control. Figures in parenthesis represent % of control activity
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Figure 3.2.1 Microsomal cvtochrome P450 activities expressed per nmol of P450
for male and female streptozotocin-induced diabetic rats
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Figure 3.2.2 Immunoblot analysis of microsomes from streptozotocin-induced diabetic 
male and female rats using anti-cytochrome P450 lA, IIBl, IIEl, IIA and 
IVA polyclonal anti-bodies
Figure A Lane 1 Control male rat microsomes
P450IA 2 Streptozotocin-diabetic male rat microsomes
3 3-methylcholanthrene-induced rat microsomes
4 Control female rat microsomes
5 Streptozotocin-diabetic female rat microsomes
Figure B Lane 1 Streptozotocin-diabetic male rat microsomes
P450IIB1 2 Control male rat microsomes
3 Control female rat microsomes
4 Streptozotocin-diabetic female rat microsomes
5 Phenobarbital-induced rat microsomes
Figure C Lane 1 Streptozotocin-diabetic male rat microsomes
P450IIE1 2 Isoniazid-induced rat microsomes
3 Control male rat microsomes
4 Control female rat microsomes
5 Streptozotocin-diabetic female rat microsomes
Figure D Lane 1 Control male rat microsomes
P450IIIA 2 Streptozotocin-diabetic male rat microsomes
3 Control female rat microsomes
4 PCN-induced rat microsomes
5 Streptozotocin-diabetic female rat microsomes
Figure E Lane 1 Streptozotocin-diabetic female rat microsomes
P450IVA 2 Control female rat microsomes
3 Clofibrate-induced rat microsomes
4 Streptozotocin-diabetic male rat microsomes
5 Control male rat microsomes
Microsomal proteins were resolved by electrophoresis in a 10% (w /v) SDS-polyacrylamide gel and 
transfered to nitocellulose. In all cases 20|ig of solubilised microsomal protein was loaded except for 
the positive controls when only lOpg of protein was loaded.
Positive controls
Animal pre-treatment
3-methylcholanthrene (25mg/kg in com oil) for 3 days. 
Phénobarbital (80mg/kg in saline) for 3 days 
Isoniazid (0.1% (w /v) in drinking water) for 7 days 
PCN (lOOmg/kg in com oil) for 3 days 
Clofibrate (80mg/kg in saline) for 3 days
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Discussion
The induction of streptozotocin-diabetes in both male and female rats resulted in a
comparable severity of diabetes-induced hyperglycaemia and hyperketonaemia. The 
levels of total cytochrome P450 in the control female were significantly lower than the 
levels in the control males. The effect of diabetes was to diminish this difference and 
therefore produce a more pronounced induction of total cytochrome P450 in the female 
animal, but there was no increase in the activity of the NADPH dependent reduction of 
cytochrome c.
The use of substrates whose metabolism is catalysed predominantly by a single 
P450 isoform revealed that there are native differences between the two sexes with respect 
to ethoxyresorufin O-deethylase, p-nitrophenol and lauric acid hydroxylase activities 
when expressed per nmol P450, although this cannot be substantiated for lauric acid 
hydroxylase activity due to the assay employed. The increased susceptibility of the 
female rat to the hepatotoxic effects of paracetamol has been attributed to the higher 
levels of the P450 1A2 protein in these animals, the proteins of which uniquely catalyse the 
dééthylation of 7-ethoxyresorufin in the livers of untreated rats (Kelly et al., 1987). The 
effect of diabetes on the lA subfamily is to increase the activity of these proteins towards 7- 
ethoxyresorufin by approximately the same degree in both sexes when expressed per nmol 
P450. Similarly, the effect of the diabetic state on the activity of the P450 IIB subfamily of i 
proteins (catalysing the depentylation of pentoxyresorufin) was also an increase and again 
by a similar fold induction.
The effect of the diabetic state on the levels of the P450 HE subfamily as
exemplified by hydroxylation of p-nitrophenol are comparable when expressed per mg
protein with similar fold inductions occurring in both male and female diabetic animals.
the P450 IIIA and P450 IVA subfamily display more overt sex-dependent differences with
the female controls having slightly higher levels than the control males but these proteins
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appear almost refractory to the diabetic state in the female while being significantly 
induced in the male diabetic animals. These findings have been confirmed by immunoblot 
analysis using monospecific antibodies to the respective cytochrome P450 families. Clearly 
these results confirm that sex-dependent differences observed in untreated animals are also 
present in the diabetic state.
From the enzyme activities, expressed per nmol P450, the induction of the 
cytochrome P450 lA and IIB subfamilies do not show any sex-dependent differences in the 
diabetic animals. If some endogenous metabolite, such as ketone bodies, was responsible for 
the induction of these subfamilies then the severity of ketosis, being similar in both male 
and female diabetic animals may provide some explanation for the observations (Table
3.2.1). Of the other families investigated, sex-dependent factors appear to be involved in 
their regulation. The levels of the P450 HE proteins differ in the male and female control 
animals and appear to be induced to differing degrees by the diabetic state. The P450 HE 
subfamily has already been shown to be inducible by a variety of small molecules such as 
acetone, ethanol and isoniazid (Ryan et al, 1986) and also in some physiological conditions 
including; fasting and starvation (Tu and Yang, 1983). As acetone is a ketone body and 
starvation and fasting also elevate the levels of circulating ketones it is possible that this 
may explain the induction of the P450 HE subfamily in the male and female diabetic 
animals. However, it does not explain the difference in the degree of induction in the sexes 
considering that the severity of hyperketonaemia was comparable in both. It has been 
reported that the levels of circulating growth hormone and its pattern of secretion are 
different in male and female diabetic animals and that diabetes causes a reduction in the 
plasma levels of growth hormone (Tannenbaum et ah, 1981, Serri and Brazeau, 1987). It has 
been suggested that P450 IIEl may be partially regulated by growth hormone and the 
greater relative reduction in the levels of growth hormone in the diabetic male may be 
involved in the sex-difference of P450 IIEl induction in diabetic animals.
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The P450 IIIA subfamily catalyses the déméthylation of ethylmorphine and 
clearly shows sex-differences in the diabetic state. The diabetic female appears to be 
refractory to the inducing effect of diabetes on this subfamily of proteins while in the male 
they are significantly induced. This subfamily has been shown to be regulated by 
glucocorticoids and growth hormone and would possibly be affected if there were 
perturbations of the circulating levels of this hormone in the diabetic male animal only.
Finally, the P450 IVA subfamily also displayed differences in the levels of control 
animals and in the response to the diabetic state. The control female animals appeared to 
have higher levels than the control males and were almost refractory to the inducing 
effects of diabetes, whereas in the male diabetic animals the proteins were highly 
induced. Previous studies have shown that compounds causing increases in plasma 
triglycerides are capable of inducing the P450 IVA subfamily as are the peroxisomal
proliferating agents (Hardwick et a l ,  1987). Diabetes is associated with the uncontrolled 
mobilisation of fatty acids from the peripheral adipose tissues and it is possible that these =! 
increased levels of circulating fatty acids are responsible for the induction. However, the 
reason why the female animals have higher levels than the males and why they are 
refractory to the inducing effect of diabetes requires further investigation.
In summary, the effect of streptozotocin-induced diabetes mellitus on the hepatic 
microsomal P450 system appears to be both sex-dependent and sex-independent depending 
on the P450 subfamily concerned. The results of this study suggest that some families may be 
enhanced directly by circulating levels of diabetes generated metabolites of intermediary 
metabolism, whereas other cytochrome P450 families may have more complex regulation 
involving a hormonal component. Whatever mechanism is responsible for the alterations, 
it is clear that pronounced sex-dependent changes of hepatic cytochrome P450 families
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occur in diabetes mellitus which, if also present in man may have implications for the
diabetic patient during the prolonged drug therapy associated with this disease. It must be 
stressed that this study only considered the effects of sex on inducible fam ilies of 
cytochrome P450 and therefore did not address the possibility of the repressive effects of : 
diabetes with respect to sex difference. Furthermore, w e did not examine the metabolism of 
com pounds which are specific for isoforms known to show pronounced sex-dependent | 
expression. Further studies should address this area more fully. |
3.3 Hepatic drug metabolism in long-term streptozotocin- 
induced type I diabetic rats.
Streptozotocin-induced insiilin-dependent diabetes mellitus is considered a model 
for spontaneous diabetes mellitus. However, there are some important differences from the 
spontaneous form of the disease in these animals which must be addressed. When overt 
diabetes is apparent the streptozotocin-induced animal does not succumb to the 
hyperglycaemia and hyperketonaemia as observed in spontaneously diabetic animals. 
This ultimately presents questions as to how the streptozotocin-diabetic animal survives 
without exogenous insulin for so many weeks, and has led to the suggestion that there may 
be some p-cell regeneration in the streptozotocin animal. This model is also associated with 
ah accelerated onset of the long-term complications such as glaucoma. For these reasons the 
period of time which the streptozotocin animal can be used as a model for spontaneous 
diabetes mellitus may be limited. In order to investigate the long-term effects of 
streptozotocin-induced diabetes mellitus on the hepatic P450 mixed-function oxidases we 
studied the diabetes-induced alterations over a period of twelve weeks.
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Animal Pretreatment
Twenty four male Wistar albino rats (180-200g) were obtained from the 
Experimental Biology Unit, University of Surrey and divided into six groups. Three groups 
served as controls while the animals in the remaining three groups each received an 
intraperitoneal injection of streptozotocin (65mg kg) dissolved in O.IM sodium citrate 
buffer, pH 4.5. One group of control and diabetic animals were killed after four, eight and 
twelve weeks post-treatment. Terminal blood samples were taken and the livers 
immediately excised and placed into ice-cold 1,15% KCl. Post-mitochondrial fractions (S9) 
were prepared as previously described (Chapter 2) and stored at -2QoC until required. 
Plasma ketone body and glucose concentrations were determined and fresh microsomal 
preparations used for the determination of mixed-function oxidase activities (Chapter 2). 
Immunological analysis was performed to confirm the results of enzyme analysis where 
appropriate.
Results
All streptozotocin-treated animals displayed the characteristics of hyperphagia, 
polydipsia and polyurea throughout the study and continued depression of body weight 
gain. Analysis of total plasma ketone body concentrations revealed that all diabetic groups 
showed significantly elevated ketone body levels throughout the study. However, as the 
study progressed the severity of ketosis in the diabetic groups became less pronounced, 
although not significantly decreased (Figure 3.3.1). The plasma glucose levels of the 
diabetic animals were significantly increased over the control groups by week four and 
remained significantly elevated throughout the duration of the study (Figure 3.3.1).
During the course of the study several of the animals suffered from glaucoma and 
were killed at the next convenient time point. As the glaucoma was considered a 
consequence of the prolonged duration of elevated plasma glucose levels the animals were
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included in the experimental data from the study.
Figure 3.3.1 Plasma glucose and ketone body concentrations in long-term streptozotocin-
diabetic rats.
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There were no significant alterations of the total microsomal protein, cytochrome 
P450, or the NADPH dependent reduction of cytochrome c for any groups at any time point
78
during the study (Table 3.3.1). However, the levels of cytochrome bg were elevated in all 
diabetic groups but these elevations were not significant until 12 weeks (Table 3.3.1).
Table 3.3.1 Effects of long-term streptozotocin-induced diabetes on some microsomal 
parameters.
PARAMETER
Microsomal protein 
(mg/ g liver)
Control Diabetic 
4wks
GROUP
Control Diabetic 
8 wks
29.2+1.20 27.3±2.9 28.5+2.30 35.1+4.0
Control Diabetic 
12 wks
26.9±3.10 33.4+2.90
Total cytochrome P450
(nmol/mgprotein) 0.43±0.05 0.55+0.03 0.50+0.04 0.56±0.03 0.49+0.06 0.66+0.07
Cytochrome bs
(nmol /  mg protein) 0.70+0.14 0.86+0.20 0.64+0.10 0.74+0.13 0.63+0.05 0.83+0.05*
NADPH cytochrome c 
reductase.
(nmol/ min/
mg protein) 19.6+2.80 22.5+1.4 14.3+2.60 12.9+2.6 15.1±0.70 14.4+0.40
Values represent mean ± s.e.m. for five animals.
* p<0.05 when compared to respective control
The activities of the specific cytochrome P450 families investigated showed 
significant increases for all substrates investigated at the four week time point. The 
dealkylation of pentoxyresorufin and ethoxyresorufin remained significantly elevated 
throughout the study period, however, the hydroxylation of p-nitrophenol and lauric add 
declined during the study with the increases becoming non-significant at the 12 week time 
point. Similarly the N-demethylation of ethylmorphine showed a similar decrease in 
activity with the increase at four weeks becoming non-significant by the eight and twelve 
week time points (Figure 3.3.2). Immunoblot analysis confirmed the findings in cytochrome 
P450 LA, HE and IVA levels of apoproteins (Figure 3.3.3)
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Figure 3.3.2 Effect of long term streptozotocin-induced diabetes on some specific 
cytochrome P450 catalysed reactions.
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Figure 3.3.3 Immunoblot analysis of long-term streptozotocin-diabetic rat microsomes using 
anti-cytochrome P450 lA, IIEl and IVAl polyclonal antibodies.
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Microsomal proteins were resolved by electrophoresis in a 10% (w/v) SDS-polyacrylamide gel and 
transfered to nitocellulose. In all cases 20pg of solubilised microsomal protein was loaded except for 
the positive controls when only lOjig of protein was loaded.
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Discussion
All animals treated with streptozotocin became diabetic as shown by the continued 
hyperglycaemia. The onset of diabetes resulted in all the expected alterations of water 
consumption, body weight gain and food intake. The resulting hyperketonaemia following 
streptozotocin-induced diabetes produced some unexpected findings, in that the severity of the 
ketosis decreased during the study period. Bellward et ah, (1988) proposed that it is the ketone 
bodies which are responsible for the induction of cytochrome P450 IIEl. Our data shows that at 
four weeks there was a significant induction of p-nitrophenol hydroxylase, a characteristic 
activity of cytochrome P450 IIEl. However, by 12 weeks this activity, although still elevated, 
was not significantly induced. During this period the severity of ketosis was declining. It is 
possible that the induction of this isoform is tightly coupled to the circulating levels of ketone 
bodies, thereby explaining the decreasing activity. In contrast, the dealkylation of ethoxy- and 
pentoxyresorufin by the P450 lA and IIB subfamilies respectively, were consistently elevated 
throughout the study. This may represent induction of these proteins at lower concentrations of 
ketones bodies than the P450 HE proteins.
Immunological detection of the cytochrome P450 IIEl protein confirmed that there was a 
decrease in the levels of the protein as the duration of diabetes progressed. Consideration of the 
other cytochrome P450 families revealed that in the case of lauric acid hydroxylase and 
ethylmorphine N-demethylase activities, chronic diabetes was also associated with an initial 
induction of activity followed by a reduction towards the levels found in the control animals. In 
the case of ethylmorphine N-demethylase activity, characteristic of P450 IIIA induction, the 
initial increase was only bordering on significance at 4 weeks with the activity returning to 
control levels thereafter.
The induction of cytochrome P450IVA is thought to be mediated partly by the 
circulating levels of plasma free fatty acids (Gibson et ah, 1990). Initially, 
streptozotocin induced-diabetes is associated with a marked hyperlipidaemia ( Prof 
P RFlatt, personal communication), but as the duration of uncontrolled diabetes
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progresses the fat deposits of the diabetic animals become diminished and so the levels of 
plasma free fatty acids fall. If the hyperlipidaemia is responsible for the induction of P450 IVA 
then we would expect to see the observed results, namely an initial induction of P450 IVA 
followed by a fall in the levels of this protein as the hyperlipidaemia subsides.
This study reveals that prolonged streptozotocin-induced diabetes is associated with an 
initial elevation of all isoforms studied. However, as the disease progresses there appears to be 
a reduction in the severity of the ketosis which is accompanied by a decrease in the levels of 
three of the isoforms studied. In human diabetic patients type I diabetes is associated with 
severe hyperketonaemia and hyperglycaemia and if not corrected, death. It is possible that the 
reduction in the plasma ketones in the long-term helps protect the streptozotocin-diabetic 
animal from the fatal consequences of the disease. This may be due to a physiological adaption 
associated with increased clearance of the ketone bodies from the plasma, a theory finding 
support from the renal hypertrophy, severe polydipsia and polyuria associated with 
streptozotocin-induced diabetic animals (Marliss et al, 1982).
In summary, it would appear that in the short-term, streptozotocin-induced diabetes closely 
resembles the physiological alterations associated with type I diabetes. However, these 
animals appear to be more tolerant to the hyperketonaemia and hyperglycaemia, presumably 
by being able to adapt and possibly excrete the ketone bodies more efficiently. A role for acetone 
metabolism by cytochrome P450 IIEl has been proposed (Casazza et al, 1984) but it is debatable 
whether the level of induction of this isoform would be able to reduce the levels of the 
circulating ketones sufficiently to allow the streptozotocin-induced animal to survive for 
prolonged periods. Further study of the role of the pancreas in long-term streptozotocin-induced 
diabetes with respect to P-cell regeneration and insulin release merits further investigation. 
Regeneration of P-cells, coupled to insulin secretion could, in part, explain the observed results, 
as insulin treatment has been shown to reverse all the diabetes-induced alterations (Chapter 
3.1; loannides et al, 1988).
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3.4 The bioactivation of chemical carcinogens in streptozotocin- 
induced type I diabetes meUitus
Much of human cancer is believed to result from exposure to chemicals, and numerous 
examples of chemically-induced carcinogenesis in experimental animals have been 
demonstrated. Most chemicals express their carcinogenicity through reactive intermediates 
and are themselves often chemically inert. The reactive intermediates are generated by 
metabolism and are usually electrophilic entities that interact with vital cellular 
macromolecules giving rise to toxicity /  carcinogenicity. The most prominent en2yme system 
involved in the metabolic activation of chemical carcinogens is the cytochrome P450- 
dependent mixed-function oxidases. Some of the families, for example cytochrome P450IA, 
are closely associated with the bioactivation of carcinogens, while others play no role or 
direct metabolism primarily towards the formation of more readily excretable products 
(loannides and Parke,1987).
Clearly, factors which modulate the levels of various cytochrome P450 proteins will 
also influence the metabolic activation of chemicals and presumably their carcinogenicity. 
Streptozotocin-induced diabetes is associated with alterations in the levels and composition 
of hepatic cytochrome P450 proteins, enhancing the synthesis of some at the expense of 
others (loannides et a l,  1988; Favreau et al., 1987; Thomas et a l,  1987; Yamazoe et a l ,  
1988). The diabetes-induced changes influence the response of diabetic rats to a number of 
chemical toxins such as bromobenzene, carbon tetrachloride (Watkins et a l ,  1982) and 
paracetamol (Price and Jollow, 1982). In view of these reports and the presence of a 
nitrosamine activating cytochrome P450 induced by diabetes mellitus, the propensity of 
diabetic animals to bioactivate established chemical carcinogens, such as aromatic and 
heterocyclic amines and nitrosamines was investigated. The generation of reactive 
intermediates was monitored by the Ames, Salmonella /  microsome assay, a test widely 
used in the detection of potential chemical carcinogens. (Maron and Ames, 1983).
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Animal pretreatment
Male Wistar albino rats (180-200g) were obtained from the Experimental Biology 
Unit, University of Surrey and randomly divided into two groups. One group received a 
single intraperitoneal injection of streptozotocin (65mg kg), dissolved in O.IM sodium citrate 
buffer, pH 4.5. All animals were killed 21 days after treatment by cervical dislocation and 
terminal blood samples obtained. Hepatic post-mitochondrial (S9) fractions were prepared 
as previously described (Chapter 2).
Metabolic activation of the chemical carcinogens by the hepatic fractions were 
determined using the Ames mutagenicity assay (Chapter 2) and employing Salmonella 
typhimurium strains TA98 and TA1530. Fresh cultures were prepared by inoculating nutrient 
broth and incubating overnight in a shaking water bath at 370C. All carcinogens, with the
exception of nitrosopiperidine and nitrosopyrrolidine were dissolved in 
dimethylsulphoxide. The S9 mixes contained 10% (v/v) of the hepatic fraction except in 
the case of the nitrosamines when it was increased to 25% (v/v) being equivalent to 0.3 and 
0.75mg of microsomal protein respectively. Activation systems, carcinogen and bacteria 
were always pre-incubated for one hour at 370C in a shaking water bath. A mutagenic , 
response was considered positive only when there was at least a doubling of the 
spontaneous reversion rate and a concentration-dependent increase in the number of 
histidine revertants.
Results
The total plasma ketone body concentrations (3-hydroxybutyrate and acetoacetate)
at the time of death were 0.33±0.06 and 1.1±0.10 mM in control and streptozotocin treated 
animals respectively (mean ± s.e.m), the plasma glucose concentrations in these groups being
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5.2 ±0.1 and 20.8 ±1.5 mM respectively. The streptozotocin-treated animals displayed the 
expected polydipsia, hyperphagia, polyuria and depressed body weight gain, 
characteristics of insulin-dependent diabetes mellitus.
Activation systems derived from control animals were more efficient than those from 
streptozotocin-diabetic animals at activating the aromatic amine, 2-aminofluorene (Figure
3.4.1). The diabetic fractions were only slightly more efficient at activating Trp-P-1 than 
control activation systems (Figure 3.4.1). However, the mutagenic response to the two cyclic 
nitrosamines, nitrosopiperidine and nitrosopyrrolidine, were markedly enhanced in the 
activation systems derived from streptozotocin-diabetic rats (Figure 3.4.2). Similarly, 
streptozotocin-induced diabetes markedly enhanced the activation of the food 
precarcinogens Trp-P-1 and Glu-P-1 (Figure 3.4.3) to mutagenic intermediates in the Ames 
mutagenicity assay.
Discussion
2-Aminofluorene is very efficiently activated by control 59, in agreement with
previous studies (Phillipson and loannides, 1983). 2-aminofluorene is bioactivated by the 
cytochrome P450 LA subfamily and especially P450 IA2 (Hammons et al.,1985) so the fact 
that diabetes induces P450 1A2, as confirmed by the results of Glu-P-1 activation is not in 
agreement with the observed decreased mutagenicity of this compound. Similarly, control 
S9 is a good activator of 2-aminofluorene (Luster et al, 1982) and yet has very low levels of 
P450 IA2. Therefore, other enzyme systems must be important and indeed the FAD- 
monooxygenases readily activates 2-aminofluorene (Hammons et aï.,1985 ■, Pelroy and 
Gandolf, 1980). Moreover, cytosol, in the absence of microsomes, can activate 2- 
aminofluorene (Ayrton and loannides, personal communication). These enzyme systems may 
be depressed by diabetes, and so explain the decreased mutagenicity of 2-aminofluorene.
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Figure 3.4.1 The effects of streptozotocin induced diabetes on the bioactivation of 
2-aminofluorene and Trp-P-2
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The metabolic activation of 2-aminofluorene was carried out using S. typhimurium  strain L 
TA 1538. The spontaneous reversion rate of 11±3 has already been subtracted. Activation of f 
Trp-P-1 was performed using strain TA 98. The spontaneous reversion rate of 10±2 has 
already been subtracted. Both precarcinogens were activated using 10% (v /v )  S9 and pre- j 
incubated with the bacteria for Ihr in a shaking water bath at 370C.
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Fieure 3.4.2 The effects of streptozotocin-induced diabetes on nitrosamine bioactivation
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The metabolic activation of two cyclic nitrosamines was performed using 25%(v /v )  S9i 
activation and em ploying Salmonella typhimurium strain TA 1530. Activation system,! 
nitrosamine and bacteria were pre-incubated for Ihr in a shaking water bath at 370C.I 
Results are expressed as mean ± s.e.m. The spontaneous reversion rate of 8+2 has already ' 
been subtracted.
88
F ig u re  3.4.3 T h e  e ffec ts  o f  s tre p to z o to c in  in d u c e d  d ia b e te s  o n  p ro te in  p v ro ly s a te s
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j Results are expressed as mean ± s.e.m. The spontaneous reversion rate of 17±2 has already 
I  been subtracted.
8 9
Glu-P-1, Trp-P-1 and Trp-P-2 are activated through N-hydroxylation, catalysed by 
the P450 I family, particularly the P450 IA2 protein (Yamazoe et al.,1988; Kato,1986). As 
the IA2 protein is induced in diabetes, it may be inferred that the increased levels of this 
protein is responsible for the activation of the above carcinogens.
Nitrosopiperidine and Nitrosopyrrolidine are activated by N-dealkylation 
catalysed by the cytochrome P450 HE subfamily and also by the P450 IIB subfamily at 
higher concentrations. Both of these families are induced in diabetes resulting in increased 
levels of the respective proteins and therefore increased activation of these compounds.
The present study clearly indicates that the activation of chemical carcinogens is 
modulated by the diabetic state. The effect is dependent on the nature of the carcinogen and 
it appears that streptozotocin diabetes has a selective rather than general effect on drug 
metabolism enzymes. Our studies have clearly shown that chemical induction of diabetes 
increases the levels of some cytochrome P450 isoforms which may provide some explanation 
for the observed effects. However it must be stressed that the present studies involving the 
Ames test focus attention exclusively on the pathways of activation and as the activation 
system, being devoid of phase II cofactors, has a very limited phase II detoxication 
capability and therefore does not mimic the in vivo situation.
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Chapter 4
Hepatic drug metabolism in the 
spontaneously diabetic BB rat
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T h e  s tr e p to z o to c in - in d u c e d  d ia b e tic  a n im a l  m o d e l  h a s  f e a tu re d  p r e d o m in a n t ly  in
the majority of studies investigating the effects of diabetes mellitus on hepatic drug 
metabolism. Numerous studies have shown that chemically-induced diabetes mellitus 
compares very well with the uncontrolled disease in humans on purely physiological 
grounds. However, the animals do not succumb to the hyperketonaemia and electrolyte 
imbalances seen in spontaneously diabetic individuals. Therefore, in terms of drug 
metabolism, the question remains as to whether the alterations associated with 
streptozotocin-induced diabetes reflect those of spontaneously diabetic animals or diabetic 
patients.
The diabetes which occurs spontaneously in the BB Wistar rat has many 
similarities with the human type I (insulin-dependent) diabetes. It occurs in a non-obese, 
laboratory rat derived from a non-inbred Wistar line. Both sexes are affected, with the 
onset of the disease occurring after the time of sexual maturation. Both genetic and immune 
factors are involved in the aetiology but their precise nature remains to be defined (Like e t 
ah, 1982). Evolution of the overt clinical syndrome occurs over a period of hours to a few 
days and an intense insulitis is observed, accompanied by selective destruction of the P- 
cells. Although insulitis may precede diabetes by a few weeks, within 7-21 days following 
the appearance of glycosuria the p-cells are completely destroyed and the islets are few, 
small and with little residual inflammation. If untreated, marked wasting of body tissues, 
including fat and muscle protein, dehydration and ketosis supervene (Marliss et ah, 1982).
Livers from diabetic BB rats demonstrated increased cyclic AMP levels but 
subnormal protein and glycogen content (Appel et ah, 1981). Isolated perfused livers of BB 
Wistar rats demonstrate increased rates of gluconeogenesis and impaired glycogenesis.
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The BB rat has not been extensively used in drug metabolism studies. Bellward et 
al., (1988) investigated the induction of cytochrome P450 IIEl (P450j) in the BB rat. After 
insulin withdrawal there was a significant increase in the activity of this isoform within 
four days. The uncontrolled animals displayed severe ketosis and there was a significant 
correlation between the plasma levels of hydroxybutyrate and immunologically detectable 
cytochrome P450 HEl apoprotein.
Chemically -induced diabetes has already been shown to modulate the levels and 
activities of various cytochrome P450 isoforms (Chapter 3.). The purpose of the present 
study was two fold:
a) to compare the alterations in hepatic drug metabolism in chemically- 
induced diabetes with the alterations occurring in uncontrolled diabetes in the 
spontaneously diabetic BB rat.
b) As human diabetic patients control the disease by single daily injections of 
insulin, it is probable that during any 24 hour period they display a range of plasma insulin 
concentrations from hyperinsulinaemic through normoinsulinaemic to hypoinsulinaemic. 
Therefore, it was of relevance to establish whether poorly insulin-controlled diabetes was 
still associated with changes of hepatic drug metabolism.
4.1 The effect of uncontrolled diabetes on hepatic drug 
metabolism in the spontaneously diabetic BB rat
Diabetes prone BB rats can exhibit a spectrum of severity of diabetic syndromes 
ranging from full-blown insulin dependent type I diabetes to an impaired glucose tolerance. 
The majority of animals however, develop overt type I diabetes and show the following 
symptoms in approximate chronological order of appearance;
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1. Depression of body weight gain
2. Mild glucosuria
3. Increased blood sugar level
4. Severe glucosuria
5. Markedly increased water consumption
6. Loss in body weight and rough coated appearance
7. Depletion of body fat with severe ketosis
8. Coma and death
Progression from symptom 1 to symptom 8 varies greatly, ranging from three days to 
two weeks. The onset of the disease is not reversible but the symptoms can be controlled by 
the subcutaneous administration of insulin.
The BB rat animal model has been predominantly used to investigate the diabetes- 
induced changes in only one cytochrome P450 protein, namely P450 IIEl. Moreover, it 
appears that the effects of uncontrolled diabetes in the BB rat are associated with 
increases in the hydroxylation of aniline and the déméthylation of dimethylnitrosamine 
(Favreau and Schenkman 1988), both activities having been attributed to P450 IIEl. The 
purpose of the present study is to establish whether the other inducible forms of 
cytochrome P450 are also perturbed in the diabetic BB rat.
Animal Pretreatment
Twelve diabetic BB/S and twelve diabetes-resistant BB/S rats were obtained from 
Dr Adrian Bone, Southampton General Hospital, Southampton. The animals had been 
diabetic for differing periods of time and were thus divided into three groups; one at 4 
weeks ± 1 week following detection of overt diabetes; one at 12 weeks ± 2 weeks and one 
group at 24 weeks ± 3 weeks following detection of diabetes. Each group contained four 
diabetic animals and four age matched diabetes-resistant controls. All diabetic animals
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were received with full medical records of body weight gain, date of detection of diabetes 
and daily insulin dose. The insulin dose ranged from 1.81 I.U to 3.6 I.U daily for the 
diabetic animals. The insulin dose administered was dependent on the body weight of the 
individual rat, with the underlying principle being sufficient insulin to maintain the body 
weight of the animal. Periodically the urine was tested for glucose and the level of 
glycated haemoglobin in the blood determined. These tests were used to monitor the 
effectiveness of the insulin regime employed and make any necessary adjustments.
The animals were housed under normal laboratory conditions (Chapter 2.) and 
allowed 48 hours to acclimatise. The animals were injected daily with long acting 
ultratard insulin (40 I.U./ml. Novo biochemicals) given subcutaneously. Following 
acclimatisation the insulin therapy for the diabetic animals was gradually reduced 
employing the following regime:
Day 1 50% of normal insulin dose
Day 2 25% of normal insulin dose
Day 3 No insulin dose
Day 4 No insulin dose
The regime employed was designed to cause a gradual decrease in circulating 
insulin with very low levels resulting after day 4. These animals are very susceptible to the 
hyperketonaemia and complete withdrawal from day 1 could have resulted in death of 
some of the animals by day 4. In view of the numbers of diabetic animals employed in the 
study no loss could be afforded. All animals were killed on the fifth day, terminal blood 
samples obtained and plasma glucose and ketone body concentrations determined. The 
livers were immediately excised, microsomal supernatants prepared and mixed-function 
oxidase activities determined (Chapter 2). Immunoblot analysis of specific cytochrome 
P450 proteins was performed to confirm any alterations in enzyme activity associated with 
the diabetic group.
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Residts
On reduction of the insulin dose the diabetic animals began to display the 
characteristic signs of uncontrolled type I diabetes mellitus. As previously reported the 
degree of severity of diabetes varied from one animal to the next (Like et ah, 1982) but by 
day four all animals displayed polyuria and polydipsia although hyperphagia was not 
apparent.
Analysis of blood plasma samples revealed that all uncontrolled animals were 
hyperglycaemic and markedly hyperketonaemic (Table 4.1.1). Total microsomal protein 
was not significantly altered in the diabetic groups and there was no age dependent 
alteration. Similarly, the levels of total carbon monoxide discernible cytochrome P450 or 
activity of the NADPH dependent reduction of cytochrome c were not altered in the 
diabetic groups. The level of cytochrome bg was elevated in all the diabetic groups but was 
statistically significant only in the 12 week and 24 week diabetic groups (Table 4.1.2).
Table 4.1.1
GROUP
Plasma glucose and ketone bodv concentrations in the spontaneouslv 
diabetic BB rat
Time from 
detection 
of diabetes
PARAMETER
Plasma glucose
3-hydroxybutyrate
+
Acetoacetate (mM)
Control
Diabetic
Control
Diabetic
Control
Diabetic
4 weeks 
4 weeks 
12 weeks 
12 weeks 
24 weeks 
24 weeks
6.8±0.54
28.2±4.r**
7.1±0.8
26.6±5.0***
5.9±0.9
32.0±5.8***
05110.1
11.410.5***
0.4310.08
1112.3***
0.4910.2
8.411.2***
Data represents mean 1 s.e.m for three animals *** p<0.001 compared to respective controls
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T a b le  4 .1 .2  S o m e  h e p a tic  m ic ro s o m a l p a r a m e te r s  in  th e  s p o n ta n e o u s ly  d ia b e tic  BB r a t
GROUP
PARAMETER
Microsomal Cytochrome Cytochrome NADPH cytochrome c
Protein P450 reductase
(m g/g liver) (nmol/mgPt) (nmol/mgPt) (nmolmin-l mgPpl)
Control 
(4 weeks)
Diabetic 
(4 weeks)
Control 
(12 weeks)
Diabetic 
(12 weeks)
Control 
(24 weeks)
Diabetic 
(24 weeks)
37.110.9 0.4010.07 0.6310.05
38.111.2 0.3410.10 0.9110.19
29.610.7 0.3810.10 05310.04
30.312.5 0.4310.05 0.8210.16*
32.010.4 0.3510.06 0 5310.05
35.111.2 0.5210.07 0.7310.10*
18.111.8
15.0+2.4
25.112.4
20.913.1
17311.0
15.012.1
Data represents mean 1 s.e.m. for three animals 
** p< 0.01 compared to respective controls
(mg Pt = mg protein)
The dealkylations of both ethoxy- and pentoxyresorufin were elevated in all 
diabetic animals (Figure 4.1.1). The déméthylation of ethylmorphine was significantly 
elevated at all time points in the diabetic groups but less pronounced in the older animals 
(Figure 4.1.2). The hydroxylations of both p-nitrophenol (Figure 4.1.2) and lauric acid 
(Figure 4.1.3) were significantly increased in the diabetic animals and did not show any 
decrease in activity with respect to the duration of diabetes (Figure 4.1.3).
Immunoblot analysis of the P450 LA, HE and IVA sub-families showed elevated 
levels of these apoproteins in the diabetic animals (Figure 4.1.4)
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Figure 4.1.3 The effect of uncontrolled diabetes in the spontaneouslv diabetic BB rat on 
lauric acid hvdroxvlation
Lauric acid hydroxylase activity
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Discussion
The spontaneously diabetic BB rat is subdivided into two different populations of
animals namely, the diabetic resistant sub-population and the diabetes prone sub­
population which, when the disease becomes overt, must be maintained on insulin in order 
to survive.
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F ie u re  4.1.4 Im m u n o b lo t a n a ly s is  o f m ic ro so m es  f ro m  u n c o n tro lle d  s p o n ta n e o u s ly  d ia b e tic
BB r a ts
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Microsomal proteins were resolved by electrophoresis in a 10% (w/v) SDS-polyacrylamide gel and 
transfered to nitocellulose. In all cases 20pg of solubilised microsomal protein was loaded except for 
the positive controls when only 10|ig of protein was loaded.
Positive controls
Animal pre-treatment
3-methylcholanthrene (25mg/kg in com oil) for 3 days. 
Isoniazid (0.1% (w/v) in drinking water) for 7 days 
Clofibrate (80mg/kg in saline) for 3 days
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When insulin was withdrawn, the animals rapidly develop signs of uncontrolled 
diabetes although the severity varied markedly between animals. The animals became 
lethargic and displayed polyuria, although they did not develop such severe polydipsia 
as observed with the streptozotocin-diabetic animals, and by day four following insulin 
withdrawal their water intake and body weight were decreasing. The severity of 
uncontrolled diabetes in the BB rat was comparable to that in the uncontrolled 
streptozotocin-diabetic rat. However duration of diabetes was not associated with 
amelioration of enzyme activity in the BB rat. This is in contrast to the situation observed 
in the long-term streptozotocin-diabetic animals (Chapter 3) where prolonged uncontrolled 
diabetes was associated with less marked alterations of drug metabolism. However, in the 
case of the BB rat, the diabetes had been controlled by daily insulin injection from onset and 
so these animals were chronically insulin-controlled diabetic animals until commencement 
of the study. Once insulin was withdrawn from these animals there appeared to be a 
pronounced variation in the onset of the characteristic symptoms of uncontrolled diabetes, 
with some animals displaying polydipsia after 24 hours while others only begin to show 
polydipsia after 48 to 72 hours. If this was also the case with the alteration of hepatic 
drug metabolism it would provide some explanation for the inter-animal variation 
observed with our studies, although when dealing with spontaneous diabetes, as with 
many other genetically determined diseases, this is to be expected and larger numbers of 
animals would be required to make the study more statistically relevant.
It would appear that the duration of diabetes does not have any major influence on 
the severity of diabetes in the BB rat and once insulin is withdrawn from these animals 
they become markedly hyperglycaemic and hyperketonaemic at any age. One of the major 
differences between the uncontrolled diabetic BB rat and the uncontrolled streptozotocin- 
diabetic animal is the length of time the animals can survive without insulin. In the case of 
the BB rat it is a matter of days whereas the streptozotocin-diabetic animals survive 
without insulin for several months. Our present studies reveal that the severity of ketosis
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is far greater in the uncontrolled diabetic BB rat than in the uncontrolled streptozotocin- 
diabetic animal, and this difference may explain the survival rate differences. As most of 
the changes in cytochrome P450 activity are comparable between the two models it is 
possible that physiological adaptation may provide some explanation as to the difference 
in survival time between the two models. It has been suggested that there is islet 
regeneration in the streptozotocin animal which helps it to survive although we have 
shown that the severity of hyperglycaemia is comparable at 4 and 12 weeks post- 
streptozotocin treatment which suggests that this is not the case (Chapter 3). One marked 
difference between the two models is the severity of polydipsia and polyuria. The BB rat 
does not show such marked polydipsia and possibly becomes dehydrated much more quickly 
than the streptozotocin-treated animal which increases its water intake in excess of 15 
times that of non-diabetic animal (Chapter 3). Therefore a possible explanation for the 
differences in survival time may be the clearance rate of the ketone bodies from the two 
models, with the streptozotocin animal being much more efficient at eliminating the toxic 
metabolites when compared to the diabetic BB rat. This may also explain why the plasma 
levels of ketone bodies are also markedly higher in the diabetic BB rat than its 
streptozotocin-diabetic counterpart (Chapter 3).
Uncontrolled diabetes in the BB rat represents an extreme condition. Although this 
study has confirmed that the diabetes-induced modifications in hepatic drug metabolism 
are comparable to the streptozotocin-diabetic animal, a further study to investigate the 
possible situation occurring in human diabetics would be of interest. In the following study 
the BB rat was again used but the animals were poorly insulin-controlled. In this way it 
was hoped that the diabetic BB rat may better represent the situation in human diabetics 
following a daily insulin regime which, although controlling the overt complications of 
the disease may itself represent a poorly insulin-controlled state.
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4.2 Hepatic drug metabolism in the poorly insulin-controlled 
spontaneously diabetic BB rat
The spontaneously diabetic BB rat provides one of the most appropriate models of
human type I diabetes mellitus, the syndrome being both genetically determined and due to 
an autoimmune response. The acute life-threatening complications of this disease; 
hyperglycaemia and hyperketonaemia, are effectively controlled in humans by the 
administration of insulin and a strict diet regime. However, even with the most strict 
regime employed most human type I diabetics present a poorly insulin-controlled state 
rather than complete normality. Therefore, studies involving complete insulin withdrawal 
from the BB rat cannot provide effective information concerning the possible effects of 
prolonged insulin controlled type I diabetes mellitus on hepatic drug metabolism. To 
investigate the effect of a more poorly insulin-controlled state upon drug metabolism we 
employed further groups of spontaneously diabetic BB rats, of differing duration of overt 
diabetes which, over a period of two weeks had their daily insulin injections altered so 
that they received both sub-optimal and excess insulin therapy than necessary to maintain 
their correct body weight.
Animal pretreatment
Twelve diabetes prone and twelve diabetes resistant BB rats were obtained from Dr
A. Bone, Southampton General Hospital, Southampton, U.K. The duration of diabetes 
varied so the animals were divided into three groups; one group of diabetic animals 
displaying overt diabetes for 4 weeks ± 1 week, one group for 12 weeks ± 3 weeks and finally 
one group for 24 weeks ±3 weeks. All animals were allowed 48 hours to acclimatise before
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commencement of treatment. The diabetic animals of each group were treated daily with 
long acting ultra tard insulin (40 I.U./ml, Novo biochemicals) given subcutaneously, the 
dose was calculated from data sheets of animal body weight gain since the detection of 
diabetes using a protocol designed by Dr A. Bone at Southampton General Hospital. On 
commencement of the study the diabetic animals received 10% decrease of their daily 
insulin dose for seven days followed by 10% excess insulin dose for a further seven days. All 
animals were killed on day 15, 16 hours after the last insulin injection and terminal blood 
samples obtained. Plasma glucose and ketone body concentrations were determined as 
previously described (Chapter 2). The livers were immediately excised, microsomal 
fractions prepared and hepatic mixed-function oxidase activities determined. 
Immunodetection of specific cytochrome P450 apoproteins were performed where 
appropriate.
Results
All animals being controlled by insulin injection, with dose determined from their 
medical history data, did not display severe polydipsia, hyperphagia or alteration in 
body weight. Analysis of the plasma ketone body and glucose concentrations revealed that 
all animals were hyperketonaemic and hyperglycaemic at the time of death. This is to be 
expected as the animals were killed some 16 hours after their last insulin injection (Table 
4.2.1).
There was no significant difference in microsomal protein, total cytochrome P450 or 
NADPH cytochrome c reductase activity in any of the groups when compared to their 
controls. However, there was an increase in the levels of cytochrome bg content in the 4 
week diabetic animals but this increase was not found to be significant (Table 4.2.2).
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T a b le  4.2.1 P la sm a  g lu c o se  a n d  k e to n e  b o d y  c o n c e n tra tio n s  fo r  th e  p o o r ly  c o n tro lle d
s p o n ta n e o u s ly  d ia b e tic  BB ra t .
GROUP Glucose (mM)
PARAMETER
3-hydroxybutyrate
+
Acetoacetate (mM)
Control
Diabetic 4 weeks 
Control
Diabetic 12 weeks 
Control
Diabetic 24 weeks
5.7 ± 0.75
23.1 ± 1.4***
6.90 ±0.15
24.1 ± 0.45***
6.40 ± 0.6 
33.6 ± 8.3***
0.38 ± 0.04 
2.40 ± 0.80**
0.24 ±0.01 
1.90 ±0.10**
0.48 ± 0.01 
2.28 ± 0.09***
Data represents mean ± s.e.m. for three animals *p<0.001 compared to control 
*p<0.01 compared to control
The hydroxylation of lauric acid and the déméthylation of ethylmorphine were 
also increased in the diabetic animals although the latter was not significantly increased 
(Figure 4.2.1). Lauric acid hydroxylation was markedly increased in all diabetic animals 
being highly significant at all time points (Figure 4.2.2). The dééthylation of 
ethoxyresorufin was enhanced in the 12 and 24 weeks diabetic animals but the effect was 
significant only in the latter diabetic animals. In contrast, the dealkylation of 
pentoxyresorufin was significantly increased in the 4 week and 12 week diabetic groups but 
not in the 24 week diabetic animals (Figure 4.2.2). The hydroxylation of p-nitrophenol, 
characteristic of P450 IIEl was increased in all diabetic animals, being significantly 
increased at all time points.
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Table 4.2.2 Microsomal parameters in the poorly controlled spontaneously diabetic 
BB rat.
GROUP
Microsomal
Protein
PARAMETER
Cytochrome Cytochrome NADPH cytochrome c 
P450 bs reductase
(mg/g liver) (nmol/mg Pt) (nmol/mg Pt) (nmol/min/mg Pt)
Control
Diabetic 
(4 weeks)
Control
Diabetic 
(12 weeks)
Control
Diabetic 
(24 weeks)
32.3+4.1
28.412.5
34.1+3.8
27.913.1
36.0+2.8
33.0+4.1
0.4810.04
0.5010.09
0.4210.04
0.3710.07
0.4610.08
0.5110.08
0.6110.03
0.7410.05
0.5810.07
0.6910.04
0.5510.08
0.8110.10
19.813.0
17.112.1
18.411.8
17.612.1
15.413.8 
14.713.0
Data represent mean 1 s.e.m. for three animals (Pt = mg protein)
Figure 4.2.1 The effect of poorly controlled diabetes in the BB rat on Ethylmorphine N- 
demethylase activity.
Ethylmorphine N-demethylase activity
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Discussion
As expected, the continued administration of insulin to the diabetic BB rats helped
ameliorate the characteristic physiological effects of polydipsia and polyuria associated 
with the uncontrolled disease. Daily insulin therapy also reduced the severity of ketosis 
compared to the previous study (Chapter 4.1). However the plasma glucose concentrations 
were comparable, clearly showing that all animals were diabetic and hyperglycaemic at 
the time of death, some 16 hours after their last insulin injection. Hyperketonaemia is a 
consequence of excessive fatty acid oxidation by the liver mitochondria and is dependent on 
the mobilisation of lipid stores around the body. When administered daily insulin, these 
animals would not be expected to become as severely ketotic as the uncontrolled animals 
because the fluctuating levels of plasma insulin would not be reduced for a sufficient period 
of time to allow uncontrolled ketogenesis by the liver. Furthermore, the next injection of 
insulin would inhibit further ketogenesis allowing clearance of the plasma ketones. 
However, the animal would be hyperglycaemic as the lower levels of insulin causes rapid 
glycogenolysis and gluconeogenesis by the liver thereby increasing the plasma glucose 
levels.
In the previous study (Chapter 4.1) uncontrolled diabetes was associated with 
similar changes in the cytochrome P450 families as observed in the streptozotodn-induced 
diabetic animals (Chapter 3). The present findings correlate well with the alterations 
encountered in the insulin-treated streptozotocin-diabetic animals in most instances. 
However, the level of insulin control appears much more effective than that in the 
streptozotocin-diabetic animal. All of the diabetic BB rats displayed the expected effects 
in the cytochrome P450 activities reported in previous studies (Chapter 3, 4.1), except that 
the level of induction is markedly reduced reflecting the control associated with even the 
poor insulin therapy. The dealkylation of ethoxy- and pentoxyresorufin, activities 
attributed to the LA and IIB subfamilies respectively, were not as extensively induced as 
found in the uncontrolled study. It is possible that if these subfamilies are partly induced
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by the hyperketonaemia associated with the diabetic state, then the reduced plasma 
ketones in the poorly controlled animals may provide some explanation for these findings. 
Insulin therapy failed to reduce the activity of the HE subfamily towards p-nitrophenol or 
the IVA subfamily towards lauric acid. However, although the diabetic animals were not 
as severely ketotic as the uncontrolled animals they still displayed quite a high level of 
ketosis which may explain the observation. Similarly, in the poorly controlled animals it 
is quite probable that the levels of circulating free fatty acids are still elevated providing 
a possible stimulus for the induction of cytochrome P450 IVAl.
It is dear from these studies that poorly insulin-controlled diabetes is associated 
with changes in hepatic cytochrome P450 families. This suggests that further consideration 
should be given to the effects of poorly insulin-controlled human type I diabetes on drug 
metabolism during the prolonged and multi-drug therapy associated with the long term 
complications of this disease.
4.3 Bioactivation of chemical carcinogens in the uncontrolled 
spontaneously diabetic BB rat
From our previous studies using the streptozotodn-induced diabetic animal model 
(Chapter 3) it was demonstrated that the diabetic state was associated with an increased 
ability to bioactivate known chemical carcinogens. We have further shown that 
uncontrolled diabetes mellitus in the BB rat is associated with similar alterations in the 
levels of cytochrome P450 families as previously observed with the chemically-induced 
model. The propensity for hepatic fractions isolated from these animals to bioactivate 
chemical carcinogens is therefore of particular relevance. Of special interest is the 
induction of the P450 IA2 and the P450 IIEl proteins as these proteins have already been 
shown to play a significant role in the bioactivation of many chemical carcinogens 
(loannides and Parke, 1987; Peng et a l, 1983).
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In our earlier study (Chapter 3) using the streptozotocin-diabetic animals we 
investigated their ability to bioactivate nitrosamines, aromatic amines and pyrolysate 
products. In this study we chose more selective chemical carcinogens, namely Glu-P-1 and 
two cyclic nitrosamines; N-nitrosopiperidine and N-nitrosopyrrolidine. These carcinogens 
are activated by specific isoforms of cytochrome P450 namely, P450IA2 in the case of Glu-P- 
1 and P450 IIEl in the case of the cyclic nitrosamines.
Animal pretreatment
Hepatic fractions derived from the previous studies already described (section 4.1)
were used for this study. Fresh overnight cultures of Salmonella typhimurium strains TA98 : 
and TA1530 were prepared by inoculating nutrient broth and incubating overnight at 370C in 
a shaking water bath. The activation system s used contained 10% (v/v) microsomal 
suspension (105000g pellet resuspended in 1.15% w /v  KCl) in the case of Glu-P-1 and 
25% (v/v) microsomal suspension for the two nitrosamines, being equivalent to 0.35 and 
0.8mg of microsomal protein respectively. Activation system, carcinogen and bacteria were 
always pre-incubated for one hour at 370C in a shaking water bath before being plated onto 
minimal nutrient plates. A mutagenic response was considered positive only when there 
was at least a doubling of the spontaneous reversion rate and a concentration dependent 
increase in the number of histidine revertants.
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Results
The data presented in Table 4.3.1 and 4.3.2 demonstrate that uncontrolled insulin-
dependent diabetes mellitus in the spontaneously diabetic BB rat was associated with 
enhanced bioactivation of both nitrosamines and the pyrolysate product Glu-P-1. The 
duration of diabetes did not influence the bioactivation of the chemical carcinogens 
employed.
Table 4.3.1 The bioactivation of Glu-P-1 by microsomal fractions from
uncontrolled spontaneously diabetic BB rats employing Salmonella 
typhimurium strain TA98.
GROUP HISTIDINE REVERTANTS PER PLATE
Control (4 weeks) 
Diabetic (4 weeks)
Control (12 weeks) 
Diabetic (12 weeks)
Control (24 weeks) 
Diabetic (24 weeks)
2.0 pg/plate 4.0 jig/plate
1010+110 1346+69
3019+96 4986+84
891+41 1100+36
2179+64 241Q±51
911+32 1341±72
3047+104 5194+49
Data represent mean±s.e.m. for triplicates.
Spontaneous reversion rate of 58±8 has already been deducted. All data for diabetic 
animals was significant (p<0.001) compared to respective controls.
Table 4.3.2 The ability of hepatic microsomal fractions from uncontrolled 
spontaneously diabetic BB rats to bioactivate two cyclic 
nitrosamines.
N-Nitrosopyrrolidine Strain TA 1530
GROUP HISTIDINE REVERTANTS PER PLATE
0.5 mg/plate 1.0 mg/plate 2.0 mg/plate
Control (4 weeks) 43+2 30+6 60+11
Diabetic (4 weeks) 78±9 148±40 297+28
Control (12 weeks) 28+5 35±8 43±7
Diabetic (12 weeks) 77±5 84±4 113+12
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T a b le  4 .3 .2  co n t...
Control (24 weeks) 54±19 89+6 40+12
Diabetic (24 weeks) 125±4 169+20 205+5
N-nitrosopiperidine Strain TA 1530
Control (4 weeks) 159±12 202+16 286+11
Diabetic (4 weeks) 174±16 258+15 308+13
Control (12 weeks) 45±3 142+6 241±6
Diabetic (12 weeks) 87+15 353+54 409+24
Control (24 weeks) 47±11 63+8 107±31
Diabetic (24 weeks) 69±9 128+24 125+31
Data represent mean±s.e.m for triplicates. Spontaneous reversion rate never 
exceeded 11±4. All data was significant (p<0.(X)l) compared to respective control.
Discussion
Immunoblot analysis of cytochrome P450 LA in streptozotocin-induced (Chapter 3.) 
and uncontrolled diabetes in the spontaneously diabetic BB rat (Chapter 4.1) showed that 
it was the P450 IA2 protein that is induced by diabetes. This observation is confirmed by 
the increased propensity for hepatic fractions from uncontrolled diabetic BB rats to 
bioactivate Glu-P-1. The bioactivation of this compound has been shown to be exclusively 
catalysed by the cytochrome P450 ÎA2 protein (Kato, 1986).
The activation of nitrosamines has been attributed to the induction of cytochrome 
P450 TIE proteins in diabetes (Peng et a l, 1983). Clearly, the increased activation of the 
two nitrosamines by hepatic fractions derived from the uncontrolled diabetic BB rat 
correlates with the increased hydroxylation of p-nitrophenol, an activity specifically 
catalysed by cytochrome P450 IIEl.
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The increased ability for the bioactivation of known carcinogens by both 
chemically-induced and spontaneously diabetic animals raises the probability that 
similar effects may be observed in human diabetic patients. Although, human diabetic 
patients are effectively controlled by insulin therapy, our study of poorly insulin-controlled 
diabetes (Chapter 4.2) demonstrates that alterations of these cytochrome P450 proteins are 
still apparent. Thus the human diabetic patient may show a greater pre-disposition 
towards chemical carcinogen activation. However, it must be stressed that the present 
study employing the Ames mutagenicity test focuses attention exclusively on the pathways 
of activation. The activation system, being devoid of phase II cofactors, has a very limited 
phase II detoxification capability and therefore cannot mimic the in vivo situation. 
Furthermore, strepto2X)tocin-induced diabetes has been associated with alteration of phase 
II enzyme activity, especially glutathione S-transferase, which effectively deactivates 
many metabolically formed reactive intermediates.
This study further confirms that it is the diabetic state that is responsible for the 
increased propensity of both the streptozotocin-diabetic and the spontaneously diabetic 
rats to bioactivate known chemical carcinogens. The induction of Glu-P-1 bioactivation has 
been previously shown to be exclusively performed by P450IA2, a protein that is induced in 
uncontrolled insulin-dependent diabetes mellitus (Chapter 3 and Chapter 4).
There does not appear to be any discernible difference between the duration of 
insulin controlled diabetes and the ability of the uncontrolled animals to bioactivate the 
carcinogens used in this study. This suggests that individuals with insulin-dependent 
diabetes mellitus of any age may show a increased propensity of carcinogen bioactivation, 
independent of the duration of the disease and also suggests that poorly controlled diabetes 
where similar alterations of the cytochrome P450 family does occur, albeit not to the same 
extent as in uncontrolled diabetes, may also show a greater pre-disposition towards 
chemical carcinogen bioactivation. However it must be stressed that the present studies 
involving the Ames test focus attention exclusively on the pathways of activation and as
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the activation system, being devoid of phase II cofactors, has a very limited phase II 
detoxication capability and therefore does not mimic the in vivo situation.
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Chapter 5
The modulation of hepatic m ixed-function  
oxidase activity by ketone bodies
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The ability of the average individual to survive long periods of food deprivation is 
made possible through a complex series of hormonal and biochemical signals that ensure 
the appropriate inter-organ redirection and utilisation of major fuels. In the early stages of 
a fast, there is a shift in liver metabolism from glucose storage to glucose production, 
coupled with other adaptations that conserve circulating glucose for maintenance of brain 
and CNS function. Crucial is the ability of most tissues in the body to switch from 
carbohydrate to a lipid-based catabolism, utilising free fatty acids mobilised from fat 
depots as their main source of energy. The liver responds uniquely by enhancing its capacity 
to convert incoming free fatty adds into ketone bodies, which serve as auxiliary fuels of 
respiration for non-hepatic tissues. As starvation progresses the blood ketone body 
concentration gradually rises to the region of 5mM, allowing these compounds to make an 
increasing contribution to the energy requirements of the brain.
Physiological ketosis, although initiated by a rise in circulating glucagon and fall 
in circulating insulin, is kept in check by the P-cells which remain responsive to stimulation 
by rising concentrations of free fatty acids and ketones, even in the presence of non­
stimulatory concentrations of glucose in the plasma. Low-level secretion of insulin 
throughout starvation modulates free fatty acid release and prevents progression to full­
blown ketoacidosis. However, this delicately balanced interplay of critical hormones and 
fuels is subject to breakdown in a variety of diseases induding diabetes mellitus.
The hallmark of all ketotic-states, whether physiological or pathophysiological, 
is insulin defidency. For many years it was believed that a fall in insulin was suffident to 
initiate ketogenesis, but it now appears that although a fall in circulating insulin is the 
major ’triggering' event for accelerated ketogenesis, there is a requirement for a relative or 
absolute excess of the pancreatic tt2-cell hormone, glucagon.
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The work of Gerich et al., (1975) and others confirmed that ketogenesis is under 
bihormonal control. The first requirement is increased fatty acid delivery to the liver, 
fulfilled by a decrease in circulating insulin and the activation of fatty acid oxidation 
brought about by an elevated glucagon/insulin ratio. Therefore, acute on-off control of 
ketogenesis is mediated primarily by the pancreatic «2- arid P-cells.
5.1 The role of ketone bodies in the modulation of hepatic mixed 
function oxidase activity.
During type I diabetes the delicate balance of ketogenesis becomes disturbed. The 
destruction of the P-cells results in low or undetectable levels of plasma insulin, which 
prevents the secretion of insulin in response to the increasing levels of plasma fatty acids. 
The decreased insulin levels result in an increased glucagon /  insulin ratio leading to 
uncontrolled ketogenesis. If this condition is not corrected by the administration of 
exogenous insulin then full-blown ketoacidosis will occur with fatal consequences. The 
alterations of hepatic cytochrome P450 activities in streptozotocin-induced diabetes 
(Chapter 3), particularly the induction of P450 IIEl (Past and Cook, 1982; Thomas et 
al.,1987), are often observed during starvation or when animals are administered acetone, or 
large doses of ethanol. It has been postulated, therefore, that the alteration in P450 
activities may be mediated by the circulating levels of ketone bodies (Peng ef a/.,1983). 
This hypothesis has already been supported by a good correlation between the plasma 
ketone body levels and the induction of cytochrome P450 IIEl (Thomas et al.,1987).
In order to investigate the role of hyperketonaemia in the diabetes-induced
alterations of the hepatic mixed-function oxidase activities, rats were rendered ketotic by 
the daily administration of medium chain triacylglycerols (Flatt et a l, 1987). The
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activities of selected substrates for the mixed-function oxidases, shown to be influenced by 
diabetes, were investigated in comparison to streptozotocin-diabetic and control rats. 
Immunodetection of cytochrome P450 proteins was also performed using monospecific 
antibodies to confirm the findings of the diagnostic stibstrates employed.
Animal pretreatment
Male Wistar albino rats (170-200g) were randomly divided into three groups. The
first group received a single intraperitoneal injection of streptozotocin (65mg/kg) in 0.5M 
sodium citrate buffer, pH 4.5; the second group received daily administration of medium 
chain triacylglycerols (fractionated coconut oil comprising; Ce not more than 2%, Cg « 56%, 
Qo -  40%, C \2  not more than 1.5%) by gastric intubation (8g/kg). The third group served as 
control. All animals were killed 21 days after the commencement of treatment. Hepatic 
microsomal fractions were prepared and mixed-function oxidase activities determined.
Body weight, food and water intake were monitored daily and blood samples from 
the cut tip of the tail of conscious rats were used for the determination of plasma glucose, 
acetoacetate and 3-hydroxybutyrate.
Immunodetection by SDS polyacrylamide gel electrophoresis and Western blotting 
to identify specific cytochrome P450 proteins was performed as previously described 
(Chapter 2).
Results
The diabetic animals displayed the normal physiological characteristics of 
depressed body weight gain, polydipsia and hyperphagia (Figure 5.1.1) while the
1 1 9
animals receiving the medium chain triacylglycerols resembled the control animals except 
for a slight decrease in body weight gain and food intake (Figure 5.1.1).
Figure 5.1.1 Effect of streptozotocin-induced diabetes (STZ) or medium chain
triacylglycerol treatment (MCT) on body weight gain, food and water 
intake.
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Plasma analysis revealed that the diabetic animals were markedly 
hyperketonaemic and hyperglycaemic throughout the study. Animals receiving the 
medium chain triacylglycerols, were hyperketonaemic but in contrast to the diabetic 
animals they were normoglycaemic (Figure 5.1.2) and displayed ketone body levels lower 
than the diabetic animals at day four (p<0.05) but comparable levels thereafter.
Figure 5.1.2 Plasma glucose and ketone body concentrations in control, streptozotocin- 
diabetic (STZ) and medium chain triacvlglvcerol treated animals (MCT)
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Microsomal cytochrome bs, cytochrome P450 and microsomal protein levels were not 
significantly affected by streptozotocin and medium chain triacylglycerol treatment (Table
5.1.1). The NADPH-dependent reduction of cytochrome c was, however, markedly 
increased in both the medium chain triacylglycerol and especially the streptozotocin- 
treated animals (Table 5.1.1). The O-dealkylations of ethoxyresorufin and 
pentoxyresorufin were significantly elevated in both the streptozotocin- and medium chain 
triacylglycerol-treated rats (Figure 5.1.3). A similar pattern emerged in the p- 
hydroxylation of aniline, and the N-demethylation of dimethylnitrosamine (Figure 5.1.3). 
Both streptozotocin and medium chain triacylglycerol treatments significantly increased 
the hydroxylation of lauric acid (Figure 5.1.4). However, the N-demethylation of 
ethylmorphine was not affected by treatment with medium chain triacylglycerols in 
contrast to the significant induction of this activity in the streptozotocin-diabetic animals 
(Figure 5.1.4). Immunoblot analysis confirmed that the increased enzymes activities 
associated with both streptozotocin-induced diabetes and medium chain triacylglycerol 
treatment correlated with increased levels of specific cytochrome P450 apoproteins (Figure 
5.1.5).
Table 5.1.1 Effect of treatment of rats with streptozotocin or medium chain 
triacylglycerols on hepatic microsomal parameters.
PARAMETER Control
GROUP
Streptozotocin
Cytochrome P450
(nmol/mg protein) 0.28±0.04 0.37±0.05
Cytochrome bs
(nmol/mg protein) 0.25±0.05 0.31±0.05
NADPH- cytochrome c 
reductase
(nmol/min/mg protein) 33±3
Microsomal protein 
(m g /g  liver) 36±4
139±5*
38±2
Medium chain 
triacylglycerol
0.36±0.04
0.32+0.02
128+4*
35±5
Data represents mean±s.e.m for five animals *p<0.001 compared to control
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Figure 5,1.3 The effect of streptozotocin-diabetes (STZ) and medium chain 
triacylglycerol (MCT) treatment on some hepatic mixed-function oxidase 
activities.
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Figure 5.1.4 The effect of streptozotocin-diabetes (STZ) and medium chain
triacvlglvcerol (MCT) treatment on some hepatic mixed-function oxidase 
activities.
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Figure 5.1.5 Immunoblot analysis of microsomal cytochrome P450 proteins from streptozotocin 
and medium chain triacylglycerol treated rats.
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Discussion
Rats treated with medium chain triacylglycerols or with streptozotocin exhibited 
marked hyperketonaemia within four days of treatment with the ketosis being sustained 
throughout the duration of the study. Streptozotocin-treated rats exhibited markedly 
higher activities in the metabolism of all substrates studied, as well as in the NADPH- 
dependent reduction of cytochrome c as previously reported by other groups (loannides e t 
a l,  1989).
Hyperketonaemia induced by the daily administration of medium chain 
triacylglycerols gave rise to similar increases in the various mixed-function oxidase 
activities, providing direct evidence for the role of ketosis in the diabetes-induced changes 
in microsomal drug metabolism. The generally higher increases observed in the 
streptozotocin treated animals may reflect the fact that these animals suffered a more 
severe ketosis than was produced by the medium chain triacylglycerol treatment. These 
results clearly demonstrate that the changes in circulating plasma glucose concentrations are 
not responsible for the diabetes-induced increases in hepatic drug metabolism. In fact 
previous studies have already shown that chronic hyperglycaemia actually decreased 
mixed-function oxidase activity (Hartshorn et a/.,1979).
The increases in dimethylnitrosamine N-demethylase and aniline p-hydroxylase 
activities in chemically induced diabetes have been attributed to the induction of 
cytochrome P450 IIEl, and it is clear from this study that the same isoform is being induced 
by the administration of medium chain triacylglycerols. The O-deethylation of 
ethoxyresorufin is a reaction exclusively catalysed by the P450 lA subfamily, and this 
protein appears to be induced by both treatments. The results of the metabolic activation of 
Glu-P-1 demonstrate that it is the P450 IA2 protein that is being induced in both cases, an 
observation confirmed by immunodetection (Figure 5.5). Immunodetection of the respective
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cytochrome P450 proteins confirms that streptozotocin and medium chain triacylglycerols 
induce the same P450 isoforms with the exception of P450IIIA which does not appear to be 
responsive to medium chain triacylglycerol treatment. This is not necessarily a surprising 
finding since inducers of this isoform are generally very large molecules such as the 
macrolide antibiotics. The cytochrome P450 IIB proteins have an important role in the 
detoxication of many drugs, the induction of this subfamily by both treatments may have 
clinical implications for diabetic patients being administered a variety of drugs to combat 
the long-term complications of the disease.
5.2 The modulation of carcinogen activation by 
hyperketonaemia
In the previous study our observations clearly demonstrate that the 
hyperketonaemia accompanying uncontrolled type I diabetes mellitus has an important 
role in the alterations in hepatic drug metabolism associated with the disease. In view of 
the fact that hyperketonaemia can occur as a result of various physiological conditions 
such as fasting or starvation and that the induction of the cytochrome P450 lA and IIE 
subfamilies has been associated with the increased metabolic activation of known 
chemical carcinogens (Phillipson et a l, 1984; Thomas et a l, 1987; Cairo et a l, 1981) it was 
decided to investigate the ability of hepatic fractions from these animals to metabolically 
activate the chemical carcinogens previously investigated with the streptozotocin diabetic 
and spontaneously diabetic BB rat hepatic fractions.
Animal pretreatment
The hepatic fractions from control, streptozotocin and hyperketonaemic animals
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were obtained from the animals used in the previous study. Metabolic activation of the 
precarcinogens to their mutagenic intermediates was determined using the Ames test and 
employing fresh overnight cultures of the various Salmonella typhimurium  strains as 
previously described (Chapter 3). All carcinogens were dissolved in dimethylsulphoxide 
and lOOpi used on each plate. Activation systems contained 10% (v/v) of the S9 fraction 
(post-mitochondrial supernatant), except in the case of the nitrosamines when the 
concentration was increased to 25% (v/v) (Ayrton et a l, 1987).
Activation system, pre-carcinogen and bacteria were pre-incubated for 1 hour at 
3 7 OC in a shaking water bath. The number of induced histidine revertants increased 
linearly with time, at least up to one hour of preincubation.
Results
The mutagenic response to the two cyclic nitrosamines N-nitrosopiperidine and N-
nitrosopyrrolidine was markedly enhanced in the presence of activation system derived 
from the animals pretreated with the medium chain triacylglycerols than from control 
animals and streptozotocin-induced diabetes gave rise to an even higher response (Table
5.2.1). Similarly, administration of medium chain triacylglycerols markedly enhanced the 
activation of the food precarcinogens Trp-P-2 and Glu-P-1 and to a lesser extent Trp-P-1 
(Table 5.2.2) and again the effect of streptozotocin-induced diabetes was to produce a more 
pronounced effect. In contrast, administration of medium chain triacylglycerols gave rise to 
a small, but significant decrease, in the mutagenicity of 2-aminofluorene at higher 
concentrations with the streptozotocin-diabetic fraction showing an even more pronounced 
decrease in the activation of this carcinogen (Table 5.2.3).
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Table 5.2.1 Metabolic activation of two cyclic nitrosamines bv streptozotocin (STZ), 
and medium chain triacylglycerol (MCT) treated animals
N-nitrosopiperidine Strain TA 1530
Concentration 
( mg /  plate) Control
Histidine revertants /  plate 
MCT STZ
05 8±1 75+10 162+9
1.0 1Q±2 110+8 202+11
15 14±3 125±5 209+7
2.0 16±3 173±7 297±16
N-nitrosopyrrolidine Strain TA 1530
05 4±1 104±10 191+7
1.0 12±2 156+9 226+18
15 18±3 173+11 279+15
2.0 23±4 180+10 350+24
Data represents mean±s.e.m for triplicates p< 0.001 for all MCT and STZ values
compared to control. Spontaneous reversion rate of 6±2 and has already been subtracted.
Table 5.2.2 Metabolic activation of the food precarcinogens Trp-P-1, Trp-P-2 and 
Glu-P-1 by fractions from streptozotocin-diabetic (STZ) and medium 
chain triacylglycerol (MCT) treated animals.
Glu-P-1 Strain TA 98
Concentration Histidine revertants /  plate
( |ig /  plate) Control MCI STZ
25 9+2 2480±121 2980+96
5.0 20+4 3604+214 4200+186
75 30±6 5001±397 5480+276
10.0 . 47±9 6364±487 7290+401
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T a b le  5.2 .2  c o n tin u e d ...
Trp-P-2
25
5.0 
75
10.0
Strain TA 98
7±2
5±3
9±2
11±3
53±13
247±56
429+61
463+39
254±41
307±68
521±84
694±75
Trp-P-1
25
5.0
75
105
Strain TA 98
178+29
328±101
649±71
742±94
302169
616+121
706+39
10581298
390187
831191
9621132
10541169
Data represents mean 1 s.e.m. for triplicates p<0.001 for all MCT and STZ values 
compared to control. The spontaneous reversion rate of 1712 and has already been 
subtracted.
Table 5.2.3 The metabolic activation of 2-aminofluorene bv streptozotocin-diabetic 
(STZ) and medium chain triacvlglvcerol treated (MCT) animals.
2-Aminofluorene Strain TA 1538
Concentration Histidine revertants /  plate
( pg /  plate) Control MCT STZ
25 9601270 12801101 12941101
5.0 16801138 1340160 1310+60
75 1940187 1560174* 1468174**
10.0 2604150 1970162** 1801162***
Data represents meanls.e.m. for triplicates. The spontaneous reversion rate of 712 has 
already been subtracted. *p<0.05; **p<0.01; ***p<0.001 compared to control.
130
Discussion
H y p e r k e t o n a e m ia  i n d u c e d  b y  th e  o r a l  a d m i n i s t r a t i o n  o f  m e d i u m  c h a in
triacylglycerols profoundly modulated the metabolic activation of major groups of 
carcinogens such as nitrosamines and both aromatic and heterocyclic amines. This is in 
concert with our previous findings that hyperketonaemia modulated the activities of the 
cytochrome P450 dependent hepatic mixed-function oxidases (Barnett et al.,1988). 
However, the effect of hyperketonaemia in the activation of chemical carcinogens is very 
much dependent on the nature of the carcinogen involved.
It is generally accepted that the initial step in the bioactivation of nitrosamines is 
an a -hydroxylation catalysed primarily by the cytochrome P450-dependent 
mixed-function oxidases (Hecker et a/.; 1979). The a-hydroxynitrosamines are unstable and 
rapidly decompose, giving rise to alkylating agents and aldehydes. Of the various 
cytochrome P450 proteins, the cytochrome P450 IIEl form plays a major role in the 
activation of many nitrosamines (Yang et a/.,1985) including N-nitrosopyrrolidine (McCoy 
et ah,1979) and presumably the increased activation by the medium chain triacylglycerol- 
treated preparations reflects the elevated levels in this protein.
The initial and rate limiting step in the activation of the heterocyclic amines Glu- 
P-1 and Trp-P-2 is an a-hydroxylation which is specifically catalysed by the cytochrome 
P450 lA subfamily and especially the P450 IA2 isoform (Kato 1986). The aromatic amine 2- 
aminofluorene is also activated by N-hydroxylation but in contrast to Glu-P-1 and Trp-P-2 
its N-hydroxylation is catalysed not only by P450 lA proteins but also by isozymes 
belonging to the P450 IIB sub-family, constitutive forms of the cytochrome as well as the 
flavine monooxygenase system (Hammons et ah, 1985) and cytosolic enzyme systems 
(Ayrton and loannides, personal communication) and so interpretation of this decreased 
mutagenicity is difficult.
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In summary, the effect of hyperketonaemia on the activation of chemical 
carcinogens closely resembles that displayed by streptozotocin-induced and spontaneously 
diabetic derived hepatic fractions. This observation together with the fact that 
hyperketonaemia gives rise to similar changes in hepatic mixed-function oxidase 
activities, as observed in uncontrolled type I diabetes, provides compelling evidence that
the diabetes-induced effects are mediated, at least partly, through the increased 
production of ketone bodies and that similar alterations would be expected in other 
physiological or pathological conditions associated with elevated ketone body production.
5.3 The effect of acetone, 3-hydroxybutyrate and 1,3 butanediol 
on hepatic drug metabolism.
The studies investigating the effects of hyperketonaemia on drug metabolism
clearly demonstrate that it is a major factor influencing hepatic drug metabolism mediated 
by the cytochrome P450-dependent mixed-function oxidases. Numerous studies have shown 
that acetone is one of the most potent inducers of cytochrome P450 IIEl (Koop et al., 1985), 
and is elevated during uncontrolled type I diabetes in animals. The inducibility of 
cytochrome P450 IIEl by acetone prompted the investigation of the possible catalytic 
activity of P450 IIEl towards this substrate. Casazza et a l, (1984) showed that this 
isoform was capable of hydroxylating acetone to acetol, a possible precursor for 
gluconeogenic enzymes. They proposed that this isoform was capable of redirecting acetone 
back into the gluconeogenic pathways rather than being excreted from the body. Acetone is 
produced by the spontaneous decarboxylation of acetoacetate produced in the liver from 
excess acetyl Co A. However, the liver also produces 3-hydroxybutyrate in equimolar 
concentrations with acetoacetate yet, in our studies of both spontaneous and chemically- 
induced diabetes, the plasma acetoacetate concentration does not appear to be as elevated 
as the 3-hydroxybutyrate concentration. This raises the question as to whether 
acetoacetate spontaneously decarboxylates at a rate significantly high enough to account
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for the discrepancy or that acetoacetate is being actively removed from the plasma. 
Furthermore, our previous studies with dietary-induced hyperketonaemia suggested that 
ketone bodies may be the inducing agents for the cytochrome P450IVA subfamily. However 
during prolonged streptozotocin-induced diabetes, the duration of induction of this isoform 
was limited even though the plasma ketone body concentration was still elevated.
To investigate the effect of individual ketone bodies on the induction of cytochrome 
P450, animals were treated with either acetone, 3-hydroxybutyrate or 1,3-butanediol, 
which is metabolised to yield all three ketone bodies (Mehlman et a l, 1975).
Animal pretreatment
Sixteen male Wistar albino rats (150-200g) were obtained from the
Experimental Biology Unit, University of Surrey and divided into four groups. One group 
served as control and received 2ml of water daily by gavage. Of the other groups; one group 
received acetone (15mmol/kg); one group 3-hydroxybutyrate, sodium salt (15mmol/kg) and 
the last group 1,3 butanediol (15mmol/kg). All doses were given in a final volume of 2ml of 
water and administered daily by gavage for three days. All animals were killed 24 hours 
after the final dose and terminal blood samples obtained. The livers were immediately
excised and microsomal fractions prepared as previously described. Mixed-function oxidase \
\   ■
activities were determined and immunological detection of specific cytochrome P450
proteins^rformed as previously described (Chapter 2).
Results
All animals were mormoglycaemic and the levels of plasma 3-hydroxybutyrate 
were slightly elevated in tlib animals treated with 3-hydroxybutyrate but significantly
elevated (p<0.01) in those treated with 1,3-butanediol (Table 5.3.1). There were no
/
significant alterations of/the plasma acetoacetate concentrations in any of the treated
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animals. None of the treatment groups showed any significant difference in microsomal 
protein, total carbon monoxide discernible cytochrome P450, cytochrome bg, or the NADPH 
dependent reduction of cytochrome c compared to control levels (Table 5.3.2).
Table 5.3.1 Plasma glucose and ketone body concentrations in acetone.
3-hvdroxvbutyrate and 1.3-butanediol treated animals.
GROUP
Control
PARAMETER
Acetoacetate 3-Hydroxybutyrate Gluco%
(mM) (mM) (mM)
0.26±0.01 0.27±0.02 5.8+0.15
Acetone 0.30+0.03 0.24+0.003 5.9+0.20
3-hydroxybutyrate 0.16±0.04 0.34±0.05 5.6+0.4
1,3-butanediol 0.23+0.05 0.47±0.02*** 6.1+0.2
Values represent meanls.e.m. for five animals. ***p<0.001 compared to control
Table 5.3.2 Some hepatic parameters in rats treated with various ketones.
PARAMETER
Protein 
(m g/g liver)
GROUP
Control Acetone 3-hydroxybutyrate 1,3-butanediol
28.711.12 32.211.4
Cytochrome P450
(nmol/mg Protein) 0.4310.02 0.4210.02
Cytochrome bg
(nmol/mg protein) 0.7310.05 0.6210.02
NADPH cytochrome c
reductase
(nmol/min/
mg protein) 16.812.2 17.711.6
32.212.6
0.46±0.05
0.6410.04
31.711.69
0.3710.02
0.6510.07
18.010.9 18.811.7
Values represent meanls.e.m. for five animals
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Similarly there was no treatment dependent alteration in the hydroxylation of 
lauric acid or in the N-demethylation of ethylmorphine. However, acetone treatment 
resulted in a significant increase in the dééthylation and depentylation of ethoxy- and 
pentoxyresorufin respectively. These increases were also observable with 3- 
hydroxybutyrate treatment, although the increases were not significant. Treatment with 
1,3 butanediol treatment did not cause any alteration of activity. The hydroxylation of p- 
nitrophenol was significantly induced by acetone and 15 butanediol treatment but not by 3- 
hydroxybutyrate treatment (Table 5.3.3). Immunological detection confirmed that the 
increases in the various cytochrome P450 activities were accompanied by increases in the 
levels of specific cytochrome P450 apoproteins (Figure 5.3.1).
Table 5.3.3 Cytochrome P450 catalysed activities in the liver of rats treated 
with various ketones.
PARAMETER
Ethoxyresorufin-O
deethylase
(pmol/min/mg protein)
Pentoxyresorufin-O
depentylase
(pmol/min/mg protein)
p-Nitrophenol 
hydroxylase 
(nmol/min/mg protein)
Lauric acid
hydroxylase
(nmol/min/mg protein)
Ethylmorphine N-
demethylase
(nmol/min/mg protein)
GROUP
Control Acetone 3-hydroxybutyrate 15-butanediol
9.7±2.0 15.1+0.7*
2.5+0.4 6.5±0.9*
16.0+1.4 13.2±2.2
13+1.6
3.5+0.9
0.9+0.15 2.9+0.07*** 0.89+023
0.76±0.08 0.66+0.05 0.61+0.04
135±2.0
7.1+1.1
2.23+0.4
1.45+0.26
0.87±0.12
10.48+2.6
Values represent meanls.e.m for five animals. *p<0.05; **p<0.01; ***p<0.001 compared to 
control.
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Figure 5.3.1 Immunoblot analysis of microsomes from acetone, 3-hydroxybutyrate and
1,3-butanediol treated rats
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1,3B = 1,3-butanediol
Microsomal proteins were resolved by electrophoresis in a 10% (w/v) SDS-polyacrylamide gel and 
transfered to nitocellulose. In all cases 20pg of solubilised microsomal protein was loaded except for 
the positive controls when only lOpg of protein was loaded.
Positive controls
Animal pre-treatment
3-methylcholanthrene (25mg/kg in com oil) for 3 days.
Isoniazid (0.1% (w/v) in drinking water) for 7 days 
Clofibrate (80mg/kg in saline) for 3 days
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Discussion
Hyperketonaemia has previously been shown to cause similar alterations in the 
cytochrome P450 mixed-function oxidase system as observed in uncontrolled type I diabetes 
mellitus of both spontaneous and chemically-induced origin (Barnett et ah, 1988). The role 
of specific ketones in the modulation of this system has not been fully investigated, 
although many studies have shown that acetone is a potent inducer of the cytochrome P450 
BEI protein (Koop et ah, 1985).
In agreement with the above studies, acetone was shown to be capable of inducing 
the cytochrome P450 BEI protein but our data also demonstrates that the molecule is 
capable of inducing both the P450 IA2 protein and the P450 BB protein. However, acetone 
did not affect the activities of the P450 BIA or the P450 IVA subfamilies. Similarly, the 
treatment of animals with 3-hydroxybutyrate caused a more modest increase in the 
activity of the P450 lA and BB subfamilies as determined by both enzyme analysis and 
immunological techniques. In contrast to acetone, the induction of the cytochrome P450IIE 
subfamily by this molecule was minimal, although a high degree of inter-animal variation 
was apparent. In common with acetone, 3-hydroxybutyrate had no effect on the levels of 
the cytochrome P450 BIA and IVA subfamilies.
The inclusion 1,3-butanediol in this study provided a compound which has been
shown to be metabolised to acetoacetate and 3-hydroxybutyrate (Mehlman et ah, 1975). 
However, this compound did not alter the levels of the P450 lA, IIB, IIIA or IVA
subfamilies but did cause an elevation of the P450 BE subfamily. The reason for this 
remains unclear at the present time.
All three treatment regimes failed to affect the activities of the cytochrome P450 
BIA subfamily. This is not necessarily an unexpected result when the chemical structures of
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typical inducers of this subfamily are considered. In the case of P450 IIIA inducers, most are 
large molecules such as the macrolide antibiotics and the immunosuppressant drug 
cyclosporin and therefore these small molecules would not be expected to cause induction of 
this subfamily. These results do however provide further evidence to support our previous 
suggestions that the induction of the P450 IIIA subfamily is due to other changes associated 
with the disease state and not by ketosis.
The effect of hyperketonaemia induced by the administration of medium chain 
triacylglycerols on the P450 IVA subfamily suggested that circulating ketone bodies may be 
responsible for the induction. The current study indicates that this is not the case and that 
other factors in diabetes mellitus may be responsible. Many studies have already shown 
that diabetes mellitus is associated with hyperlipidaemia (Dunn, 1990) an effect that 
would have occurred when animals were treated with medium chain triacylglycerols. 
When considering our previous study of prolonged uncontrolled diabetes in the 
streptozotocin-diabetic animal (Chapter 3) we showed that as the duration of disease 
progressed the levels of the P450 IVA protein began to decrease to levels similar to those of 
control animals. These observations suggest that it may be the increased levels of 
circulating fatty acids, associated with acute uncontrolled type I diabetes, that are 
responsible for the induction of this isoform of cytochrome P450.
In agreement with previous studies, acetone is a potent inducer of cytochrome P450 
IIEl (Ryan ei a l ,  1986). Previous investigations have shown a correlation between the 
levels of plasma 3-hydroxybutyrate and the levels of cytochrome P450IIE catalysed  
reactions (Bellward et ah, 1988). However in our study 3-hydroxybutyrate did not affect 
the activity of P450 IIEl. Uncontrolled diabetes m ellitus is associated w ith a severe 
ketosis which can show marked inter-animal variation in severity. It is possible that a 
correlation between the levels of cytochrome P450IIE1 and plasma 3-hydroxybutyrate 
concentration does exist but that this is not the major inducing species for P450 IIEl.
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Casazza et al., (1984) have already shown that cytochrome P450 IIEl is capable of 
hydroxylating acetone to acetol, presumably the first step in shunting acetone back into the 
gluconeogenic pathways. Our results would tend to suggest that the levels of acetone in the 
plasma are more^mportant than those of 3-hydroxybutyrate in terms of inducing potential.
In our previous studies it was observed that the levels of 3-hydroxybutyrate in the 
plasma are usually several fold higher than those of acetoacetate. The one compound not 
investigated in this study was acetoacetate due to problems obtaining sufficient quantities 
in the form of a non-toxic salt.
Finally, this study suggests that the various ketone bodies have differing effects on  ^
the cytochrome P450 families, with acetone being the most effective inducer of the P450 lA, 
IIB and HE subfamilies and it will be necessary to investigate the role of acetoacetate in  ^
the modulation of cytochrome P450 families in view of our present findings. It has been J 
suggested that as 3-hydroxybutyrate caused very modest changes in the parameters ; 
examined it may be due to the fact that this compound is not readily absorbed. However, * 
when Mehlman , ef a/.,(1975) examined the effects of oral administration of 3- ' 
hydroxybutyrate to animals they found significant elevations in the plasma levels of this ; 
compound. As our data for plasma levels represents terminal samples, ie 24 hours after the ; 
last administration, it is probable that the levels of this ketone body had returned to -, 
within normal plasma ranges.
139
Chapter 6
The effect of other insulin-ah errant 
conditions on hepatic drug metabolism
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6.1 The effect of type II diabetes mellitus on hepatic drug 
metabolism
Although type I diabetes is the most severe form of diabetes mellitus, maturity
onset or type II diabetes represents the most common form of the disease. It is characterised 
by a relative lack of insulin due to a resistance of the target cells to insulin combined with 
faulty secretion of insulin by the P-cells of the pancreas. This type of diabetes is associated 
with hyperglycaemia but rarely with ketosis. The condition is usually effectively 
controlled by diet and drug therapy. Complications associated with type II diabetes 
include hypertension and obesity and the disease can represent a mild hyperinsulinaemic 
condition as insulin resistance can result in increased secretion by the P-cells. In view of the 
dramatic changes in the hepatic cytochrome P450-dependent mixed-function oxidase 
system observed with type I diabetes, the investigation of the effects of type II diabetes bn 
hepatic drug metabolism is necessary to complete our investigations into the effects of 
diabetes mellitus on drug metabolism. Previous studies by Rouer and Leroux (1981) have 
shown that spontaneously hyperglycaemic mice show some slight quantitative differences 
in their mixed-function oxidase activities although only limited investigations were 
performed.
Animal pretreatment
Six male spontaneously obese hyperglycaemic (ob/ob) mice and six normal lean 
littermates, 16 weeks of age, were obtained from Aston university. After an initial period of 
acclimatisation the animals were killed by cervical dislocation. The livers were 
immediately excised and the gall bladder removed before microsomal fractions were 
prepared and mixed-function oxidase activities determined (Chapter 2).
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Results
The obese mice were hyperglycaemic but not hyperketonaemic. The
hyperglycaemia was not as marked as seen in the insulin-dependent diabetic animals 
(Table 6.1.1). The obese animals did not show any alteration of microsomal protein, 
cytochrome bg, total cytochrome P450 or the NADPH-dependent reduction of cytochrome c 
(Table 6.1.2).
Table 6.1.1 Plasma glucose and ketone body concentrations in obese and lean
mice
GROUP
PARAMETER Lean Obese
Glucose (mM) 5.610.2 11.211.4**
Acetoacetate 
+ 3-hydroxybutyrate
(mM) 0.4010.01 0.3810.1
Data represents meanls.e.m. for six animals. ** p<0.01 compared to control
Determination of specific cytochrome P450 activities did not reveal any significant
differences from the activities encountered in the lean animals (Table 6.1.3). However, 
investigation of enzymes involved in phase II conjugation reactions revealed that the obese 
mice did have significantly lower glutathione S-transferase activity and levels of total
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glutathione (Table 6.1.3). This was coupled with a slight elevation in the ability to reduce 
oxidised glutathione.
Table 6.1.2 Hepatic microsomal parameters for the obese and lean (ob/ob) mice
GROUP
PARAMETER Lean Obese
Protein
(m g/g liver) 26.010.9 28.111.2
Cytochrome P450
(nmol / mg protein) 0.2110.05 0.1910.01
Cytochrome bg
(nmol /  mg protein) 0.4510.1 0.5110.1
NADPH-cytochrome c 
reductase
(nmol/ min/ mg protein) 5.510.7 7.112.0
Data represents meanls.e.m. for six animals
Discussion
Type II diabetes is associated with a moderate hyperglycaemia which is
effectively controlled by a dietary regime supplemented in some cases with oral 
hypoglycaemic drug therapy. The obese mice in this study were not severely 
hyperglycaemic and were not ketotic. Previous studies undertaken by Rouer and Leroux 
(1981) have shown that the effect of type II diabetes on the hepatic mixed-function oxidase 
system is minimal. In the present study we have investigated the effects of this form of 
diabetes on a more extensive range of cytochrome P450 activities. This confirmed that type 
II diabetes does not appear to influence the mixed-function oxidase system to any great
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extent. It is possible that the absence of ketosis in these animals may explain the lack of 
induction of specific isoforms of cytochrome P450, whose induction, in some cases has 
already been correlated with circulating levels of ketone bodies (Bellward et al., 1988).
Table 6.1.3 The effects of tvpe II diabetes on hepatic cytochrome P450 activities.
glutathione S-transferase. glutathione reductase and cellular glutathione 
levels
PARAMETER
GROUP
Lean Obese
Ethoxyresorufin O-deethylase 
(pmol resorufin /  min/ mg protein)
Pentoxyresorufin Odepentylase 
(pmol resorufin/ min/ mg protein)
p-Nitrophenol hydroxylase 
(nmol/min/ mg protein)
Ethylmorphine N-demethylase 
(nmol/min/ mg protein)
Lauric acid hydroxylase 
(nmol/min/ mg protein)
9.912.1
0.410.2
0.810.07
14.011.1
1.8410.7
8.612.8
0.510.2
0.9112.4
15.112.4
2.3110.6
Total glutathione (mM) 7.810.5 4.810.7*
Glutathione S-transferase 
(pmol/ min/ mg protein)
Glutathione reductase 
(nmol GSSG/ min/ mg protein)
1.4810.06
644124
0.3410.06'
782172
Data represent meanls.e.m. for six animals. **p<0.01; ***p<0.001 compared to lean mice.
Grant and Duthie (1987) investigated the effects of streptozotocin-induced 
diabetes in the rat on the activities of conjugating enzymes in isolated rat hepatocytes.
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Their studies revealed that chemically-induced diabetes caused a decrease in the cellular 
levels of reduced glutathione but that the resynthesis of glutathione was faster in the 
diabetic animals. They also showed that the conjugation of l-chloro-2,4-dinitrobenzene 
and 3,4-dichloronitrobenzene, two substrates for glutathione S-transferases, was deficient 
in the diabetic animals. This indicates that these animals may be more susceptible to 
xenobiotic induced toxicity. In the present study similar findings have been found with the 
obese mice.
In summary, it would appear that type II diabetes mellitus has little influence on 
hepatic drug metabolism although the alterations in the glutathione conjugating species 
and enzymes are of interest and merit further investigation.
6.2 The effect of hypertension on hepatic drug metabolism
It has been recognised for many years that hypertension and diabetes (or impaired
glucose tolerance) frequently occur together. However, the pathogenetic relationship 
between the two common disorders remains elusive. The time course and natural history of 
hypertension differs markedly between patients with type I diabetes mellitus and those 
suffering from the type II form of the disease. In the former blood pressure is normal at the 
onset of diabetes and frequently remains normal during the first 5 - 1 0  years of diabetes. 
Hypertension typically develops with the onset of renal insufficiency. In patients who had 
type I diabetes for more than 30 years, approximately 50% will have hypertension
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(Christleib et a l, 1981). This group is almost entirely represented by patients that have 
developed diabetic nephropathy.
In contrast to type I diabetes, those with type II diabetes are often hypertensive at 
the time of diagnosis of the disease. The increase in blood pressure is correlated with the 
increased prevalence of obesity and the greater age associated with sufferers 
(approximately 60% of this population is over 60 years old).
In both type I and type II diabetes, the impact of hypertension on excess morbidity 
and mortality is substantial. It is well known that diabetes is associated with an increased 
risk of death from renal failure, coronary artery disease and cerebrovascular disease. When 
hypertension is superimposed, the risk from all causes may be exacerbated by as much as 
four fold (Dupree and Meyer, 1976).
Our previous studies have examined the direct effects of the diabetic state on 
hepatic drug metabolism and established unequivocally that insulin-dependent diabetes 
can markedly alter the activities of various cytochrome P450 isoforms. As hypertension is 
probably the most common complication of diabetes mellitus it was of interest to 
investigate whether hypertension could itself directly influence the levels of hepatic 
cytochrome P450 isoforms.
Animal pretreatment
Five male WKY non-hypertensive and five male SHR hypertensive rats were
obtained from Charles River Laboratories, England at nine weeks of age. After two weeks of 
acclimatisation and to allow the hypertension to develop (usually at nine weeks of age)
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the animals were killed. The livers were immediately excised, microsomal preparations 
prepared and mixed-function oxidase activities determined as previously described 
(Chapter 2). The effect of hypertension on the phase II enzyme, glutathione transferase 
was investigated with two substrates; l-chloro-2,4-dinitrobenzene and 3,4- 
dichloronitrobenzene. All assays and conditions employed are described in detail in 
Chapter 2. Immunological detection of specific cytochrome P450 proteins employing 
monospecific antibodies were used to confirm enzyme results where appropriate.
Results
The hypertensive animals had normal appearance, and no adverse effects due to
the condition were evident. The hypertensive condition did not influence microsomal 
protein, cytochrome P450 or the NADPH-dependent reduction of cytochrome c. However, 
the hypertensive animals did show a significant decrease in the levels of cytochrome bg 
(Table 6.2.1).
With respect to the diagnostic substrates employed to investigate specific 
cytochrome P450 activities, the hypertensive animals did show a slight, but non­
significant decrease in the ability to hydroxylate lauric acid. There was no alteration of 
the activity towards the dealkylation of pentoxyresorufin or the hydroxylation of p- 
nitrophenol. The hypertensive animals did however show a significant increase in the 
dééthylation of ethoxyresorufin indicative of alteration of the activities of the P450 lA  
subfamily (Table 6.2.2).
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T a b le  6.2.1 T h e  e ffec t o f  h y p e r te n s io n  o n  so m e  h e p a tic  m ic ro so m a l p a r a m e te r s
in  s p o n ta n e o u s ly  h y p e r te n s iv e  ra ts .
GROUP
PARAMETER
Microsomal protein 
(mg /  g liver)
Cytochrome bg 
(nmol /  mg protein)
Cytochrome P450 
(nmol /  mg protein)
NADPH cytochrome c 
reductase activity 
(nmol /  min /  
mg protein)
Control
26.410.46
0.9210.04
0.3910.04
Hypertensive
26.610.5
0.5910.07**
0.3410.02
25.612.4 25.813.4
Data represent mean+s.e.m. for five animals. **p<0,01 compared to control
Previous studies have reported that the hypertensive state was associated with 
the induction of the P450 IIIA proteins (Schenkman ef al., 1989) although the activity of 
the hypertensive microsomes towards ethylmorphine, a substrate of this isoform, showed 
no difference from control levels.
Discussion
Spontaneous hypertensive rats (SHR) have previously been shown to have shorter 
hexobarbital sleeping times and enhanced rates of microsomal ethylmorphine N-
148
demethylase activities (Greenspan and Baron, 1981; Merrick et al., 1976). Such effects are 
indicative of alteration of the microsomal mixed-function oxidase activity. However, our 
data shows that at 10 weeks of age the SHR animals did not display an increase in the 
activity of ethylmorphine N-demethylase, an activity specifically associated with the 
cytochrome P450 IIIA subfamily. It is possible that the induction of this isoform takes 
longer to manifest itself and would not be apparent at onset of hypertension, since in their 
studies Schenkman et al. (1989), used animals which had been hypertensive for many 
weeks.
Table 6.2.2 The effects of hypertension on specific cvtochrome P450-catalvsed 
reactions in spontaneously hypertensive rats.
PARAMEIER
GROUP
Control Hypertensive
Ethoxyresorufin-O-
deethylase
(pmol/min/mg protein)
Pentoxyresorufin-O-
depentylase
(pmol/ min/ mg protein)
p-Nitrophenol hydroxylase 
(nmol/min/ mg protein)
Lauric acid hydroxylase 
(nmol/min/ mg protein)
Ethylmorphine N- 
demethylase 
(nmol/min/ mg protein)
12.9±1.4
5.3±1.3
1.91±0.1
10.0±0.5
27.7+0.8
22 .6+2 .0'
5.13+0.8
1.98±0.2
7.91±0.7
27.3±1.0
Data represents mean+s.e.m. for five animals ** p<0.01 compared to control
1 4 9
Schenkman et al., (1989) have shown that there was essentially no observable
difference in the activity of aniline hydroxylase a reaction predominantly catalysed by
cytochrome P450IIE1 which is supported by our data using the more specific substrate p-
nitrophenol. Similarly, no alteration was observed in the activity of lauric acid
*
hydroxylation or the depentylation of pentoxyresorufin (cytochrome P450 IVA and P450IIB 
subfamilies respectively).
Of possibly greater interest is the fact that hypertension was associated with a 
modest elevation in cytochrome P450IA activity. This subfamily has already been 
associated with the bioactivation of numerous compounds (loannides and Parke, 1985) and 
is also induced during uncontrolled type I diabetes mellitus. It is not clear from the present 
study whether one or both proteins in this subfamily were increased.
In conclusion, the effect of short-term hypertension on hepatic drug metabolism 
appears to be a modest, but selective induction of the P450IA subfamily at the onset of the 
disease may be followed by further alterations in other cytochrome P450 families as the 
condition progresses. Clearly measurements of blood pressure in the SHR animals would 
have been advantageous in determining the severity and onset of hypertension.
6.3 The modulation of hepatic mixed-function oxidase activity by 
hyperinsulinaemia
Hypoinsulinaemia induced by the administration of diabetogenic compounds such 
as streptozotocin in rats has been associated with marked alterations of the hepatic
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cytochrome P450 composition (Bellward et flZ.,1987; Favreau and Schenkman, 1988; Barnett 
et al., 1990a and 1990b). As a result diabetic rats have been shown to be more susceptible to 
the hepatotoxicity of haloalkanes (Watkins et al., 1988) and hepatic preparations from 
these animals were more efficient at activating many chemical carcinogens (loannides e t 
al., 1988; Flatt et al., 1989). Two factors can be identified as being responsible for the 
changes in the hepatic cytochrome P450 complement; mobilisation of lipid from adipose 
tissues together with excessive fatty acid oxidation resulting in hyperketonaemia and a 
reduction in circulating growth hormone levels (Barnett et al.,1990a and 1990c; Barnett et 
al, 1988; Bellward et a l, 1987; Tannenbaum, 1981).
As an absolute lack of circulating insulin is associated with such marked 
alterations of hepatic cytochrome P450 levels it was of interest to investigate the effect of 
hyperinsulinaemia on the cytochrome P450 system. Enteropancreatic endocrine cancer is 
associated with hyperinsulinaemia, due to excessive secretion of insulin by an islet cell 
tumour. Hyperinsulinaemia occurs as insulin secretion is not regulated by circulating 
nutrient levels (Friesen, 1982). The model of hyperinsulinaemia used was the serially 
transplantable radiation-induced rat insulinoma (Chick et a l, 1977). When transplanted 
into NEDH rats, the tumour is characterised by rapid growth and the insulinoma-bearing 
rats display marked hyperinsulinaemia, severe hypoglycaemia and neuroglycopenic comas 
within one month following transplantation (Flatt et al.,1986). The metabolic effects 
consequent to transplantation of the tumour are similar to those associated with 
spontaneous insulinoma in man (Friesen, 1982), rendering these rats an appropriate model 
(Flatt et a l, 1986, 1987).
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Animal pretreatitient
Male Wistar albino (150-200g) and New England Deaconess Hospital (NEDH, 150- 
180g) rats were obtained from the Experimental Biology Unit, University of Surrey. The 
NEDH rats were transplanted with radiation-induced tumour from a donor male NEDH 
rat. The tumour and surrounding capsule were rapidly removed from the donor and the 
minced tumour (0.15ml/rat) was implanted subcutaneously into the subscapular region of 
lightly anaesthetised rats using a 16 gauge needle. Plasma glucose levels were determined 
following withdrawal of blood samples from the tail tip of conscious rats. The animals 
were sacrificed when they displayed severe hypoglycaemia (plasma glucose levels 
approximately 2mM). In a second study the Wistar albino rats received daily subcutaneous 
administration of insulin (Novo Industries, long acting monocompotant human insulin, 40 
l.U./ml) at doses of 10 l.U./kg or 20 l.U./kg for four days and were killed 24 hours after the 
last administration.
In both studies livers were immediately excised and hepatic microsomal fractions 
prepared as previously described (Chapter 2). Microsomal protein, total carbon-monoxide 
discernible cytochrome P450 and cytochrome bg were determined as well as the NADPH 
dependent reduction of cytochrome c. The activity of cytochrome P450 lA and KB proteins 
towards ethoxy- and pentoxyresorufin, respectively were investigated and in addition the 
hydroxylations of p-nitrophenol and lauric add (catalysed predominantly by the P450 HE 
and P450 IVA subfamilies respectively). The N-demethylation of ethylmorphine was 
employed to monitor the activity of the P450 IIIA subfamily (Chapter 2). Immunological 
detection of specific cytochrome P450 proteins employing monospecific antibodies was used 
to confirm results were appropriate.
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The metabolic activation of Glu-P-1 to mutagens was monitored using the Ames 
mutagenicity test (Chapter 2). The activation system contained 10% (v/v) of microsomal 
preparation (25% w /v) and was supplemented with glucose-6-phosphate dehydrogenase (1 
unit/plate). Glu-P-1 (2pg/plate) was dissolved in dimethylsulphoxide. Activation system, 
bacteria {Salmonella typhimurium strain TA 98) and Glu-P-1 were pre-incubated for 1 hour 
at 3 7 0 c  in a shaking water-bath.
Results
As expected the insulinoma bearing rats exhibited markedly lower glucose levels 
when compared to control rats, but no significant differences were observed in the plasma 
ketone body levels (Table 6.3.1 A).
Table 6.3.1 Plasma glucose and ketone bodv concentrations in insulinoma- 
bearing and insulin-treated rats.
B
GROUP
Animal group Glucose 3-hydroxybutyrate Acetoacetate
(mM) (mM) (mM)
Control 6.1+03 03610.05 0.1410.04
Insulinoma 2.8+0.4" 0.4210.02 0.2110.04
Control 5.110.2 03110.02 0.0810.01
Insulin (10 lU/kg) 4.610.2 03210.01 0.1210.04
Insulin (20 lU/kg) 4.510.3 0.1610.04 0.09i0.01
Data represents mean ±s.e.m. for five animals. *p<0.01 compared to control.
The hepatic O-deethylation of ethoxyresorufin and the N-demethylation of 
ethylmorphine were significantly higher in the insulinoma-bearing rats whereas, in
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contrast, p-nitrophenol oxidation and lauric acid hydroxylation were significantly lower 
when compared to controls (Table 6.3.2). Hepatic microsomal preparations from insuHnoma- 
bearing rats were markedly more efficient than preparations obtained from control animals 
at converting Glu-P-1 to mutagenic intermediates in the Ames test (Table 6.3.3A).
Immunoblot analysis employing antibodies to the P450 I family revealed that the 
insulinoma-bearing animals had higher levels of the P450 IA2 apoprotein (Figure 6.3.1A).
Table 6.3.2 Hepatic microsomal mixed-function oxidase activitv in insulinoma- 
bearing rats.
PARAMETER Control
GROUP
Insulinoma-bearing
Ethoxyresorufin O-deethylase
(pmol/min/mg protein) 6.610.6
Pentoxyresorufin O-depentylase 
(pmol/min/mg protein) 3.410.9
p-Nitrophenol hydroxylase
(nmol/min/mg protein) 1.4610.09
Ethylmorphine N-demethylase 
(nmol/min/mg protein) 2.210.3
Lauric acid hydroxylase
(nmol/min/mg protein) 2.110.2
Cytochrome bg
(nmol/mg protein) 0.3810.03
Cytochrome P450
(nmol/mg protein) 0.3810.03
Microsomal protein
(mg /g  liver) 27.310.5
19.112.9'
4.210.4
0.9310.03'
4.610.4'
1.410.2*
0.3810.02
0.3810.02
28.211.6
Data represents meanls.e.m for five animals *p<0.05; **p<0.01; ***p<0.001
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c o m p a re d  to  c o n tro l.
Table 6.3.3 Bioactivation of Glu-P-1 to mutagens bv microsomal preparations 
from insulin-treated and insulinoma-bearing rats.
Animal Group Mutagenic response 
(Histidine revertants/mg protein)
Control
Insulinoma-bearing
477179
48811204
B
Control
Insulin (10 lU/kg) 
Insulin (20 lU/kg)
23051147
39051237
59671272
Data represent meanls.e.m. for five animals. Spontaneous reversion rate of 45110 
histidine revertants/ plate has already been subtracted. All data is significant 
(p<0.001) compared to control.
Rats pretreated with insulin, at two dose levels, had slightly lower levels of 
plasma glucose but this was not significant (Table 6.3.1B). Of the mixed-function oxidase 
activities studied only the O-deethylation of ethoxyresorufin was higher in the hormone- 
receiving animals (Table 6.3.4). Moreover, insulin administration gave rise to a dose- 
dependent increase in the bioactivation of Glu-P-1 to mutagens in the Ames test (Table 
6.3.3B). A dose-dependent increase following insulin administration was also seen in the 
P450IA2 microsomal apoprotein level (Figure 6.3.1B).
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Table 6.3.4 The effect of insulin administration on hepatic microsomal 
cytochrome P450 catalysed reactions.
GROUP
PARAMETER
Ethoxyresorufin O-deethylase 
(pmol/min/mg protein)
Control
13±2
Insulin Insulin
(10I.U./kg) (20 LU/kg)
19.1±r 20±3*
p-Nitrophenol hydroxylase 
(nmol/min/mg protein) 1.2±0.1
Ethylmorphine N-demethylase 
(nmol/min/mg protein) 8.2+1.4
0.9+0.1
10.3+2.1
1.0+0.2
11.1+ 1.8
Cytochrome P450 
(nmol/mg protein)
Microsomal protein 
(mg /g  liver)
0.40+0.05 0.51±0.01 0.46+0.04
35.0+3.6 34.5+2.0 39.0+2.0
Data represents mean+s.e.m for five animals *p<0.05; **p<0.01 compared to 
control.
Discussion
The insulinoma-bearing animals displayed a significantly higher ethoxyresorufin
O-deethylase activity, a reaction catalysed exclusively by the P450 lA subfamily and in 
particular the P450 lA l (Phillipson et ah, 1984). In order to discern between the two P450 
lA isoforms, the ability of hepatic microsomal preparations from insulinoma-bearing and 
control rats to convert the pre-mutagen Glu-P-1 to active mutagens
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Figure 6.3.1 Immunoblot analysis of microsomes from insulinoma-bearing and insulin-treated
rats using polyclonal antibodies to cytochrome P450
FIGURE
AP4501A
B P450IA
Lane 1,2,3 Control rat microsomes
4 3-Methylcholanthrene-induced rat microsomes
5.6.7 Insulinoma-bearing rat microsomes
Lane 1,23 Control rat microsomes
4 3-Methylcholanthrene-induced microsomes
5.6.7 101.U/kg insulin treated rats
8,9,10 20 LU/kg insulin treated rats
Microsomal proteins were resolved by electrophoresis in a 10% (w/v) SDS-polyacrylamide gel and 
transfered to nitocellulose. In all cases 20pg of solubilised microsomal protein was loaded except for 
the positive controls when only lOjig of protein was loaded.
Positive controls
Animal pre-treatment
3-methylcholanthrene (25mg/kg in com oil) for 3 days.
Fig.  6 . 3 . 1
V -s.
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7 8 10
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in the Ames test was examined as this reaction is catalysed exclusively by the P450IA2 
protein (Kato, 1986). Activation of Glu-P-1 to mutagens was markedly more efficient in 
microsomal preparations derived from the insulinoma-bearing animals when compared to 
controls, indicating that the rise in the O-deethylation of ethoxyresorufin may have been 
due to the increase in the A2 protein. Immunoblot analysis confirmed this finding in that 
microsomes from the insulinoma-bearing animals had higher levels of the P450 IA2 
apoprotein than the control animals and that the P450IA2 protein was induced rather than 
the P450 LAI protein.
( Insulinoma-bearing rats also exhibited significantly higher levels of 
ethylmorphine N-demethylase activity compared to the control animals, an enzyme 
closely associated with the P450 IILA subfamily (Wrighton et al., 1985a). In contrast to the 
above findings hyperinsulinaemia reduced microsomal p-nitrophenol and lauric acid 
hydroxylations, two activities associated with the P450 HE and IVA subfamilies. The O- 
dealkylation of pentoxyresorufin, a reaction used to monitor P450 HB activity (Lubet et al., 
1985) was unaffected by the hyperinsulinaemic condition. Since the levels of total 
cytochrome P450 were unchanged by treatment it may be inferred that the observed 
increases in P450 IA2 and HIA levels may occur at the expense of other cytochrome P450 
subfamilies including the P450 HE and IVA. It has already been established that some 
agents may selectively induce the levels of one family of cytochrome P450 while decreasing 
others (Favreau and Schenkman, 1988a). Finally, the NADPH-dependent reduction of 
cytochrome c was unaffected by hyperinsulinaemia indicating that the flow of electrons to 
cytochrome P450 is unlikely to be impaired.
It is logical to argue that the observed changes in hepatic cytochrome P450 proteins 
in the insulinoma bearing animals may not be the result of the hyperinsulinaemia and the 
ensuing hypoglycaemia, but is the consequence of the physiological changes brought about 
by the presence of an invasive tumour. In order to address this point and to evaluate the
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contribution of hypoglycaemia, Wistar albino rats were treated with insulin in order to 
ensure hyperinsulinaemia is the causative factor in these changes and that the effects are 
not limited to the NEDH strain of rat. A slight drop in the plasma glucose levels following 
insulin administration was noted but the effect was not statistically significant indicating 
that hypoglycaemia was not responsible for the changes observed. A modest but statistical 
increase was observed in the O-deethylation of ethoxyresorufin. The increased ability of 
hepatic microsomes from insulin-treated rats in activating Glu-P-1 to mutagens indicates 
that the enhanced O-deethylation of ethoxyresorufin is due to the P450 IA2 protein and 
this is further substantiated by the immunoblot analysis. Although a modest increase was 
also seen in the N-demethylation of ethylmorphine the effect did not reach statistical 
significance. Thus, in general, the effects induced by insulin administration resemble those 
brought about by the subscapular transplantation of the insulinoma but the effects are much 
less pronounced. This is not surprising since in the insulinoma-bearing rats, not only is the 
degree of hyperinsulinaemia much higher, as exemplified by the severe hypoglycaemia, 
but also the hyperinsulinaemia and hypoglycaemia are maintained by continuous tumour 
secretion (Flatt et a/.,1986) whereas, following daily subcutaneous administration of 
insulin, the plasma levels insulin would fluctuate widely as the excess plasma insulin in 
removed.
The effects of hyperinsulinaemia on drug metabolism, in contrast to 
hypoinsulinaemia, has not received much attention, and the hormonal and other 
biochemical changes that may occur have not been explored. In streptozotocin-induced 
hypoinsulinaemia, the modulation of cytochrome P450 changes have been attributed to the 
high levels of ketones (P450 I, IIB, HE) that function as inducing agents, and to modulation 
of growth hormone levels that play a major role in the regulation of some cytochrome P450 
proteins such as P450 III (Barnett et ah, 1989, 1990a and b). In the present study no 
significant change was noted in the circulating levels of ketone bodies so that the first 
mechanism may be excluded. Moreover, hyperketonaemia causes a marked increase in the
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microsomal levels of the P450 HB proteins (Barnett et a/.,1990a), which was not induced in 
the hyperinsulinaemic condition. It is possible that hyperinsulinaemia triggered the 
release of an endogenous planar substrate that can act as a selective inducer of P450 IA2 
although other mechanism may also be operative. It should be noted that the 
physiological function of the P4501 family has yet to be established.
In summary, the present study demonstrates that hyperinsulinaemia causes a  ^
modest, but selective induction in the hepatic levels of P450 IA2, an enzyme closely  ^
associated with the activation of chemical carcinogens, particularly those containing an  ^
exocyclic amino group (loannides and Parke, 1990).
I
It has been suggested that the trauma caused by the injection of 0.15ml of minced
tumour into the subscapular region of lightly anaesthetized animals may have caused the : 
observed changes some 21 days post-treatment. Although, this was not examined by sham- 
injection of the control animals, previous work performed on plasma parameters, which are ! 
usually altered during stress, displayed no alteration other than those expected from the 
presence of an insulinoma (Flatt et a l, 1986).
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Chapter 7. 
D iscu ssio n
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7.1 Alteration of hepatic drug metabolism in streptozotocin-
induced type I diabetes mellitus
It is now recognised that by far the most important microsomal system in the 
metabolism of xenobiotics is the cytochrome P450-dependent mixed-function oxidase 
system, an enzyme system characterised by broad substrate specificity. It achieves this by 
existing as a number of distinctly different families, each consisting of two or more proteins 
with differing substrate specificity. The diabetes-induced changes in the metabolism of 
endogenous and exogenous substrates reflects the alteration in the levels of the specific 
cytochrome P450 families.
The recognition that type I diabetes mellitus is associated with changes in 
cytochrome P450 proteins followed the studies of Past and Cook (1982) who isolated a 
diabetes-inducible form with high turnover towards aniline, the hydroxylation of which 
is consistently increased in type I diabetes mellitus. This isoform was later characterised as 
P450 IIEl, a protein induced in rats and rabbits by a variety of chemicals (Koop et al., 1985). 
Subsequent studies by ourselves and others have revealed that streptozotocin-induced 
diabetes causes alterations of many other cytochrome P450 families involved in the 
biotransformation of xenobiotics. The polycyclic aromatic hydrocarbon-inducible P450 I 
family is induced in both chemically-induced and spontaneous type I diabetic animals 
(loannides et a/., 1988; Yamazoe et al.,1988; Barnett et al.,1990). The same workers also 
demonstrated increases in the apoprotein and activities of the phenobarbital-inducible 
P450 IIB subfamily. Increased levels and activities were also observed in the steroid 
inducible P450 III family (Barnett et al., 1990). Moreover, streptozotocin-induced diabetes 
has been shown to influence the hepatic levels of sex-specific constitutive forms of 
cytochrome P450 endowed with steroid hydroxylase activity (Favreau and Schenkman, 
1988). Finally, streptozotocin-induced diabetes and spontaneous type I diabetes enhanced 
the levels of the cytochrome P450 IV family (Barnett et al., 1990).
162
In our studies of the streptozotocin-induced diabetic animal (Chapter 3), we found 
that the alterations of hepatic drug metabolism was due to the diabetic state itself and not 
a consequence of the administered diabetogen. Furthermore, insulin therapy of 
streptozotocin-diabetic animals has revealed that although insulin is capable of reversing 
the diabetes-induced changes in drug metabolism they do not always return to normal 
levels. This suggests that even strictly insulin-controlled diabetics may still be influenced 
by the disease as far as xenobiotic metabolism is concerned.
Sex-differences in the diabetes-induced changes in hepatic drug 
metabolism
Sex-differences in the diabetes-induced alterations have been observed in the
streptozotocin-induced diabetic animal. Although the increase in aniline hydroxylase 
activity is not sex-specific, the déméthylation of aminopyrine is depressed in the male but 
elevated in the female, and hexobarbital and aryl hydrocarbon hydroxylase activities 
decreased only in the male (Reinke et al., 1978; 1979; Warren et al., 1983).
In our investigations of sex-differences in streptozotocin-induced diabetes mellitus 
we found that when expressed per nmol of total cytochrome P450, the induction of 
cytochrome P450IA and IIB subfamilies did not show sex-spedfic differences. Of the other 
families investigated sex-dependent factors appeared to be involved in the level of 
induction of cytochrome P450 HE, HIA and IVA subfamilies. In all cases the control females 
had higher levels than the control males, but the diabetic males showed more pronounced 
induction of these isoforms. Clearly, sex-specific differences in the levels of various 
cytochrome P450 families may have pharmacological and toxicological implications for 
drug therapy regimes.
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Long-term diabetes mellitus and hepatic drug metabolism
Most studies using either chemically-induced or spontaneously diabetic animals 
used the animals one month after the onset of diabetes and the long-term effects have been 
totally neglected. There is experimental evidence that the effect of chronic diabetes on 
xenobiotic metabolism may differ from that seen in the early stages of diabetes despite the 
fact that circulating glucose levels may be similar (Dixon et aZ.,1963; Skett and Joels, 1985). 
The degree of inhibition of the microsomal metabolism of diazepam, lignocaine and 
imipramine was much more pronounced in rats 3 days after streptozotocin administration 
than after 20 days, although hepatotoxic effects of the streptozotocin causing changes in 
metabolism cannot be ruled out at 3 days (Skett and Joels, 1985). In studies of chronic 
streptozotocin-induced diabetes, we investigated hepatic mixed-function oxidase activities 
at 4 ,8  and 12 weeks following streptozotocin treatment of male rats. Our data shows that 
after 4 weeks the initial, severe hyperketonaemia began to subside, although still being 
significantly elevated at 12 weeks. This correlated with a decrease in the activities of the 
some of the cytochrome P450 families investigated. In particular, the induction of 
cytochrome P450 HI became less apparent after 4 weeks and became comparable to control 
animals from week 8 onwards. The induction of the cytochrome P450 IVA subfamily also 
decreased and-was only slightly elevated by 12 weeks following streptozotocin treatment. 
As streptozotocin-induced diabetes progressed the diabetic animals lost much of the fat 
stored in their adipose tissues. This would have led to a fall in the circulating levels of free 
fatty acids which, if responsible for the induction of the cytochrome P450 TVAl activity, as 
previously suggested (Gibson et al., 1990), would result in a fall in the level of induction of 
P450 IVAl. These observations further support the role of hyperketonaemia and 
hyperlipidaemia in the alterations of hepatic drug metabolism.
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7.2 Hepatic drug metabolism in the spontaneously diabetic BB 
rat
Of significant interest is the fact that the streptozotocin-induced diabetic animals 
can survive for more than 12 weeks without insulin. This suggests that either the animals 
do not develop diabetes as severely as genetically susceptible animals, which survive for 
only a few days without insulin, or that the streptozotocin-induced diabetic animals 
undergo a physiological adaptation in order to withstand the high levels of plasma ketone 
bodies.
Examination of uncontrolled diabetes in spontaneously diabetic BB rats at 1,3 and 6 
months after onset, revealed that when insulin therapy was withdrawn, the animals 
quickly became hyperglycaemic and hyperketonaemic and showed all of the characteristic 
changes in mixed-function oxidase activity as observed in the streptozotocin-induced 
diabetic animals. Furthermore, these changes were not age-dependent, with similar affects 
being evident at 1 month and 6 months following onset of diabetes. The severity of the 
ketonaemia in these animals was several fold higher than that observed in the 
streptozotocin-induced diabetic animals, and withdrawal of insulin therapy could only be 
tolerated for a few days before the animals succumbed to the life-threatening effects of the 
disease. In these animals the plasma levels of ketone bodies was always several fold 
higher than that observed in the streptozotocin-induced diabetic animal. However, this 
was not associated with a greater induction of cytochrome P450 HE than that found in the 
chemically-induced animals. This finding raises the possibility that 3-hydroxybutyrate 
may be a poor inducer of cytochrome P450 IIEl, and that acetone, and possibly acetoacetate, 
are the physiologically important inducers of this isoform. This would support the role of 
cytochrome P450 HE in the hydroxylation of acetone to acetol, and the possibility for a 
physiological role for cytochrome P450 HE in the salvage of acetone for use as a substrate 
for gluconeogenesis (Casazza et a l, 1984).
165
Alterations of hepatic drug metabolism in insulin treated spontaneously 
diabetic BB rats
Our investigations of poorly insulin controlled spontaneously diabetic BB rats 
demonstrated that modulation of the mixed-function oxidases does occur in these animals, 
albeit less pronounced than when the disease is uncontrolled. These findings suggest that 
even when strictly controlled by insulin therapy, human diabetic patients may display 
some of the alterations of drug metabolism associated with the uncontrolled condition. 
Clearly, these findings have pharmacological as well as toxicological implications when 
considering the multi-drug therapy used to treat the complications of this disease. 
However, one must always be cautious when evaluating the implications to humans from 
responses observed in animal models. Our studies, using both chemically-induced and 
spontaneously diabetic rats, suggests that the BB rat is a more relevant model for human 
diabetes, apart from the fact that it is spontaneously occurring. Long-term streptozotodn- 
diabetic rats began to display alterations of drug metabolism which were not observed in 
the long-term diabetic BB rats. Furthermore, the ability of the streptozotocin-induced 
diabetic animals to survive without insulin therapy for more than 12 weeks, raises 
questions as to whether this model is appropriate.
7.3 Diabetes and chemical toxicity
Since type I diabetes modulates the levels of various cytochrome P450 isoforms, it is 
inevitable that the response of the diabetic individual to the toxicity/  carcinogenicity of 
chemicals will be altered. In studies using the Ames mutagenicity assay to study the 
activation of chemical carcinogens, hepatic preparations from both chemically-induced 
and spontaneously diabetic animals were more effective at activating carcinogens such as
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nitrosamines and heterocyclic amines (loannides et al., 1988; Flatt et ’ al.,1989; Barnett et 
al.,1990), but in contrast, preparations from diabetic animals were less efficient at 
activating 2-aminofluorene.
Many studies have shown that type I diabetic animals are more susceptible to the 
hepatotoxicity induced by haloalkanes such as carbon tetrachloride, chloroform and 1,1,2- 
trichloroethane and other hepatotoxins (Watkins et al.,1988; Hanasono et al., 1975). The 
increased susceptibility to carbon tetrachloride may be due to the higher levels of the 
cytochrome P450 HE subfamily which is induced in diabetic animals and catalyses the 
generation of hepatotoxic trichloromethyl radical (Watkins et a l, 1975).
The induction of the cytochrome P450 UB subfamily by type I diabetes suggests that 
there will be alteration in the pharmacokinetics of many drugs administered to the 
diabetic, as this subfamily is associated with the deactivation of many therapeutic 
compounds. Similarly, alterations in the levels of the P450 III subfamily, which 
metabolises large molecular weight compounds including drugs such as the macrolide 
antibiotics and the immunosuppressant cyclosporin, could pose further complications.
7.4 Possible mechanisms of the diabetes-induced changes in the 
metabolism and toxicity of chemicals.
The onset of diabetes is accompanied by numerous and marked changes in the
physiological function of the living organism, one or more of which may be responsible for 
the observed alterations in the metabolism of xenobiotics. Type I insulin-dependent 
diabetes is associated with severe hyperglycaemia and hyperketonaemia, either or both 
of which might be responsible for the changes in the bio-transformation of chemicals. Early 
studies showed that prolonged intravenous infusion of glucose did not modify the 
mixed-function oxidase activities (Ackerman and Liebman, 1977) and chronic 
hyperglycaemia decreased activities such as aniline hydroxylase (Hartshorn et al., 1979),
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an activity readily induced by diabetes mellitus. Furthermore, when animals where 
treated with N-methylacetamide, a compound which produced an insulin-resistant 
condition similar to type II diabetes mellitus, the ensuing hyperglycaemia did not alter 
mixed-function oxidase activity (Peters et aZ.,1966), further demonstrating that it is not the 
hyperglycaemia which is responsible for the diabetes-induced effects on drug metabolism.
The role of ketone bodies
It has been suggested that compounds which promote ketosis stimulate mixed- 
function oxidase activities, including aniline hydroxylase (Mehendale et a l ,1977), raising 
the possibility that the ketone bodies may have a prominent role in the diabetes-induced 
changes. The major ketone bodies are 3-hydroxybutyrate and acetoacetate formed from the 
partial oxidation of fatty acids within the hepatic mitochondria. Acetoacetate 
equilibrates with 3-hydroxybutyrate and both ketone bodies are released into the blood. 
Acetone is believed to be formed non-enzymically through the decarboxylation of 
acetoacetate. When carbohydrate metabolism is impaired and free fatty acid levels rise as 
a result of increased lipolysis, ketone bodies form the third most important blood-borne 
energy source for extrahepatic tissues after glucose and free fatty acids. The primary 
physiological role of the ketone bodies is to serve as substrates for the brain, a tissue that 
cannot take up free fatty acids. Therefore, during carbohydrate deprivation the ketone 
bodies limit the expenditure of glucose in the brain and thus spare proteins which would 
otherwise be catabolised.
In our study using rats rendered hyperketonaemic, but remaining normoglycaemic, 
mixed-function oxidase activities were increased. This correlated with induction of the 
same cytochrome P450 isoforms as observed in streptozotocin-induced diabetes (Barnett e t 
al,19SS), thereby implicating the increased ketone body levels seen in diabetes (Barnett et 
al,1990 and 1990). As in diabetes, increased levels of P450 I and P450 HB proteins were
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noted. Moreover, a good correlation between plasma ketone levels and the hepatic levels of 
P450 HE has been reported (Bellward et ah, 1988). Hyperketonaemia also occurs during 
fasting (Tu and Yang, 1983; Miller and Yang 1984) and excessive alcohol consumption, 
although alcohol-induced ketoacidosis in man is rare, and all of these conditions are 
associated with the induction of cytochrome P450 HE (Koop et ah, 1987; Hong et ah, 1987). 
It appears that this protein is active in the metabolism of acetone, being the only isoform of 
six purified isoforms capable of oxygenating acetone to acetol (1-hydroxyacetone). 
Futhermore, this isoform was the most active protein in the further hydroxylation of acetol 
(Koop and Casazza, 1985). It is reasonable to assume that the increase in the levels of 
cytochrome P450 HE is an adaptive response to deal with the high levels of ketone bodies 
present in diabetes mellitus (Casazza et ah, 1984).
Further work examining the effects of acetone, 3-hydroxybutyrate and 1,3- 
butanediol revealed that acetone was capable of inducing the cytochrome P450 lA, HB and 
HE subfamilies. 3-Hydroxybutyrate caused less pronounced elevations of cytochrome P450 
lA and HB and did not significantly effect the levels of P450 HE. None of the ketones 
administered had any effect on the cytochrome P450 HI or P450 IV subfamilies. 1,3- 
Butanediol did show induction of cytochrome P450 HE but not of any other isoforms. These 
observations confirm that ketone bodies can cause similar alterations of hepatic 
cytochrome P450 proteins as observed in both chemically-induced and spontaneously 
occurring diabetes. However, there was no induction of the cytochrome P450 IVA subfamily 
in contrast to the significant induction of this subfamily in diabetes and medium chain 
triacylglycerol treated animals (Barnett et ah, 1990c). It has been proposed that the P450 
IVA subfamily is induced by hyperlipidaemia, a condition associated with diabetes (Dunn, 
1990). Therefore, the observations from this study support the theory that the increased 
levels of plasma free fatty acids associated with type I diabetes is responsible for the 
increased cytochrome P450 IVA activity.
Ketoacidosis would also be expected to mediate the diabetes-induced changes in
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the susceptibility to the toxicity of chemicals since these are brought about by changes in 
the complement of hepatic cytochrome P450 proteins. The ability of preparations from the 
livers of diet-induced hyperketonaemic rats to activate various precarcinogens was very 
similar to that encountered in the streptozotocin-induced diabetic animals (Barnett e t 
flZ.,1990). Moreover, pretreatment of rats and mice with ketogenic substances, like diabetes, 
exacerbated the toxicity of carbon tetrachloride (Traiger et al.,1972; Hewitt and 
Plaa,1979). However, ketone bodies cannot account for all the diabetes-induced changes in 
mixed-function oxidase activity and chemical toxicity. One of the diabetes-induced 
isoforms of cytochrome P450, namely P450 III A, was not inducible by dietary 
hyperketonaemia suggesting that other factors must be involved. Insulin-dependent 
diabetes impairs growth hormone secretion in the rat and as a result growth hormone levels 
are markedly suppressed (Tannenbaum, 1981; Yamazoe et al; 1989a). Low levels of growth 
hormone have been associated with increased levels of P450 III subfamily (Lemoine et al., 
1988; Kamataki et al., 1985). Similarly, growth hormone can modulate the levels of male- 
specific form P450 nC2 (Morgan et a l, 1985; Kamataki et al., 1985).
A mechanism for the diabetes-induced alterations of hepatic drug metabolism can 
therefore be proposed. Ketone bodies are the predominant inducing species, being 
responsible for the induction of the cytochrome P450 lA, IIB and HE subfamilies (Figure
7.1). However, the hyperlipidaemia accompanying type I diabetes has a direct inducing 
effect on the cytochrome P450 IVA subfamily (Figure 7.1). The complex interactions between 
insulin and other hormones is perturbed during type I diabetes. This causes many 
alterations in the levels and secretory patterns of other hormones including growth 
hormone (Tannenbaum, 1981; Yamazoe et al.; 1989b). Growth hormone has been implicated 
in the regulation of many isoforms of cytochrome P450 including; P450 IHA proteins and 
maintenance of the sex-specific constitutive isoforms (Wrighton et al.,1985a; 1985b; Figure
7.1). This suggests that the alteration of the cytochrome P450 HIA proteins may be a 
consequence of the reduced levels of growth hormone in diabetic rats (Thummel and 
Schenkman, 1990).
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7.5 The effects of other insulin-aberrant conditions on hepatic 
drug metabolism
The effects of type II (non insulin-dependent) diabetes on hepatic drug metabolism
are much less pronounced than those of type I diabetes. As type II diabetic mice are not 
hyperketonaemic, this may not be an unexpected finding. However, they are 
hyperglycaemic, providing further evidence that hyperglycaemia is not responsible for the 
observed changes in hepatic drug metabolism in type I diabetes. Similarly, hypertension 
was not associated with any significant alterations of hepatic drug metabolism in the 
spontaneously hypertensive rat. Hypertension is frequently a complication of type II 
diabetes and therefore type II diabetic mice may have also been hypertensive. Thus it may 
have been predicted that hypertension in the rat would not be associated with marked 
alterations of drug metabolism.
Hyperinsulinaemia was associated with the induction of the cytochrome P450 lA  
subfamily in both insulinoma-bearing rats and rats injected with monocompotent long- 
acting insulin. This finding is of interest and suggests that the endogenous interactions of 
insulin and the effects of these interactions on drug metabolising enzymes merits further 
investigation.
7.6 Conclusion
There can be no doubt that the influence of insulin-dependent diabetes mellitus on 
the biotransformation of xenobiotics is marked and of clinical and toxicological importance. 
Insulin-dependent diabetes mellitus modifies the cytochrome P450 composition of the liver 
and possibly other tissues and in this way perturbs the metabolic pathways of chemicals. It
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is therefore not surprising that the response of diabetic animals to the toxicity of chemicals 
is altered. However, the lack of any systemic study of the effects of diabetes on human drug 
metabolism precludes any extrapolation of the animal data to man. It may be argued that 
since human diabetes is corrected by a strictly controlled insulin regime, no hormonal 
changes or ketosis usually occur . However, the possibility that the diabetic patient, even 
when on daily insulin therapy, is still influenced by the disease, as far as the ability to 
cope with chemicals is concerned, cannot be ruled out and can only be answered by in vivo 
studies in humans.
173
HORMONAL REGULATION OF CYTOCHROME P450
The intricate interplay between hormones and cytochrome P450 regulation is most clearly 
demonstrated by sex-imprinting of gene expression. Most studied are the male-specific and 
female-specific P450 iso forms, P450IIC11 and P450IIC12 respectively. The expression of 
P4501IC11 is dependent on androgen exposure during the neonatal period and adulthood. 
Thus, castration of neonates abolishes P450IIC11 expression while castration of adults only 
partially decreases expression of this isoform. This partial effect is eliminated if rats are 
administered testosterone during adulthood, directly demonstrating a role for adult 
testosterone (Gonzalez, 1989). Similarly, testosterone injection to castrated rats during the 
first three days of life also results in significant P450IIC11 expression at adulthood, 
consistent with the proposal that this enzyme is one of the hepatic proteins subjected to 
neonatal imprinting or programming by androgen exposure.
The role of pituitary hormones in the regulation of sex-specific P450 isoforms has 
been extensively investigated (Kato et al., 1986; Morgan et al, 1985). Adult male rats have 
pulsatile secretions of pituitary growth hormone, while adult females have more constant 
levels, and these patterns are determined by both neonatal androgen exposure and adult 
testosterone levels (Jansson et ah, 1985). Growth hormone secretion is also involved in the 
regulation of the female specific P450IIC12. Continuous infusion of growth hormone re­
establishes levels of female-specific P450IIC12 in hypophysectomised female rats (Kato e t 
ah, 1986). Growth hormone also has suppressive effects on gene expression. For example, 
hypophysectomy of male and female rats results in a 5-fold to 10-fold respective increase in 
P450IIE1 which can be partially reversed when these rats are treated with growth 
hormone.
Effect of Diabetes on P450 Regulation
The secretion of several hormones are known to be modulated directly and 
indirectly by diabetes. Thus diabetic rats are considered to be a good models to understand 
the regulatory influence of endocrine hormones on hepatic cytochrome P450. The hepatic 
content of cytochrome P450IIC11 is known to be increased by pulsatile secretion of growth 
hormone, whereas the level of P450IIC12 is shown to be increased by continual presence of 
serum growth hormone levels in adult rats. In diabetes mellitus serum growth hormone 
levels are reduced and Yamazoe et ah, 1989b recently indicated that the constitutive and 
inducible levels of expression of phenobarbital-inducible P450IIB1 and P450IIB2 was 
regulated suppressively by this hormone. Therefore, the reduced levels of this hormone in 
diabetes may explain the induction of these isoforms. Furthermore, growth hormone has 
been implicated in the suppressive regulation of cytochrome P450IIIA2 and P450IIE1 
regulation. However, this hormone has not been associated with the regulation of the 
cytochrome P450IA or P450IVA subfamily of proteins. Obviously, diabetes affects the levels 
of the cytochrome P450 proteins by a variety of mechanisms. Recently, the regulation of 
cytochrome P450IIE1 activities in diabetes has been extensively studied providing evidence 
for several regulatory sites in the expression of this protein.
Regulation of P450IIE1 in Diabetes
In spontaneously diabetic rats or in rats made diabetic by treatment with 
diabetogens, P450IIE1 levels are induced to 6-fold above the levels seen in control rats. This 
increase is accompanied by up to a 10-fold increase in P450IIE1 mRNA in the absence of an 
increase in transcription of the IIEl gene (Koop and Tierney, 1990). When diabetic rats are 
given insulin the effect is reversed. Therefore, in the diabetic rat either the IIEl mRNA s 
stabilised or the efficiency of pre-mRNA is markedly enhanced. P450IIE1 is not detected in 
neonatal liver but significant levels of P450IIE1 RNA are detectable within a few hours. 
The increase in MRNA is coincident with transcriptional activation of the P450IIE1 gene.
The onset of transcription is accompanied by the déméthylation of cytosine residues 
upstream from the transcription start site in the P450IIE1 gene 1 day after birth with 
additional déméthylation detectable at 1 and 10 weeks after birth (Koop and Tierney, 
1990). The transcriptional activation of P450IIE1 gene at birth is in sharp contrast to the 
regulatory mechanisms employed in the adult where mRNA and protein stabilisation are 
the most important factors in the regulation of enzyme level. In almost all cases, elevated m 
RNA is absent in situations where hormonal changes are involved . The induction of 
P450IIE1 by the diabetic state is variable. The increase in both the enzyme concentration 
and the mRNA is reversed by insulin administration. Initial suggestions were made that 
the induction of P450IIE1 by the diabetic state was due to an increase in the ketone body 
levels in the circulation. However, fasting conditions do not produce high enough ketone 
levels to account for the induction observed.
Growth hormone levels are depressed in diabetic animals and may have an 
important role in P450IIE1 induction. However, Thummel and Schenkman, 1990 found that 
while both male and female rats have elevated P450IIE1 , the diabetic state has no effect 
on the circulating growth hormone concentration in females. These investigations also 
reported that administration of growth hormone to diabetic males failed to reverse the 
effect of diabetes. These results suggest that there are probably more than one mechanism 
important in the induction of P450IIE1 in diabetic rats. On involves the stabilisation of the 
m l^ A  while the other operates through increased mRNA translation or decreased protein 
degradation. There have been few studies examining stabilisation of P450IIE1 mRNA and 
further work needs to be performed before conclusive statements can be made. For all 
chemical inducers examined in adult animals there is no significant increase in the hepatic 
concentration of P450IIE1 mRNA. Therefore, it is suggested that P450IIE1 is primarily 
induced by post-transcriptional mechanisms. Support for this mechanism involving a 
decrease in P450IIE1 degradation as a result of protein stabilisation is provided by a number 
of investigations. In diabetes mellitus two mechanism are probable; i) Direct stabilisation 
of the protein resulting in decreased degradation. This is performed by interactions of 
ketone bodies, predominantly acetone, with P450IIE1 protein thereby preventing 
degradation, ii) Hormonal influence. Gene transcription, possibly receptor mediated which 
may be due to the lack of growth hormone suppression of gene transcription in diabetes.
The regulation of expression of P450IIE1 is extremely complex an involves both 
transcription and post-transcriptional mechanisms. In adult animals and presumably man, 
the control of degradation of the enzyme is one of the principle components in the regulatory 
pathway. The figure below outlines the possible regulation of P450IIE1 by diabetes 
mellitus.
The regulation of cytochrome P450IIE1 (Gonzalez, 1989)
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